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Parkinsonism is a clinical rather than aetiologic entity, since it is associated 
with several pathological processes that damage the extrapyramidal system. Its 
many causes are divided into two categories:1 
1. neurodegenerative parkinsonism:  
A. primary Parkinson’s disease: idiopathic Parkinson’s disease (IPD) and 
familial Parkinson’s disease 
B. atypical parkinsonian syndromes (APS) also called parkinson-plus 
syndromes: multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP), diffuse Lewy body disease (DLBD) and corticobasal 
degeneration (CBD) 
C. hereditary degenerative diseases (e.g. Wilson’s disease, Huntington’s 
disease, Panthothenate kinase associated neurodegeneration) 
2. secondary parkinsonism (associated with e.g. infectious agents, drugs, 
vascular disease, brain neoplasm, hydrocephalus, and psychogenic 
disorders) 
IPD is the most prevalent type of parkinsonism and accounts for approximately 
75-80% of all involved patients.2,3 In this introduction, therefore, the main focus 
is on parkinsonism caused by IPD. The other parkinsonian syndromes are 
discussed briefly. The clinical criteria of IPD, the APS and essential tremor are 
mentioned in the appendix A. 
Epidemiology of IPD   
The mean age of onset is 60; young onset IPD (onset <40 years) accounts for 
less than 5% of the cases. In the Netherlands IPD affects about 50.000 people 
and is therefore the second most common neurodegenerative disorder after 
Alzheimer’s dementia.4 The prevalence of IPD in industrialised countries is 
generally estimated to be 0.3% within the entire population and approximately 
0.5-1% among persons 65 to 69 years of age, rising to 1-3% among persons 
aged 80 years and older.5 In comparison, the prevalence of probable 
Alzheimer’s disease is 1-3% among patients between 65 to 69 year of age, 
18% in those aged 75 to 84 years and up tot 47.2% in those over 85 years.5,6  
Reported annual incidence rates of IPD range from 0.04-0.26 per 1000 person-
years. The incidence of parkinsonism and IPD increases with age, with 
incidence rates for IPD increasing from 0.008 per 1000 person-years in the age 
group 0 to 29 years, 0.3 in subjects aged 55 to 65 years, to 4.4 per 1000 
person-years for those aged 85 years and older.7,8 In comparison with IPD, the 
incidence of APS is significantly lower, for instance 0.05 per 1000 person-years 
for PSP and 0.03 for MSA for the age group 50 to 99 years.8 Some studies 
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report a higher prevalence of IPD in men than in women with a ratio of up to 
2:1, although other studies found no significant differences.7,9,10 IPD is 
expected to impose an increasing social and economic burden on societies as 
population ages. 
Aetiology and pathophysiology of IPD 
IPD was first described by James Parkinson in 1817.11 Nowadays, almost two 
hundred years later, the exact cause of IPD is still unknown. The aetiology is 
probably multi-factorial, with contributions of variable significance from 
hereditary predisposition, environmental toxins, and ageing.  
The main pathological features are the loss of neuromelanin containing 
dopaminergic neurons of the nigrostriatal pathway, particularly those in the 
pars compacta of the substantia nigra (SN) and the identification of Lewy 
bodies. Lewy bodies are inclusions within the cytoplasm of neurons that are 
composed of α-synuclein, as well as other proteins including ubiquitin and 
neurofilament protein.12,13 Post-mortem studies of IPD patients have revealed 
three other major changes in the SN: 1) evidence of oxidative stress, 2) 
increased iron levels with reduced ferritin buffering and 3) mitochondrial 
injury.14 Nevertheless, the intracellular cascade of events leading to 
accumulation of Lewy bodies and the dopaminergic cell death is still unknown. 
Clinical signs of IPD 
The classic tetrad consists of resting tremor, cogwheel rigidity, bradykinesia, 
and postural reflex impairment.3 However, early symptoms may be mild and 
aspecific and make a clinical diagnosis difficult. The onset of symptoms is 
usually so insidious, that patients can rarely pinpoint when the first symptoms 
appeared. Disease onset predates the expression of clinical manifestations of 
IPD, which by 18F-fluorodeoxyglucose with Positron Emission Tomography 
(PET) has been estimated to be about 4.5 years. By the time patients become 
symptomatic approximately 60% of the nigral dopaminergic neurons have been 
lost and the striatal dopamine content has been reduced by approximately 
80%.15  
Besides the well-known aforementioned motor symptoms, the IPD patient often 
experiences substantial non-motor symptoms like fatigue, hyposmia, pain, 
sleep disorders, neuropsychiatric disturbances and cognitive impairment. 
Diagnosis of IPD 
During life the diagnosis of IPD is based on clinical criteria (see appendix A).3 
The main difficulty in the clinical diagnosis of IPD is to distinguish the disease 
from essential tremor or other parkinsonian syndromes that resemble specific 
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features of IPD. The uncertainty of diagnoses based on clinical examination is 
evident in several studies.16-22 For example Meara and colleagues found that 
only 74% (298 of 402) of patients, who received anti-parkinsonian drugs, 
fulfilled the UK Parkinson’s Disease Society brain bank clinical diagnostic 
criteria for IPD: 53% were diagnosed as having probable IPD, 21% possible 
IPD and in 26% the diagnosis IPD could not be made at all.18 
Clinical criteria at best lead to a diagnosis of probable IPD, while a definite 
diagnosis requires post-mortem confirmation. There are a few neuro-
pathological studies which have shown that even in the final stages of the 
disease, the clinical diagnostic accuracy for IPD varies between 75-90%.16,19-22 
Therefore, purely on clinical grounds, it can be difficult to differentiate IPD from 
other parkinsonian syndromes like vascular parkinsonism, drug induced 
parkinsonism and APS. This is especially true in the early stages of the disease 
when patients often do not yet fulfil the clinical criteria and physical findings can 
be subtle. In those cases the best clinical practice is to take time for follow-up 
to see if re-examining the patient then reveals features that may lead to a 
probable diagnosis. 
Treatment and prognosis of IPD 
Since the mechanisms that cause nigral dopaminergic neurons to degenerate 
are unknown, and the diagnosis always is made when the degenerative 
process is considered irreversible, there are no possible curative or preventive 
therapeutic options. The typical course of IPD is a gradual worsening over a 
decade or more, corresponding with ongoing neuronal loss. Therapy can exist 
of supportive treatment, drug treatment and neurosurgical interventions. 
Examples of supportive treatment are physiotherapy, occupational therapy and 
speech therapy. The drug treatment is dependent on the phase and severity of 
the disease. In early IPD most patients will be sufficiently treated with 
monotherapy of a dopaminergic agent (i.e., levodopa, dopamine receptor 
agonists, amantadine and MAO-B inhibitors). Of these dopaminergic drugs 
levodopa has an established role as the most efficacious antiparkinsonian 
agent, well documented after decades of clinical use. In a later phase of the 
disease most IPD patients will need a combination of various dopaminergic 
agents. If IPD is complicated by cognitive impairment, depression or 
hallucinations/psychosis cholinesterase inhibitors, antidepressive agents or 
antipsychotic drugs can be indicated, respectively.23 
If oral therapy fails in advanced PD there are some additional options. For 
instance, the dopamine receptor agonist apomorfin can be given 
subcutaneously.24 Levodopa can also be given continuously by a tube in the 
duodenum or a continuous drip placed subcutaneously in selected patients with 
advanced IPD.25 Furthermore, deep brain stimulation of the subthalamic 
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nucleus, pallidum, or thalamus by the neurosurgeon can be extremely helpful in 
carefully selected patients.26,27 
Although the introduction of symptomatic treatment such as levodopa has 
prolonged survival, IPD patients still exhibit a higher mortality risk as compared 
to healthy controls.28  
Diagnostic tools 
Since the clinical diagnosis of IPD is often made late or even missed there is a 
clear need for an accurate diagnostic tool, ideally with presymptomatic 
detection qualities. Such a diagnostic tool could not only help to diagnose and 
treat patients in the early stages of the disease but also facilitate the 
development of preventive drugs. 
Several diagnostic modalities have been proposed to diagnose IPD: functional 
imaging with PET or Single Photon Emission Computer Tomography (SPECT), 
transcranial duplex scanning (TCD), olfactory and neuropsychological tests, 
biomarkers and DNA tests.29-32 
Especially neuro-imaging techniques like PET and SPECT scans can facilitate 
early diagnosis in patients with inconclusive parkinsonian symptoms in 
specialised settings.33-37 PET scans are at least as accurate as SPECT scans. 
However, the clinical use of PET is limited by the relative short half-life of its 
radioactive tracers (only hours), its high costs and its sporadic availability (in 
the Netherlands only 24 of the 140 hospitals) in comparison with SPECT. The 
PET technique is, therefore, not further discussed in this thesis.  
Different radiotracers can be used in SPECT to visualise the nigrostriatal 
system. Presynaptic tracers are used to visualise the dopamine reuptake 
transporters, and postsynaptic radiotracers to assess dopamine receptor 
density. Although widely available, SPECT scans are only performed in a 
minority of patients suspected of having IPD. This is probably due to the fact 
that additional diagnostic tests such as SPECT are not part of the criteria to 
diagnose IPD.3 The rationale is an ongoing debate on the diagnostic accuracy 
of SPECT scans in differentiating IPD from other parkinsonian disorders. 
Especially its ability to discriminate between the various parkinsonian 
syndromes in which the dopaminergic system is involved, such as IPD, MSA, 
PSP and DLBD is under discussion.35 
In 1995 an alternative method to visualise the alterations in the cerebral 
dopaminergic pathways has been proposed: transcranial duplex scanning 
(TCD) of the SN in the brainstem.32 The technical aspects of visualising the SN 
and other brain structures by TCD are explained in the appendix C.  
Several publications consistently showed that up to 90% of IPD patients have 
an increased echointensity of the SN.38-42 In healthy subjects and in patients 
with essential tremor this hyperechointensity of the SN is found in only 
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10%.43-46 It is noteworthy that healthy subjects with an increased echointensity 
can potentially be true positives since 60% of them also have decreased 
nigrostriatal function on PET scan. These results suggest that TCD as well as 
PET scans can be helpful in identifying patients potentially at risk to develop 
IPD.40,43 Longitudinal follow-up studies are necessary to see if these 
asymptomatic subjects will develop IPD in the future.  
Since TCD is widely available, less costly than SPECT and more comfortable 
for the patients its seems to be a promising technique. However, before TCD 
can be implemented in daily clinical practice it is desirable to investigate its 
reliability and attributive diagnostic value in comparison with already existing 
techniques like SPECT scintigraphy. 
Scope and aims of the study 
In this thesis we firstly investigated the diagnostic accuracy of SPECT in 
parkinsonian patients. Secondly, we studied the accuracy of TCD in the 
differential diagnosis of IPD. Finally, the combination of both techniques in the 
diagnostic work-up of patients with unclear clinical parkinsonism was assessed.  
The aim of chapter 2 and 3 was to analyse the accuracy of SPECT in the 
diagnostic work-up of parkinsonian patients. In chapter 2 we present a meta-
analysis of all existing literature on the diagnostic accuracy of both pre- and 
post-synaptic dopaminergic SPECT imaging in the differential diagnosis of IPD. 
In chapter 3 we present the results of a study on the diagnostic accuracy of an 
initial pre-synaptic or post-synaptic SPECT scan in our own clinic. The study 
included 248 patients with an unclassified parkinsonian syndrome who 
underwent SPECT imaging between 2001 and 2006. The results of the SPECT 
imaging were compared with the clinical diagnosis after follow-up. 
The aim of chapter 4 and 5 was to explore the diagnostic accuracy of TCD. In 
chapter 4 the existing literature on the use of TCD in parkinsonian patients is 
systematically reviewed. In chapter 5 we investigate the inter-observer as well 
as intra-observer variability of TCD.  
The aim of chapter 6 and 7 was to analyse the diagnostic value of TCD in 
comparison with presynaptic SPECT scans. In chapter 6 we show the results of 
a study that took place between 2000 and  2006, in which 95 patients with 
clinical parkinsonism of unclear origin were investigated with TCD and pre-
synaptic dopaminergic SPECT imaging. After a mean follow-up of fourteen 
months the patients were re-examined by an independent movement disorder 
specialist, whose clinical diagnosis was compared with the results of the 
additional tests. In chapter 7 we present the protocol of a prospective trial, 
which currently is in progress. In this study we will evaluate the diagnostic 
accuracy of TCD and SPECT, but also of motor tests, cognitive tests and smell 
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tests in patients with parkinsonism of unclear origin. We have already enrolled 
250 consecutive patients, who were referred to the neurology outpatient clinics 
of two teaching hospitals, for analysis of clinically unclear parkinsonism. The 
definitive clinical diagnosis will be made by two independent movement 
disorder specialists, after a follow-up of two years. The study started in 2006 
and the follow-up will be completed in January 2010.  
In chapter 8 a summary and implications of the findings presented in this thesis 
are argued and directions for future research are briefly discussed. 
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Parkinson’s disease (IPD) is the second most common neurodegenerative disorder. One of the 
most widely used techniques to diagnose IPD is a Single Photon Emission Computer Tomography 
(SPECT) scan to visualise the integrity of the dopaminergic pathways in the brain. Despite this 
there remains some discussion on the value of SPECT in the differential diagnosis of IPD. We did a 
meta-analysis of all the existing literature on the diagnostic accuracy of both pre- and post-synaptic 
SPECT imaging in the differential diagnosis of IPD. 
 
Methods 
Relevant studies were searched in Medline, EMBASE and Cochrane databases with back-
searching of their reference lists. We limited our analysis to studies with a clinically relevant 
methodology: i.e. when they assessed the ability of SPECT to provide 1. diagnosis of IPD in an 
early phase vs. normalcy; 2 diagnostic differentiation between IPD and essential tremor (ET); 3. 
distinguishing between IPD and vascular parkinsonism (VP); 4. delineation of IPD from atypical 
parkinsonian syndromes (APS). Gold standard was, dependent on the study type, clinical 
examination at initial visit or follow-up, and/or response to dopaminergic agents. 
 
Results 
The search gave 185 hits, of which we deemed 32 suitable for our analysis. From these we 
recalculated the diagnostic odds ratio of SPECT for the clinical questions above. The pooled odds 
ratio (with 95%CI) for presynaptic SPECT scan’s ability to distinguish between early IPD and 
normalcy was 60 (13-277). For the ability to differentiate between IPD and ET this ratio was 210 
(78-563). The ratio for presynaptic SPECT’s ability to delineate IPD from VP was 105 (32-348). The 
mean odds ratio for the presynaptic SPECT scans to differentiate between IPD and APS was 2 (1-
4), and for the postsynaptic SPECT imaging this was 19 (10-36). 
 
Conclusions 
SPECT with presynaptic radiotracers is relatively accurate to differentiate patients with IPD in an 
early phase from normalcy, patients with IPD from those with ET, and IPD from VP.  
The accuracy of SPECT with both presynaptic and postsynaptic tracers to differentiate between 
IPD and APS is relatively low. 
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Background 
Parkinson’s disease (IPD) is the second most common neurodegenerative 
disorder with a life-time risk of 2% in males and 1.3% in females.1 In most 
cases the diagnosis of IPD is straightforward when cardinal clinical signs and 
symptoms as bradykinesia, rigidity, and resting tremor are present.2 However, 
these main features of IPD are shared, at least in part, by atypical parkinsonian 
syndromes (APS, i.e. multiple system atrophy [MSA] and progressive 
supranuclear palsy [PSP]) or secondary parkinsonism (i.e. vascular 
parkinsonism [VP], drugs induced parkinsonism [DIP]) and essential tremor 
(ET). Besides delineating IPD from the above parkinsonian disorders, 
distinguishing IPD from normality can also be difficult, especially in early stage 
of the disease.3 
The gold standard for the diagnosis of IPD is post-mortem neuropathological 
examination.2,4 Neuropathological studies show that even at end-stage disease 
the clinical diagnostic accuracy for IPD varies between 75-90%, with MSA and 
PSP accounting for most false positives.2,5-7 Diagnostic accuracy is certainly 
less than 90% in earlier disease, as Litvan et al. found that the median 
sensitivity for the diagnosis of IPD increased from 73% at the first visit to 80% 
to the last visit after a mean follow-up of nine years, and the median positive 
predictive value increased from 46 to 64%.8 
A reliable test to diagnose IPD is important for two reasons. Prognosis and 
management of IPD and other parkinsonian disorders differ considerably, and 
an objective disease marker would facilitate the development of neuro-
protective therapies.9,10 Several procedures have been proposed to diagnose 
IPD: functional imaging with Positron Emission Tomography (PET) or Single 
Photon Emission Computer Tomography (SPECT), transcranial sonography, 
olfactory- and neuropsychological tests, biomarkers and genetic tests.11-14 
At the moment neuro-imaging techniques like PET and SPECT are the most 
widely used diagnostic tools.9 PET is at least as reliable as SPECT, but its use 
in routine clinical practice is limited by high costs and a relative short half-life of 
its radioactive tracers.15-18 Different radiotracers can be used to visualise the 
nigrostriatal system. Presynaptic tracers are used to visualize the dopamine 
transporter, and postsynaptic radiotracers to assess dopamine receptor 
density. Examples of presynaptic radiotracers that can be used in SPECT are 
Iodine-123-beta-CIT, Iodine-123-Ioflupane (FP-CIT), Iodine-123-IPT and 
99mCT-TRODAT-1 (TRODAT). Examples of postsynaptic tracers are Iodine-
123-iodobenzamide and Iodine-123-Iodobenzofuran.19 
Despite its widespread use, there is no consensus about the value of SPECT in 
the differential diagnosis of IPD. First, comparisons between this functional 
dopaminergic imaging and the ultimate gold standard, autopsy-proven IPD, are 
almost non-existent.20,21 Second, using a surrogate gold standard in the form of 
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a long-term clinical follow-up, the ability of SPECT to discriminate IPD from 
normality and/or other parkinsonian disorders and to distinguish one of the 
atypical parkinsonian syndromes from the other varies greatly among different 
studies. Comparing these studies is difficult, as they use different radiotracers 
and SPECT techniques, and, more importantly, involve different patient 
populations. A major issue here is that many studies use clearly-defined later-
stage patients that are obviously not representative for the diagnostic problem 
that one wants to solve with a SPECT.  
With this perspective of clinical relevance we did a meta-analysis of all the 
existing literature on the diagnostic accuracy of both pre- and post-synaptic 
SPECT in the differential diagnosis of IPD. We defined studies as clinically 
relevant when they dealt with the ability of SPECT to identify IPD in patients 
with diagnostic uncertainty, to delineate IPD from the other parkinsonian 
disorders and ET, and to provide an early diagnosis of IPD in patients with little 
signs and symptoms. 
Methods 
Data sources 
Meta-analysis was done according to current methodological recommend-
dations.22-24 We searched MEDLINE using the following terms: IPD, 
parkinsonian, MSA, PSP, VP and ET. We searched for MeSH terms and free 
text words. All in combination with SPECT and clinical trial. No beginning data 
limit was used. The search was updated until 9 January 2006. Only English-, 
Dutch- and German language studies were considered, because the 
investigators were familiar with these languages. The bibliographies of selected 
articles were screened for potentially suitable references which were then 
retrieved. We also searched the EMBASE and Cochrane database (Wiley 
InterScience) using the same search strategy.  
Study selection 
Two investigators (AV, WW) screened the full text of potential relevant articles 
using the inclusion criteria. For this we use a standard form combined with a 
modified QUADAS score, see Table 2.1 (form available upon request).25 In all 
cases the investigators reached consensus. Studies were selected if the 
subject of the study was in one of the following three areas:   
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1. Patients who underwent SPECT because of diagnostic uncertainty.  
2. Cross-sectional study of already diagnosed patient categories, in which 
SPECT was tested as a means to differentiate between various 
parkinsonian syndromes.  
3. Cross-sectional studies with patients with known IPD in an early stage 
(Hoehn & Yahr stage 2 or less) vs. normal healthy controls, in which SPECT 
was tested as a means to provide an early diagnosis. 
Exclusion criteria 
The following exclusion criteria were used: 1) whole article not available, 2) 
language different from English, German or Dutch, 3) studies including only 
advanced IPD patients vs. healthy controls, and studies with other main 
categories, e.g. dementia, 4) study population with less than 10 patients, 5) if 
the numbers of true positives, false negatives, true negatives and false 
positives with a cut-off point of two standard deviations (SD) from the mean of 
the control group were not available or could not be derived the study was 
excluded. When the study included more than 85 patients we contacted the 
corresponding author to ask for the raw data (see below). 
We chose this approach, because we expected a substantial cut-off point effect 
in the included studies. We did not want to be dependent upon the assumption 
that the diagnostic odds ratio’s in our study would not be affected by 
differences in the individual cut-off points. To reduce heterogeneity we decided 
to choose one common cut-off point for all studies. We took a cut-off point of 
two standard deviations (SD) after consulting with nuclear imaging experts in 
our hospital and the University Hospital of Amsterdam. Both departments use a 
cut-off point of 2 SD’s below healthy controls. So we recalculated all results 
from all studies using the individual data from tables and figures in the 
published paper, using this new cut-off point. If recalculation was not possible 
(when data for individual patients were not traceable from the manuscript), we 
excluded the study. This exclusion leads to bias, of course. We feel, however, 
that, as these studies did not adhere to recommended guidelines by not 
providing the raw scan results  to allow the construction of the diagnostic 2x2 
table, we did not exclude the methodologically best studies.24 
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Legend to Table 2.1 
 (-) indicates a “no” or indicates that there was not sufficient information to make a proper 
assessment. 
1) Number of patients of the particular study that were included in this meta-analysis. Healthy 
controls, patients without a relevant disease, or patients with an inconclusive diagnosis were 
not included.  
2) Study methodology: 
 I = patients with an inconclusive diagnosis. Diagnostic accuracy of SPECT was determined 
with a surrogate gold standard 
 II = cross sectional study of already diagnosed patient categories 
 III = early IPD vs. normalcy 
3) Gold standard: 
 cf = clinical criteria after follow-up 
 cc = clinical criteria without follow-up 
 dd = effect of dopaminergic drugs or apomorphine test 
 fd = clinical criteria after follow-up & effect of dopaminergic drugs or apomorphine test 
4) Radiotracers: beta = Iodine-123-beta-CIT, fpcit = Iodine-123-Ioflupane, tr = Iodine-123-IPT and 
99mCT-TRODAT-1, ibzm = 123I-iodobenzamide, ibf = Iodine-123-Iodobenzofuran, epide = 
Iodine-123-epidepride. 
5)  t = region of interest determined with a template 
 m = region of interest manually encircled 
6) c-putamen = contralateral putamen, c-pc = contralateral putamen/caudate ratio 
7) (yes) if the drugs that interfere with the radiotracers were stopped properly or if the subjects did 
not use dopaminergic drugs at the moment of the SPECT. 
 (-) if this information was not given or if dopaminergic drugs were not stopped properly. 
Data extraction and analyses 
Sensitivity, specificity and the odds ratio was calculated for each study 
separately, and the pooled odds ratio’s (OR) for all studies together. Although 
we tried to reduce heterogeneity by recalculating study results using one 
common cut-off point, we still expected a threshold effect, because of 
differences in patients, SPECT machinery, radiotracers etc. Therefore, 
according to recommendations by Deekes and Egger we used diagnostic 
OR’s.26 
For studies with zeroes in one or more cells 0.5 was added to all four cells of 
the 2x2 table. Trials with a sensitivity of 100% and a specificity of 0% were not 
excluded, however the pooled OR’s were also calculated without such studies 
(See # in the legends of Figure 2.4, 2.5 and 2.6).   
All results were put in software SPSS 11.0 for Windows and later converted to 
Stata/SE9.  
The metan and metareg commands were built in Stata/SE9. Because of the 
heterogeneity of the selected studies we used a random model to calculate the 
diagnostic odds ratios. Heterogeneity was calculated with the I 2.27 




The search on Medline (SPECT & clinical trial) gave 1503 hits. When we added 
all parkinsonian disorders we limited the Medline search to 56 relevant hits.  
In the Cochrane database we found 26 hits and in Embase 45 hits, but no 
additional clinical studies above the ones found in Medline. With cross-
reference searching we found an additional 128 relevant trials. See flowchart. 
Together with our own retrospective study of 248 patients with unclear 
parkinsonism who underwent SPECT in the period 2001 to 2006, this resulted 
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Of these 185 we excluded 153 studies (See appendix D). Seven were excluded 
because of the language criteria and 85 articles were excluded as they did not 
deal with one of our three designated areas of clinical relevancy: most of them 
were about techniques, dementia or drug efficacy. We excluded an additional 
61, because the absolute numbers with a cut-off point of two standard 
deviations below the control group were not available or could not be derived. 
We mailed the authors of the four studies with more than 85 patients, to ask for 
missing data29-32, and received a response from one.30 We wanted to acquire 
raw data from relatively large studies that would have a substantial impact on 
our meta-analysis; there were four large studies with more than 85 patients, the 
rest involved smaller numbers in the 20-35 range. We thus sought to contact 
the authors of these four studies, as we felt that studies with less than 85 
subjects would have a very limited impact on the overall scores. 
Of the 32 trials left (See appendix D) seven dealt with diagnostic uncertainty 
including a clinical follow-up as surrogate gold standard, twenty studies were 
cross-sectional including subjects with known parkinsonian disorders, and six 
studies involved patients with early IPD. One clinical study fitted as well in the 
early IPD groups as in the study group of known parkinsonian disorders.33 Of 
the seven follow-up studies, five were prospective. Of these prospective 
analyses, two included untreated new patients with parkinsonism34,35, and three 
included patients with inconclusive parkinsonism or with a questionable effect 
of anti-parkinsonian medication.28,36,37 Two of the seven follow-up studies were 
retrospective: Lokkegaard and colleagues retrospectively investigated 90 
consecutive patients referred for Beta-CIT SPECT for various reasons, and a 
non-treating neurologist obtained the final diagnosis from the clinical records of 
the patients.38 Stoffers et al. retrospectively analysed the SPECT scans of 72 
patients with an initial diagnosis of IPD, who were then re-diagnosed after 
various intervals.39 The demographic and methodological characteristics of all 
included studies are visible in Table 2.1. The absolute numbers of the 2x2 
tables of all included trials are shown in Table 2.2.    
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Table 2.2 Two by two tables for all included trials. 
 True positive False negative True negative False positive 
Early IPD vs normalcy   
Presynaptic     
Asenbaum ’98  23  6  30  0 
Haapanimie ‘01  16  13  21  0 
Huang ‘01  32  2  17  0 
Muller ‘98  14  10  15  0 
Schwarz ‘00   28  0  9  0 
V. Laere (tracer FP-CIT) ‘04  15  24  10  0 
V. Laere (tracer: TRODAT) ‘04  3  34  10  0 
IPD vs ET   
Presynaptic 
    
Booij ‘00   7  1  5  0 
Benamer ‘00  127  3  25  2 
Plotkin ‘05  24  1  11  0 
Eerola ‘05   92  0  16  0 
Vlaar ‘06  90  22  20  1 
Lokkegaard ‘02  44  1  8  0 
Asenbaum ‘98  23  6  32  0 
Lee ‘‘99  10  1  12  3 
Postsynaptic        
Vlaar ‘06  48  33  6  7 
Plotkin ‘05    25  0  0  11 
IPD vs VP   
Presynaptic 
     
Vlaar ‘‘06  90  22  14  0 
Booij ‘00  7  1  4  0 
Eerola ‘05  92  0  11  4 
Lokkegaard ‘02  44  1  3  1 
Gerschlager ‘02  18  2  12  1 
Postsynaptic        
Vlaar ‘06  65  16  8  4 
IPD vs APS   
Presynaptic 
    
Booij ‘‘00  7  1  1  2 
Benamer ‘00  127  3  1  27 
Plotkin ‘05  24  1  3  18 
Eerola ‘05  92  0  1  11 
Stoffers ‘05  30  32  2  6 
Lokkegaard ‘02  44  1  2  13 
Kim ‘02  18  0  1  12 
Lu ‘04  36  0  6  43 
Messa ‘98  13  0  0  5 
Pirker ‘02  26  10  3  7 
Vlaar ‘06  90  22  4  13 
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 True positive False negative True negative False positive 
Postsynaptic     
Schwarz ‘93  45  2  9  6 
Schwarz ‘97  30  4  8  1 
Schwarz ‘98  53  5  5  2 
Buck ‘95  17  0  3  3 
Kim ‘02  18  0  5  8 
Oertel ‘93  49  12  6  0 
Oyanagu ‘02  7  0  2  4 
Pirker ‘97  9  0  0  10 
Plotkin ‘05  25  0  9  12 
Schwarz ‘94  19  0  1  1 
Seppi ‘04  12  5  13  2 
Tatsch ‘91  18  0  20  4 
Schelovsky ‘93  30  0  8  6 
Vlaar ‘06  65  16  16  10 
MSA vs PSP   
Presynaptic 
    
Vlaar ‘06  19  0  1  9 
Plotkin ‘05  7  0  1  5 
Pirker  7  2  2  4 
Pirker  18  0  1  9 
Kim ‘02  11  2  1  7 
Benamer ‘00  4  1  0  2 
Postsynaptic         
Buck ‘95  5  2  6  0 
Kim ‘02  1  1  2  2 
Plotkin ‘05  7  6  6  2 
Vlaar’06  10  4  3  6 
v. Royen ‘93  13  4  1  3 
In the statistic analyses +0.5 was taken to be able to use zeroes in the calculations.  
IPD idiopathic Parkinson’s disease, APS atypical parkinsonian syndromes, MSA multiple system 
atrophy, PSP progressive supranuclear palsy, ET essential tremor, VP vascular parkinsonism, n 
number of studies 
Results of the pooled study data analysis 
We recalculated the diagnostic power of SPECT for the following clinical 
problems: 1. diagnosis of IPD in an early phase vs. normalcy; 2 diagnostic 
differentiation between IPD and ET; 3. diagnostic differentiation between IPD 
and vascular parkinsonism; 4. diagnostic differentiation between IPD and 
Atypical Parkinsonian Syndromes (APS) consisting of MSA and PSP.  
1. Diagnosis of IPD in an early phase vs. normalcy 
Pooled data from selected studies were used to calculate the diagnostic 
accuracy of SPECT to differentiate between IPD and normalcy.33,40-44 All six 
cross-sectionals (utilising presynaptic tracers) with patients with known IPD in 
an early stage (Hoehn & Yahr score of 2 or lesser) had a specificity of 100%. 
However sensitivity varied from 8 to 100%. The pooled odds ratio with a 95%CI 
was 60 (13-277). See also Figure 2.1. 
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.00001 1 60.000
Author (n PD, n controls)          
Odds ratio
(95% CI)
235 Asenbaum (n= 29 ,30)
52 Haapanimie (n = 29, 21)
455Huang (n= 34,17)
42Muller (n = 24,15)
1083Schwarz ’00 (n = 28, 9 )
13v Laere:- FP-CIT    (n = 62,10)
2- TRODAT (n = 64,10 )
60  (13 , 277)Overall (95% CI)
Odds Ratio
Heterogeneity (I-squared) = 0.00
IPD versus healthy controls
Presynaptic radiotracer
Author (n IPD, n controls) Sensitivity Specificity
Asenbaum (n= 29, 30) 79% 100%
Haap nimie (n= 29, 21) 55% 100%
Huang (n= 34, 17) 94% 100%
Muller (n= 24, 15) 58% 100%
1083Schwarz ’00 (n= 28, 9) 100% 100%
13v Laere:- FP-CIT    (n= 39, 10) 38% 100%
2- TRODAT (n= 37, 10 ) 8% 100%





















Figure 2.1 Diagnostic differentiation of patients with idiopathic Parkinson’s disease (IPD) in an 
early phase versus healthy controls.  
 Presynaptic radiotracer.33.40-44  
  
 ■: surface of square represents the weight of the study.  
 FP-CIT: Iodine-123-Ioflupane; TRODAT: 99mCT-TRODAT-1, n: number of subjects, 
CI: confidence interval  
 #: all of these studies have a specificity of 100% so the pooled odds ratio should 
therefore be infinite. The pooled odds ratio of 60 is caused by STATA software’s 
procedure for handling zero cells in the 2x2 table.   




2. Diagnostic differentiation between IPD and essential tremor (ET)  
Data from selected studies33,36,38,45-48 and our own clinical follow-up study28 
were pooled and pooled odds ratios for diagnostic power of SPECT were 
calculated as described. 
For presynaptic radiotracers the pooled odds ratio with 95% CI of the eight 
studies together was 210 (78-563). See also Figure 2.2. All studies scored high 
sensitivity and specificity.  
Thesis_Vlaar_v3.pdf   32 26-6-2009   9:23:25




















Figure 2.2 Patients with idiopathic Parkinson’s disease (IPD) versus essential tremor (ET). 
 Presynaptic radiotracer.36,38,45-48,84  
 * follow-up trial 
 
 
For calculation of these odds ratios in studies with postsynaptic radiotracers we 
found two studies: one cross-sectional study (sensitivity 100%, specificity of 
0%) and our own follow-up study (sensitivity 60%, specificity 46%). The pooled 
odds ratio with 95%CI was 2 (0.4-5).28,46 
Two studies compared the diagnostic accuracy of the treating physician with 
SPECT in its capacity to delineate IPD from ET.28,38 Clinical diagnosis in these 
trials reached a sensitivity of respectively 76% and 87% and a specificity of 
50% and 80%. The odds ratio with 95%CI of the two studies together is 
9 (3-28).  
3. Diagnostic differentiation between IPD and vascular parkinsonism (VP)   
Pooled data from selected studies were used to calculate the diagnostic 
accuracy of SPECT to differentiate between IPD and VP.28,36,38,47,49  
Using presynaptic radiotracers the five studies all scored high sensitivity and 
specificity for SPECT to differentiate between IPD and VP. The pooled odds 
ratio with 95%CI of all five studies together is 105 (32-348). See also Figure 
2.3. 
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Figure 2.3 Diagnostic differentiation of patients with idiopathic Parkinson’s disease (IPD) versus 
vascular parkinsonism (VP). Presynaptic tracer.28,36,38,47,49 
 * follow-up trial 
 
 
We were not able to find any trials except our own trial with postsynaptic 
tracers aimed at this diagnostic problem. We found a sensitivity of 80%, 
specificity of 67% and an odds ratio of 95%CI of 8 (2-30).  
Lokkegaard et al. and we mentioned the diagnostic accuracy of the clinician to 
differentiate IPD from VP and found a sensitivity of respectively 87% and 76% 
and a specificity of respectively 0% and 63% with a odds ratio 95%CI of 3 
(0.5-18).28,38 
4. Diagnostic differentiation between IPD and atypical parkinsonian syndromes 
(APS) 
Pooled data from selected studies were used to calculate the diagnostic 
accuracy of SPECT to differentiate between IPD and APS (MSA and  
PSP).18,28,0,34-39,46-48,50-59 
When using presynaptic tracers all trials scored moderate to high sensitivity, 
but with a low specificity. Combining all eleven trials the mean odds ratio with 
95% CI for the presynaptic tracer to differentiate between IPD and the two APS 
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Figure 2.4 Diagnostic differentiation between idiopathic Parkinson’s disease (IPD) and atypical 
parkinsonian syndromes (APS, i.e. MSA & PSP). Presynaptic radiotracer.28,30,36,38,39,46-
48,50-52  
 *  follow-up trial  
# the pooled odds ratio remains unchanged after excluding the study of Messa ’98 
(sensitivity 100%, specificity 0%).    
 
 
When using postsynaptic tracers the fourteen trials scored together a pooled 
odds ratio 95% CI of 19 (10-36). See Figure 2.5.  
Four follow-up studies compared the diagnostic accuracy of the treating 
physician with SPECT in its capacity to delineate IPD from the two APS. 
Clinical diagnosis in these trials reached a high sensitivity, but a low specificity. 
The pooled odds ratio 95% CI was 9 (2-34). See Figure 2.6.  
The diagnostic accuracy of SPECT to differentiate MSA from PSP was low for 
both the presynaptic and postsynaptic radiotracers. With presynaptic racers 
sensitivity of the six trials was extremely high (78-100%), however specificity 
was low (0-33%). The five studies with postsynaptic tracers scored moderate 
sensitivity (50-71%) and specificity (25-100%).  
The pooled odds ratio with 95% CI was 2 (0.6-7) for the presynaptic tracers 
and 2 (0.8-6) for the postsynaptic tracers.28,46,48,50,52,56,60,61 
Odds ratio
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Figure 2.5 Diagnostic differentiation of patient with idiopathic Parkinson’s disease (IPD) versus 
atypical parkinsonian syndromes (APS i.e. MSA & PSP). Postsynaptic 
radiotracers.18,28,34,35,37,46,50,53-59 
 * follow-up trial: 
 Schwarz 1993: this trial can be seen as follow-up trial (gold standard is long-term 
effect of levodopa) but also as a cross-sectional trial. In that last case the 
sensitivity is 79% and the specificity 100%. 
 Schwarz 1997: We used clinical signs that are (in)compatible with IPD as gold 
standard. If the effect of long-term levodopa is taken as gold standard the 
sensitivity is 100% and specificity is 67%.   
 Schwarz 1998: We used clinical signs that are (in)compatible with IPD as gold 
standard. If the effect of long-term levodopa is taken as gold standard the 
sensitivity is 100% and specificity is 50%.  
 #  after excluding the study of Pirker 1997 (sensitivity 100%, specificity 0%) the pooled 
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Figure 2.6 Diagnostic differentiation of patients with idiopathic Parkinson’s disease (IPD) versus 
atypical parkinsonian syndromes (APS, i.e. MSA & PSP) based on the clinicians’ initial 
prediction.28,34,38,39  
 * follow-up trial 
 # after excluding the studies with a sensitivity of 100% and a specificity of 0% (Stoffers 
2005 and Schwarz 1998) the pooled odds ratio (95%CI) did not change 
significantly: 6 (1-40). Both trials diagnosed all patients as having IPD at the 
beginning of the trial. 
 
Discussion 
To our knowledge this is the first meta-analysis of the literature on the 
diagnostic value of SPECT in patients with parkinsonian syndromes. Before 
discussing the actual results we would like to point out some methodological 
problems. 
We were very strict in including studies. To compare the results from selected 
studies we defined positive tests as values equal with or exceeding two 
standard deviations below healthy controls. When authors defined their positive 
results otherwise, we recalculated these, where possible. However, as many 
studies did not include raw data, we had to reject these, as we were then not 
able to (re)calculate the absolute numbers of true positive, false negative, true 
negative, and false positives with a cut-off point of two standard deviations.  
We dichotomised the radiotracers utilised into two groups: presynaptic and 
postsynaptic tracers. By doing this we assumed that all tracers in one group 
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have a similar reliability. This seems to be reasonable for beta-CIT and FP-CIT, 
especially when the SPECT result of the parkinsonian patient is expressed as a 
percentage of the binding ratios found in healthy controls.62,63 
Besides the use of different equipment, comparison between studies is also 
hampered by the different methods that investigators use to calculate the tracer 
binding. In some studies the striatum was encircled manually and others used 
predefined templates. The striatum was judged visually (compatible or not 
compatible with IPD) or fully automated quantitatively by others. Finally, and 
possibly the greatest confounding variable: in some studies the SPECT results 
are judged by investigators unaware of the clinical records, but in more than 
half of the studies blinding of the investigator is not mentioned.  
Another methodological shortcoming in our meta-analysis is the great variability 
in clinical criteria used to classify patients; many authors do not even mention 
these. A major issue here is that most studies use clearly-defined later-stage 
patients that are obviously not representative for the diagnostic problem that 
one wants to solve with a SPECT. We thus limited our analysis to those studies 
that addressed the diagnostic accuracy in clinically relevant situations: early 
IPD, follow-up studies and studies with known parkinsonian diseases. All the 
measures mentioned above were taken to minimise heterogeneity, which was 
actually shown to be minimal as calculated by the I2 statistic.27 Despite this, 
interpreting of the results should be done with caution, as postsynaptic tracer 
binding in APS can be normal in an early stage of disease with a decrease later 
on64. Finally, strict age-matching is not done in all studies, but is mandatory as 
tracer binding in general decreases with age.65-67 
These methodological problems do, however, allow one important conclusion 
to start with: as we derived only 32 papers suitable from a starting number of 
185, there is a paucity of methodologically sound and clinically relevant papers 
on this subject. Below we would like to discuss our results according to the 
predefined clinically relevant situations. 
Diagnosis of IPD in an early phase vs. normalcy   
Our meta-analysis confirms the general opinion that SPECT is relatively 
accurate to differentiate between patients with IPD in an early stage and 
healthy controls. The difference in sensitivity between trials can not be 
explained solely by different radiotracer usage. Especially the difference with 
the two studies using TRODAT is obvious.41,43 An explanation may be that the 
use of a template vs. hand-circling of the striatum leads to lower diagnostic 
specificities.40,42,43 Other possible explanations for the lower sensitivity scores 
in the study of van Laere et al. are their consecutive inclusion of patients and 
their clinic being a tertiary referral centre.43 
Thesis_Vlaar_v3.pdf   38 26-6-2009   9:23:26
 Meta-analysis of the literature on diagnostic accuracy of SPECTS⏐39 
 
Schwarz and Asenbaum were the only two authors who used two standard 
deviations below the normal controls as cut-off.33,42 In the other four studies we 
recalculated the absolute numbers of true positive, false negative etc. by 
ourselves, which led in all four studies to lower numbers for diagnostic 
accuracy.40,41,43,44 Apart from this different cut-off point, higher sensitivity figures 
in several large trials (normal SPECT scans in 5-10% of clinically definitive IPD 
patients) are probably explained by the disease stage of the patients.68-70  
Asenbaum’s, Haapaniemi’s and Muller’s were the only studies which 
mentioned blinding of the investigators.33,40,44 It is perhaps not surprising that 
these authors found lower numbers for diagnostic accuracy than Huang and 
Schwarz (See Figure 2.1).41,42 
Diagnosis of IPD versus essential tremor (ET) 
The results of our meta-analysis confirm the general opinion that SPECT with 
presynaptic tracers is highly accurate to differentiate between patients with IPD 
and ET. Lee et al. scored lowest specificity. A possible explanation is that they 
included not only patients with ET but as well patients with isolated postural 
tremor and postural in combination with resting tremor.45 
Diagnostic differentiation between patients with IPD versus 
vascular parkinsonism (VP) 
According to the results of the meta-analysis we conclude that presynaptic 
SPECT scans can accurately differentiate between patients with IPD and VP. 
The specificity, however, is only moderate in the studies of Lokkegaard and 
Eerola.38,47 VP is a somewhat controversial clinical concept and the differences 
found in the studies we analysed probably reflect the variability in clinical 
definition. Whereas Lokkegaard et al., Gerschlager et al., and Eerola et al.38,49 
used strict inclusion criteria, Booij et al. did not.36,47 This point is illustrated in 
the paper by Loberboym et al., who investigated twenty patients with VP with 
FP-CIT SPECT. Nine had a normal presynaptic SPECT scan but eleven had 
decreased striatal tracer binding. All nine patients with normal presynaptic 
SPECT scan had no reaction on levodopa treatment, however five of the 
eleven with decreased striatal FP-CIT binding did have.71 Although SPECT with 
presynaptic tracers scored high accuracy in differentiation between IPD and 
VP, conventional techniques like CT and MRI may still be necessary as 
additional diagnostic tools.  
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Diagnostic differentiation between patients with IPD versus 
atypical parkinsonian syndromes (APS) 
This meta-analysis confirmed the generally accepted view that presynaptic 
tracers cannot distinguish between IPD and APS. However, we also found that 
postsynaptic SPECT is not very good at this. A negative postsynaptic SPECT 
scan does not exclude APS. The positive predictive value of abnormal 
postsynaptic SPECT for the diagnosis of APS is high, making a reduced 
postsynaptic radiotracer binding likely to exclude a diagnosis of IPD. However, 
patients with IPD in our meta-analysis do show loss of dopamine-receptor 
binding. Studies which used IBZM scored higher accuracy than studies with 
Iodine-123-Iodobenzofuran or Epidepride.50,53,56,59 If the trials are excluded 
which used other tracers than IBZM the mean 95%CI odds ratio only increased 
to 21 (11-44). 
Some studies, excluded for this meta-analysis, found excellent accuracy for the 
postsynaptic tracer to differentiate between IPD and APS.19,64,72-77 Schulz et al., 
who investigated thirty-two MSA patients, found similar results as in our meta-
analysis: only a significant loss in 63% of the patients using IBZM-SPECT with 
two standard deviations under controls (IPD patients) as cut-off point.78 Results 
of the studies by Berding and Bettin are in line with these.79,80 
Possible explanations for the difference in results may be difference in cut-off 
points (many authors use only one SD below healthy controls), and the use of 
special techniques claimed by some to enhance diagnostic accuracy, e.g. 
asymmetric indices, caudate/ putamen ratio, presynaptic/postsynaptic ratio of 
tracer binding, speed of decline in follow-up.30,36,76,81,82 One other explanation of 
the low discriminating value of postsynaptic SPECT imaging is the reversible 
down regulation of dopamine receptors by dopaminergic drugs.83 If the drugs 
are not stopped appropriately, the scan result can be false positive. In our 
meta-analysis we found nine studies where potentially interfering medication 
was not discontinued  appropriately or these did even not mention whether this 
medication was discontinued (and if, for how long) before the scan. 
Conclusion 
There is a paucity of methodologically sound and clinically relevant papers on 
the diagnostic accuracy of SPECT in parkinsonian syndromes. Our meta-
analysis confirms the general opinion that SPECT is relatively accurate to 
differentiate between patients with IPD in an early stage and healthy controls. 
We were also able to confirm the general opinion that SPECT with presynaptic 
tracers is highly accurate to differentiate between patients with IPD and ET. 
Although SPECT with presynaptic tracers scored high accuracy in 
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differentiation between IPD and VP, conventional techniques like CT and MRI 
may still be necessary as additional diagnostic tools. This meta-analysis 
confirmed the generally accepted view that presynaptic tracers cannot 
distinguish between IPD and APS. However, we also found that SPECT with 
postsynaptic tracers is not very good at this. 
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Single Photon Emission Computer Tomography (SPECT) is one of the most employed techniques 
in the diagnostic work-up of idiopathic Parkinson’s disease (IPD). Despite of its widespread use, 
the exact diagnostic accuracy of this technique in parkinsonian syndromes remains controversial.  
 
Methods 
In this study we investigated the diagnostic accuracy of an initial 123I-ioflupane (FP-CIT) and/or 123I-
iodobenzamide (IBZM) SPECT to differentiate between IPD and other parkinsonian disorders. 248 
patients underwent a SPECT scan because of an as yet unclassified parkinsonian syndrome in our 
clinic between 2001 and 2006. Gold standard was the clinical diagnosis derived from the latest 
available clinical record, or, when this was not possible, a new complete physical and neurological 
examination by a blinded movement disorder specialist neurologist. Mean follow-up between 
SPECT and the latest clinical information was 18 months (range 3 months- 5 years).  
 
Results 
223 of the 248 patients were clinically definitely diagnosed after follow-up: IPD 127, atypical 
parkinsonian syndromes (APS) 27, essential tremor (ET) 22, vascular parkinsonism (VP) 16, drug-
induced parkinsonism (DIP) 5, doubt between IPD and APS 2, other diseases without 
dopaminergic involvement 24.  
The mean odds ratio (OR, 95% CI) for FP-CIT SPECT’s ability to distinguish between IPD and ET 
was 82 (11-674); between IPD and VP 61 (8-490); between IPD and DIP 33 (2-697) and between 
IPD and APS was 1 (0-4). The odds ratio for the IBZM SPECT tracer to differentiate between IPD 
and APS was 7 (2-17).  
 
Conclusions 
FP-CIT SPECT is accurate to differentiate patients with IPD from those with ET, and IPD from VP 
and DIP. The accuracy of both FP-CIT and IBZM SPECT scans to differentiate between IPD and 
APS is low. 
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Introduction 
Idiopathic Parkinson’s disease (IPD) is the second most common 
neurodegenerative disorder with a prevalence in industrialised countries of 
0.3% in the entire population and about 1% in people over 60 years of age.1 
The exact cause of IPD is still unknown, but the main pathological hallmark of 
the disease is the loss of dopaminergic neurons in the basal ganglia.2 
Diagnosis is based on clinical criteria.3 In most cases the diagnosis of IPD is 
straightforward when cardinal clinical signs and symptoms as bradykinesia, 
rigidity, resting tremor and postural instability are present.3 However, solely on 
clinical grounds it is, especially in the early stages, often difficult to differentiate 
IPD from other parkinsonian syndromes. Diseases resembling IPD in an early 
stage are diseases which might resemble early-stage IPD are atypical 
parkinsonian syndromes (APS, i.e. multiple system atrophy [MSA] and 
progressive supranuclear palsy [PSP]) or secondary parkinsonism (i.e. 
vascular parkinsonism [VP], drugs induced parkinsonism [DIP]) and essential 
tremor (ET).4-9 Since the prognosis and medical treatment are different in the 
various parkinsonian syndromes, an accurate and early diagnosis is essential 
for optimal counselling.  
Single Photon Emission Computer Tomography (SPECT) is widely used to 
visualise the integrity of the nigrostriatal dopaminergic system. SPECT with 
various tracers labelling presynaptic dopamine transporters (such as 
123I-ioflupane (FP-CIT)) has been shown to correlate with clinical severity and 
disease progression of IPD.10-14 The uptake of these radiotracers, however, has 
also to been shown to be decreased in the atypical parkinsonian syndromes 
(APS: i.e. MSA, PSP and DLBD).15-18 SPECT with tracers labelling 
postsynaptic dopamine receptors (such as 123I-iodobenzamide (IBZM)) have 
been used to differentiate IPD from APS.17,19,20 Some have suggested even 
that the combination of presynaptic SPECT and postsynaptic SPECT scan 
gives better discrimination between IPD and APS.17,21 Despite its widespread 
use, the exact diagnostic accuracy of these techniques in parkinsonian 
syndromes remains controversial.22-24   
In the present study we investigated the diagnostic accuracy in 248 patients in 
whom FP-CIT and/or IBZM SPECT scans were performed because of 
uncertainty on the diagnosis of their parkinsonian syndrome. 
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Patients and methods 
Subjects  
We see an estimated 250 new patients (primary and secondary referrals and 
requests for second opinions) with parkinsonism in our Neurology outpatient 
clinic each year, of which about 20% are referred for SPECT scintigraphy. 
Patients who did not undergo SPECT scanning were mainly patients 
presenting with a clear unequivocal diagnosis of their parkinsonism, and 
referrals who already had SPECT scintigraphy elsewhere.  
From February 2001 tot February 2006 301 patients with parkinsonism were 
subjected to a SPECT scan in our hospital. Fifty-three patients were excluded 
because they already had a clear diagnosis and underwent SPECT as part of a 
diagnostic work-up for a Deep Brain Stimulation procedure, where one wants to 
exclude diagnoses other than IPD. The included 248 patients all suffered an as 
yet unclassified parkinsonian syndrome.  
Depending on the clinical differential diagnosis of the neurologist a FP-CIT 
(n=80), an IBZM SPECT (n=38) or both scans (n=130) were performed.  
The study was approved by the University Hospital Maastricht Institutional 
Review Board and all patients who were re-examined clinically to reach a 
definite diagnosis gave informed consent. 
Fifty-nine percent of the 248 patients were male. The mean age was 65 years 
with a range from 21 to 96 years (standard deviation (SD) 11 years). The initial 
probable diagnosis of the neurologist before SPECT imaging was IPD in 125 
patients, APS (MSA, PSP or DLBD) in 41 patients, VP 9, ET 10 and DIP in 2 
patients. In 61 cases the initial probable diagnosis was solely defined as 
parkinsonism. For the clinical diagnosis after follow-up see Table 3.1. 
The mean Hoehn and Yahr score was 2.4 (range 1 to 5; sd 1.2). Of all patients 
37% were on dopaminergic drugs before they were referred for SPECT 
scanning.  
The mean duration of the complaints before SPECT imaging was 45 months 
(range 2 to 250; sd 45) and the clinical follow-up after the SPECT scan was at 
least 3 months with a mean (SD) of 18 (15) months. If a patient underwent both 
scans, the mean elapsed time between the FP-CIT and IBZM SPECT was 40 
days (range 1-1460; median 5; sd 178 days). 
Acquisition of clinical data and final clinical diagnosis 
Two investigators (AV, TN) checked each patient record and filled in a standard 
form. The investigators established a clinical diagnosis according to generally 
accepted clinical criteria.3,8,25-28 If the investigators did not reach consensus, or 
if the patient did not fulfil the accepted criteria for a final diagnosis, a movement 
disorder specialist neurologist (AW, WW) was asked for advice. In case of 
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persistent discussion, the movement disorder specialist could decide to contact 
the referring neurologist, to phone the patient or to ask the patient to visit the 
clinic for re-examination by a movement disorder specialist neurologist (AW, 
FV, WW). 
 




























64 (56 - 72) 44 ♀, 83 ♂ 2  (1 - 3) 30  (12 - 60) 16  (8 - 36) 7 
APS 
n=27 
67 (67 - 73) 14 ♀, 13 ♂ 3 (2 - 4) 23 (12 - 39) 13  (4 - 24) 8 
 
IPD or APS 
n=2 
59 (40 - 75) 2 ♀, 0 ♂ 1.5 (1 - 2) 48 (36 - 60) 20 (12 - 28) - 
ET 
n=22 
68 (62 - 74) 11 ♀, 11 ♂ 2 (1 - 2) 48 (27- 114) 20 (9 - 39) 2 
VP 
n=16 
73 (66 - 78) 3 ♀, 13 ♂ 3  (2 - 4) 24 (12 - 42) 7  (4 - 29) 4 
DIP 
n=5 
60 (58 -68) 2 ♀, 3 ♂ 3  (2 - 4) 48 (19 - 72) 12 (4 - 33) 1 
other 
n=24 
65 (53 -78) 13 ♀, 11 ♂ 3 (2.5 - 3) 36 (11 - 63) 7  (4 - 24) 2 
inconclusive 
n=25 
68 (57 - 77) 12 ♀, 13 ♂ 2 (2 - 4) 36 (13 - 72) 3  (1 - 20) 6 
total 
n=248 
67 (58 - 74) 100 ♀, 148 ♂ 2  (2 - 3) 36 (12-60) 13 (5 - 27) 30 
IPD: idiopathic Parkinson’s disease; APS: atypical parkinsonian syndromes; ET: essential tremor; 
VP: vascular parkinsonism; DIP drug induced parkinsonism; n: number of subjects; IR: interquartile 
range; H&Y: Hoehn and Yahr.  
* Hoehn and Yahr scores are formally restricted to IPD, but we have assessed these also in the 
other patient groups to facilitate comparison between these groups. 
 
SPECT 
In this study FP-CIT (General Electrics Health, Eindhoven, The Netherlands) 
was used to visualise the integrity of the presynaptic dopaminergic system and 
IBZM (General Electrics Health, Eindhoven, The Netherlands) to visualise the 
postsynaptic dopamine receptors. Medication which could interfere with the 
radiotracer was stopped at least five half-life times before the SPECT scan was 
made. SPECT scans were performed with a triple head camera (MultiSPECT3, 
Siemens, Ohio, USA) equipped with high-resolution collimators. A semi-
automatic template model programme was used to calculate the ratios between 
left striatal and right striatal and occipital regions, respectively. Total time of 
acquisition was 30 minutes (45 seconds per frame for 40 views per detector), 
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zoom factor: 1.00 and the matrix size: 128 x 128. Filtered back-projection 
acquisition was performed.29 
Images were filtered using a Butterworth filter with a cut-off value of 0.4-0.5 and 
an order of 5. The ratios were corrected using Alderson's brain phantom with 
known activities in the caudate nucleus and putamen. A binding of two 
standard deviations (sd) below or above healthy controls was considered as 
abnormal (FP CIT 8.25, sd 1.85 for putamen and 7.76, sd 1.77 for caudate 
nucleus. IBZM for striatum 3.58, sd 0.18). The scans were analysed by a 
nuclear specialist blinded for the clinical diagnosis.  
Data analysis 
Descriptives are presented as median and inter-quartile ranges, unless 
otherwise specified. To determine the accuracy to differentiate between IPD, 
ET and other parkinsonian syndromes sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV) and diagnostic odd’s ratio (OR) 
with its 95% confidence intervals (95% CI) were calculated. This was 
determined for the initial probable diagnosis of the neurologist, FP-CIT- and 
IBZM SPECT results and the combination of both. Finally, we calculated the 
additional value of judging the caudate nucleus FP-CIT binding ratios in 
comparison with only putamen FP-CIT binding.  
All descriptive analyses were made with software SPSS 11.0 for Windows 
(SPSS, Chicago, IL) and the accuracy parameters were determined with 
Stata/SE9. 
Results 
In 154 of the 248 cases the investigators reached consensus and were certain 
enough to make a final diagnosis from the clinical records alone, according to 
generally accepted criteria.3,8,25-28 Of the remaining ninety-two patients five 
patients had died, two could not be traced and two lived outside the district.  
In twenty-seven of the eighty-five patients still without final diagnosis the 
referring neurologist was phoned and in five cases the patient, to obtain 
information about the follow-up period. Finally fifty-three patients were asked to 
visit for re-examination. Forty-five of these gave informed consent. Most 
important reasons for refusing consent for re-examination were decreased 
mobility, living in a nursing home and anxiety. Figure 3.1 presents a flowchart 
of patients in- and excluded from the analysis. 
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Figure 3.1 Flowchart  
 n: number of patients; RN: resident in neurology; MD: movement disorder specialist. 
 
In 223 of the 248 patients the final clinical diagnosis after follow-up was known: 
IPD in 127 patients, APS in 27 (n=17 MSA, n=8 PSP, n=2 DLBD), unclear but 
IPD or APS in 2, ET in 22, DIP in 5 and VP in 16 patients. Of the sixteen 
patients diagnosed with VP six underwent MRI-scan and ten underwent CT-
scan. In ten of the sixteen patients vascular lesions were visible in typical 
places according the criteria formulated by Zijlmans et al.26 All the other 
patients had suffered at least one stroke, but their vascular lesions on CT or 
MRI-cerebrum were at non-typical places like capsula interna, parietal or 
occipital lobe. However, all patients had parkinsonism and a time relationship 
(acute or delayed) between stroke and parkinsonism or in case of multiple 
subcortical white matter lesions an insidious onset of parkinsonism and no 
exclusion criteria for VP.  
Twenty-four patients were diagnosed with another diagnosis without 
dopaminergic involvement (i.e. no clear indication of parkinsonism [n=8], 
psychogenic parkinsonism [n=1], normal pressure hydrocephalus [n=2], 
Alzheimer’s disease [n=4], autonomic failure [n=1], corticobasal degeneration 
[n=1], frontotemporal dementia [n=1], alcohol abuse [n=1], Meige syndrome 
n=248











Asked for informed consent for 
re-examination
n=32 / 94 
Phone call







n=25 no clinical diagnosis 
n=2 doubt between PD or APS
n=221 clear clinical diagnosis
n=9 / 94
Not asked for informed consent
-2 outside district
-5 died without diagnosis
-2 not retracedn=45 / 53 informed consent
n=42 / 53 
clear diagnosis
n=11 / 53  
diagnosis unclear
Thesis_Vlaar_v3.pdf   53 26-6-2009   9:23:27
54⏐Chapter 3 
[n=1], Niemann-Pick syndrome [n=1], familiar dominant tremor [n=1], dystonia 
[n=1], inconclusive but no dopaminergic involvement [n=1]).  
 
The absolute tracer binding rates of FP-CIT and IBZM SPECT scans for each 
parkinsonian subgroup are shown in Figure 3.2A and 3.2B. From these figures 
one sees that the median of the absolute putamen FP-tracer binding ratios in 
the IPD group as well as in the APS group is decreased compared with for 
















Figure 3.2 A. Box plot of the median FP-CIT binding ratios and interquartile ranges for each 
subgroup 
 B. Box plot of the median IBZM binding ratios and interquartile ranges for each 
subgroup 
 IPD: idiopathic Parkinson’s disease, APS: atypical parkinsonian syndromes,  
 VP: vascular parkinsonism, ET: essential tremor, DIP: drug induced parkinsonism. 
 
The striatal IBZM binding ratios in the APS group for example are decreased in 
comparison with the IPD group. However, discrimination between the groups is 
difficult, because of a large overlap in ranges.   
Besides the diagnostic accuracy for the different subgroups of patients we also 
determined the accuracy of SPECT and the initial probable diagnosis of the 
clinician for each individual patient separately. A summary of the results of 
presynaptic and postsynaptic SPECT scanning for all patients in the different 
subgroups of the final diagnoses (IPD, ET, VP and APS) is given in Table 3.2. 
From this table the numbers of true positives, true negatives, false positives 
and false negatives are derived to calculate the sensitivity, specificity, PPV, 
NPV and mean odd’s ratio (OR) for the differentiation between IPD versus ET, 
IPD versus VP, IPD versus DIP and IPD versus APS. An overview is given in 
Figure 3.3. 
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As shown in Figure 3.3, FP-CIT SPECT’s ability to distinguish between patients 
with IPD and patients with ET is high. FP-CIT scans are also relatively accurate 
to differentiate patients with IPD from those with VP or DIP. In these three 
situations sensitivity is 80% and specificity 95-100%. With a positive predictive 
value (PPV) of above 95% an abnormal FP-CIT SPECT scan is highly 
predictive for IPD. However, the negative predictive value (NPV) of a normal 
SPECT for ET, VP or DIP is low (15-48%). This is a consequence of the fact 
that not only twenty of the twenty-one ET patients and all fourteen VP and four 
DIP patients had a normal FP-CIT SPECT scan, but also twenty-two of the 112 
IPD patients.   
The addition of IBZM SPECT only leads to a small (not statistically significant) 
increase in accuracy in the discrimination between patients with IPD from VP 

















Figure 3.3 Accuracy of FP-CIT SPECT, IBZM SPECT, the combination of FP-CIT & IBZM 
SPECT, and the initial diagnosis of the clinician to predict clinical diagnosis after 
follow-up. 
IPD: idiopathic Parkinson’s disease, ET: essential tremor, VP: vascular parkinsonism, 
DIP: drug induced parkinsonism, APS: atypical parkinsonian syndromes (i.e. MSA, 
PSP, DLBD), PPV: positive predictive value, NPV: negative predictive value, clinician: 
initial diagnosis of the clinician, n: number of subjects. 
a = True positives: IPD patients with decreased or increased IBZM binding ratios.      
 True negatives: ET patients with normal IBZM SPECT. 
b =  True positives: ET, VP and DIP patients with normal FP-CIT and normal (or 
decreased) IBZM binding ratios.  
 True negatives: IPD patients with all other SPECT combinations. 
c =  True positives: IPD patients with normal or increased IBZM binding ratios.  
 True negatives: VP, DIP and APS patients with decreased IBZM binding ratios. 
d =  True positives: APS patients with the combination normal FP-CIT and decreased 
IBZM binding or a combination of decreased FP-CIT as well as decreased IBZM 
binding ratios. 




(95% CI) sensitivity specificity
82 80% 95%PD versus ET FP-CIT
1 59% 46%(N= 127, N= 22) IBZM (a)
17 92% 58%FP-CIT & IBZM (b)
12 76% 80%clinician
61 100%        39%PD versus VP FP-CIT
8 80% 67%(N= 127, N= 16) IBZM (c)
110 92% 90%       FP-Cit & IBZM (b)
5 76%clinican
36 80% 100%PD versus DIP FP-CIT
2 80% 50%(N= 127, N= 5) IBZM (c)
56 92% 100%       FP-Cit & IBZM (b)
3 76% 50%clinician
1 80% 24%PD versus APS FP-CIT
7 80% 62%(N= 127, N= 27) IBZM (c)
8 79% 69%FP-Cit & IBZM (d)
3 76% 47%clinician
S cifi ity PPV NPV
           99%          48%IPD versus ET 
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           92%          58%
           98%          22%
80%          100%          100%        39%IPD versus VP
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56⏐Chapter 3 
Table 3.2 SPECT results for each patient subgroup. 
IPD: idiopathic Parkinson’s disease, APS: atypical parkinsonian syndromes, ET: essential tremor, 
VP: vascular parkinsonism, DIP: drug induced parkinsonism; = : normal FP-CIT or IBZM tracer 
binding ratios; ↓: tracer binding of 2 sd below healthy controls; ↑: tracer binding of 2 sd above 
healthy controls; none = SPECT was not performed; n: number of subjects.  
* APS: atypical parkinsonian syndromes (i.e. multiple system atrophy, progressive supranuclear 
palsy and diffuse Lewy body disease).  
FP-CIT tracer binding was decreased in 7 of the 9 MSA, 4 of the 6 PSP and both DLBD patients; 




The differentiation between IPD and APS (PSP, MSA and DLBD) by both FP-
CIT and IBZM SPECT scored relatively low accuracy. Specificity and NPV are 
low, as 62% of the APS patients and 20% of the IPD patients have lowered 
striatal IBZM tracer binding. The combination of FP-CIT and IBZM SPECT 
scored only minimally increased accuracy. See Figure 3.3. 
We expected APS patients to have a more diffusely decreased striatal FP-CIT 
binding rate in comparison to patients with IPD, showing mainly a selective loss 
of tracer binding in the putamen: we calculated the additional value of judging 
the FP-CIT uptake in the caudate nucleus in comparison with only the uptake in 
the putamen. The FP-CIT binding of the caudate nucleus was decreased 
(>2 sd below the mean of the healthy controls) in fourteen of the 127 IPD 
patients with IPD, one of the fifteen MSA patients and in two of the nine PSP 
patients and in none of the three patients with DLBD. All patients with low 
caudate FP-CIT binding ratios also had decreased putamen FP-CIT binding. 
So with an odd’s ratio (95% CI) of 1 (0.3-4) judging of the FP-CIT tracer binding 
IBZM Final clinical diagnosis  FP-CIT 
= ↑ ↓ None 
= 22   4   9   1   8 
↓ 90 21 19 13 37 
IPD n=127 
None 15   8   5   2   - 
=   4   -   -   4   - 
↓ 13   2   3   7   1 
APS*     n=27 
 
 None 10   3   2   5   - 
IPD/APS  n=2 ↓   2   -  1 -   1 
= 20   5   5   2   8 
↓   1   -   -   -   1 
ET     n=22 
 
 None   1   1   -   -   - 
= 14   2   1   7   4 VP     n=16 
 None   2   1   -   1   - 
=   4   1   -   1   2 DIP     n=5 
 None   1   1   -  -   - 
= 16   5   -   1 10 
↓   4   2   -   1   1 
Other     n=24         
 
None   4   1   3   -   - 
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in the caudate nucleus does not lead to an increase of accuracy to differentiate 
between IPD and APS. 
In the present study differentiation among the different atypical parkinsonian 
syndromes MSA, PSP and DLBD was not accurate with FP-CIT SPECT: seven 
of the nine MSA patients, as well as four of the six PSP patients and two of the 
three DLBD patients had abnormal FP-CIT SPECT scan results. IBZM SPECT 
could not discriminate between patients with MSA and PSP: IBZM binding 
ratios were decreased in ten of the fourteen MSA and in six of the nine patients 
with PSP. All three patients with DLBD had a normal to high striatal IBZM 
binding.   
Finally, the diagnostic accuracy of FP-CIT and/or IBZM SPECT in this study 
was always higher than the initial probable diagnosis by the clinician before the 
SPECT. See also Figure 3.3. 
Discussion 
To our knowledge this is the largest retrospective study on the diagnostic value 
of the FP-CIT and IBZM SPECT scan in patients with parkinsonian symptoms 
of unknown origin. In our study we focused on the diagnostic delineation of IPD 
vs. ET, VP, DIP and APS.  
Using FP-CIT SPECT to differentiate IPD from ET we found a high odd’s ratio 
of 82 for overall diagnostic accuracy. In this diagnostic situation the positive 
predictive value was 99%, and the negative predictive value 48%, so we 
conclude that FP-CIT SPECT scans are sensitive in detecting IPD, but not 
capable in excluding IPD when negative. This is partly inherent to our study 
design: the low number of patients with other diseases than IPD obviously 
leads to a low negative predictive value. These results are in accordance with 
data from a recent meta-analysis.30 
A possible explanation of the finding that twenty-two of 112 IPD had normal 
FP-CIT scans is that SPECT can be normal in early stages of disease.10-14 In 
our study population twelve of the 248 patients underwent a second FP-CIT 
SPECT at various time points; in these cases accordance with the ultimate 
clinical diagnosis rose from four to ten patients (data not shown).  
Another explanation for the relatively high number of false negative IPD 
patients is the quantitative analysis of the SPECT scans. We recalculated the 
accuracy to differentiate patients with IPD from those with ET for visual 
qualitative judgement: sensitivity increased from 80 to 94%, NPV from 48 to 
71%, specificity and PPV stayed unchanged. This is in accordance with recent 
data from  Marshall et al.31 
All patients with VP had a normal FP-CIT SPECT binding. IBZM SPECT scan 
was normal to high in four and decreased in eight patients with VP. Our results 
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accord with the study by Tzen et al.32, who found normal presynaptic 
radiotracer binding in VP. However, Plotkin and Lorberboym found VP patients 
with decreased both presynaptic and postsynaptic radiotracer bindings.33-35 
These conflicting results probably reflect the controversy surrounding the 
diagnostic criteria of VP.26 Future studies in this field should include well-
defined patient populations and a brain MRI scan to give additional information 
about vascular lesions in the basal ganglia and within basal ganglia-cortical 
projections. Theoretically FP-CIT and IBZM binding is expected to be normal in 
VP patients, when clear vascular lesions in the basal ganglia have been 
excluded. Moreover, SPECT scans in these cases should be interpreted 
visually, to appreciate the abnormal pattern of receptor uptake that is probable 
typical for VP. 
Our five DIP patients had normal FP-CIT scans. This accords with the studies 
by Burn and Lavalaye.36,37 Hypothesizing that DIP is primarily a post-synaptic 
problem, one would expect IBZM SPECT to yield lower binding ratios. We 
could not confirm this as we found two normal and one abnormal IBZM SPECT 
in this population.38 As we could not retrieve information on the medication at 
the moment of the scan, we do not feel comfortable to draw firm conclusions 
from this small sample. 
Using SPECT scans to delineate IPD from APS gave disappointing results in 
our study for FP-CIT, IBZM as well as the combination of both SPECT scans. 
With only 62% of the APS patients having decreased striatal postsynaptic 
tracer binding, but also 20% of the IPD patients, the specificity and negative 
predictive value of IBZM are relatively low. 
The literature on this is somewhat conflicting. There are eight studies in which 
postsynaptic SPECT is fairly accurate, and these found postsynaptic receptors 
mainly affected in APS and normal or up-regulated in IPD.39-46 Schulz, who 
investigated thirty-two MSA patients, found similar results as in our meta-
analysis: only a significant loss in 63% of the patients with IBZM.19 However, a 
problem is that IPD, especially in later stages, can give low striatal postsynaptic 
radiotracer binding too. A study by Schwarz et al. confirmed our finding that 
reduced postsynaptic tracer binding makes IPD unlikely but does not 
completely exclude IPD.47  
A major shortcoming of our study is that we did not re-examine all patients, 
blinded for the SPECT results. We only invited patients of whom the clinical 
diagnosis could not be derived from the clinical records or the referring 
specialist. We tried to reduce bias by having two independent observers read 
the clinical records critically, to check if the patient fulfilled the accepted clinical 
criteria of one of the parkinsonian disorders. In any case of doubt the patient 
was invited for re-examination. Nevertheless, all diagnoses that were not 
checked by an independent, blinded physician may still be biased in favour of 
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accurate prediction by the SPECT, as these data were known by the treating 
physician. 
Finally, a clinical follow-up is still only a surrogate gold standard.23 
Clinicopathological studies show that 2-25% of the patients with IPD are 
classified incorrectly in the final stage of their disease, even by specialists in 
movement disorders.4-6 Comparisons between functional dopaminergic imaging 
and the ultimate gold standard, autopsy-proven IPD, are almost non-
existent.48,49 Although practically and ethically difficult, only post-mortem 
analysis will conclusively prove whether or not the clinical diagnosis of IPD was 
correct in those cases. 
In summary, in these 248 patients with initially unclassified parkinsonism, 
roughly 76% of the ordered FP-CIT scans accurately predicted the final clinical 
diagnosis after follow-up. In 10% of the patients a clinical diagnosis after follow-
up could not be made.   
To differentiate patients with IPD from ET, VP and DIP the FP-CIT SPECT has 
an additional value above the initial clinical diagnosis. However, because the 
relative high number of false negative FP-CIT SPECT scans in IPD patients a 
normal FP-CIT scan does not exclude IPD. 
To differentiate patients with IPD from those with APS, both FP-CIT and IBZM 
SPECT scan have no additional value above the initial probable diagnosis of 
the clinician who ordered the SPECT scan. 
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Transcranial duplex scanning (TCD) of the substantia nigra (SN) is increasingly used to diagnose 
idiopathic Parkinson’s Disease (IPD). Up till now 70 diagnostic studies have been published, not 
only on investigation of the SN, but also of the lenticular nucleus (LN) and the Raphe nuclei (RN).  
 
Methods 
We systematically reviewed all diagnostic TCD studies in parkinsonian patients up to June 2008.  
 
Results 
We found 35 eligible studies. Of the 1534 IPD patients investigated in the 35 studies 200 (13%) 
had an inconclusive SN-TCD. An increased echointensity of the SN was seen in 1167 (87%) of the 
1334 IPD patients, 276 (12%) of the 2340 healthy controls and in 41 (30%) of the 138 patients with 
an atypical parkinsonian syndrome (APS). 
On the contrary, a pathological LN-TCD was found more often in APS patients (79%) than in IPD 
patients (23%) and healthy controls (6%). A decreased echointensity of the RN was found more 
often in depressed (46%) than in non-depressed IPD patients (16%). 
 
Conclusions 
SN-TCD accurately differentiates between patients with IPD and healthy controls, but not between 
patients with IPD and APS. LN-TCD is only moderate accurate to delineate IPD from APS, but 
combinations of SN- and LN-TCD may be more promising. RN-TCD has only marginal diagnostic 
accuracy in diagnosing depression in IPD and non-IPD patients. Before TCD can be implicated 
more research is needed to standardise the TCD technique, to investigate TCD in non-research 
settings and to determine the additional value of TCD in comparance with already clinical 
implicated techniques like SPECT imaging. 
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Introduction 
The diagnosis of idiopathic Parkinson’s disease (IPD) and other parkinsonian 
disorders, such as multiple system atrophy (MSA), progressive supranuclear 
palsy (PSP) or vascular parkinsonism (VP), is based on clinical criteria.1-5 In 
patients with the essential clinical symptoms such as bradykinesia, rigidity, and 
resting tremor, diagnosis of IPD is usually straightforward, however early in the 
disease it can be difficult to differentiate among the various parkinsonian 
disorders purely on clinical grounds. In the early stages of the disease it can 
also be difficult to differentiate a parkinsonian tremor from an essential tremor 
(ET). The gold standard for the diagnosis of IPD is post-mortem 
neuropathological examination. Neuropathological studies have shown that 
even at end-stage disease the clinical diagnostic accuracy for IPD varies 
between 75–90%, with MSA and PSP accounting for most false positives.3,6,7 
As prognosis and management differ considerably among the various 
parkinsonian syndromes an early correct diagnosis is of cardinal importance. 
Several procedures and combinations of different techniques have been 
proposed to diagnose IPD: olfactory- and neuropsychological tests, 
biomarkers, DNA tests and functional imaging with MIBG scintigraphy, Positron 
Emission Tomography (PET) or Single Photon Emission Computer 
Tomography (SPECT).8-12  
The SPECT scan is presently the most widely used diagnostic test for 
parkinsonian syndromes. Nevertheless, its diagnostic accuracy is still 
debated.13 
A recently developed diagnostic tool is transcranial duplex scanning (TCD). 
Using this technique Becker and colleagues were the first to report 
hyperechointensity of the substantia nigra (SN) in patients with Parkinson’s 
disease.14 Several studies found that 90% of IPD patients show this SN 
hyperechointensity, which is presumably caused by an increased iron 
content.14-19 Only in about 9% of healthy individuals this increased 
echointensity is found. TCD can also visualise the Raphe Nuclei (RN) and the 
Lenticular Nucleus (LN). The echointensity of the LN is postulated to 
differentiate between IPD and other parkinsonian syndromes. Differences in 
echointensity of  the RN are reported to be associated with depression in 
patients with or without parkinsonism.  
Since the first report, numerous studies on the diagnostic accuracy of TCD in 
parkinsonian syndromes have been published, including a systematic review, 
which considered all papers published before 2003.20 Since several more 
research groups started TCD and the majority of the papers on this subject is 
published after 2003 we did an updated systematic review. 
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Technical aspect 
TCD is a non-invasive, fast, and patient-friendly technique, which is employable 
at the bedside. Mostly, the technique is applied for the examination of the 
intracranial vessels.21  
Since 15 years TCD is also used to visualise other brain structures, such as the 
mesencephalon.22 With TCD the echointensity of various brain structures can 
be studied. Changes in echointensity seem to reflect changes in tissue 
impedance due to glial reaction, alterations in cell density and iron content.14,16 
TCD is performed by placing the ultrasound transducer on the temporal bone in 
front of the ear. In most patients (approximately 80-90% 23) the temporal bone 
window is appropriate to acquire a 2-dimensional image of the intracranial 
structures. Typically, a low-frequency phased array transducer is used with a 
frequency range of 1-4 MHz being focussed at a depth of 6-8 cm. The depth 
range ideally is chosen to allow for the visualisation of the contralateral side of 
the skull. The mesencephalon becomes visible as an echolucent, butterfly-
shaped structure, surrounded by the basal cisterns characterised by a higher 
echointensity. Normally, the mesencephalon has a predominantly homo-
geneous aspect; in most cases a small hyperechogenic stripe can be discerned 
within the area of the substantia nigra (SN). However, in up to 90% of the IPD 
patients the SN is clearly visible due to its large hyperechointense area as 
compared to the surrounding brainstem tissue.  
Other brain structures like the lenticular nucleus (LN) and the Raphe Nuclei 
(RN) can be visualised by TCD as well. The LN are visible in an axial section at 
the level of the thalamus. The LN is only discernable when its echointensity is 
abnormally increased compared with the surrounding brain parenchyma. An 
increase in echointensity of one or both of the LN might differentiate between 
APS and IPD.20,24,25 
Finally, the RN are visible in the same axial section as the SN. Normally the RN 
are visible because they are hyperechointense in comparance with the 
adjacent brainstem parenchyma. A decrease in the echointensity of the RN is 
reported to be associated with depression in both patients with and without 
parkinsonism.23,26 
 
Different scorings systems are used by different research groups, however the 
various methods agree on the main points. Generally the echointensity of the 
SN is evaluated by ipsilateral TCD examination. The SN-TCD is scored 
abnormal if the SN is pathological at least at one side (uni- or bilateral).  
The echointensity of the SN can be judged qualitatively or quantitatively. In the 
qualitative way the SN can be scored by judging whether or not a typical 
hyperechointensity in the area of the SN is present. Most investigators, 
however, did use the quantitative method: measuring the area of 
hyperechointensity by encircling the hyperintense area. Normal values depend 
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on the ultrasound device which is used, but approximately an area of <0.2 cm2 
is defined as normal and an area of >0.25 cm2 as pathological.17,18,27 For the 
quantitative method excellent intra- and inter-observer agreement has been 
reported with kappa values of 0.80-0.85.16,18,28-30 The LN as well the RN are 
always scored qualitatively (hyper-, iso-, or hypoechointense). 
Systematic review of the literature 
We systematically reviewed the literature by searching Ovid Medline databases 
and cross-referenced clinical trials published in this field until June 15 2008. 
Both, medical subjects headings (MESH) terms and text words were used: 1) 
ultrasound, sonography or duplex scanning, 2) substantia nigra (SN), Raphe 
nuclei (RN), lenticular or lentiform nucleus (LN) and 3) parkinsonian, 
parkinsonism, IPD, MSA, PSP, ET or APS.  
Two investigators (AV, AB) screened the full text of potentially relevant articles. 
Papers were only included into the review if information on the following items 
was supplied: 1) patient population, 2) ultrasound system applied, 3) TCD 
procedures of assessment and quantification of echointensity, 4) number of 
true positive, false positive, true negative and false negative TCD results with 
the clinical diagnosis as the gold standard.  
Additionally, we mentioned the number of sonographers, if the sonographers 
were blinded for the clinical diagnosis and if the included patients were 
diagnosed or yet undiagnosed.  
 
Papers were excluded if: 1) the full article was not available, 2) the language 
was other than English or German, 3) brain structures other than the SN, LN or 
RN were studied, 4) and if studies did not include patients with neuro-
degeneratieve parkinsonism (IPD, APS i.e. MSA, PSP, diffuse Lewy body 
disease, corticobasal degeneration), patients with secondary parkinsonism (ET, 
VP, drug-induced parkinsonism [DIP]) or patients with ET, healthy controls and 
patients with depression. 
Data extraction and analysis 
The studies were sorted into three categories, either studying the SN, LN or the 
RN. The number of patients with a normal and abnormal echointensity of, 
respectively, the SN, LN and RN are given in Tables 4.1-4.3. We used cut-off 
points defined by the original authors. A TCD was considered inconclusive if 
either there was an inappropriate temporal bone window or the sonographer 
judged the target structure as borderline hyperechointense. Sensitivity and 
specificity were calculated for each brain structure and patient category 
separately. The following patient categories were studies: 1) neuro-
degenerative parkinsonism A) IPD and B) APS (MSA, PSP, diffuse Lewy body 
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disease, corticobasal degeneration), 2) patients with non-degenerative forms of 
parkinsonism i.e. vascular, drug-induced, infectious, 3) patients without 
parkinsonism (ET, healthy controls).  
Results 
Overview 
The Medline search resulted in 68 hits. We found no additional clinical studies 
searching the Cochrane and Embase databases. Cross-reference searching 
added another four relevant trials. Of these 72 studies we excluded 37. The 
reasons for exclusion for as follows: of eighteen studies only an abstract 
existed, two articles did not fulfil the language criteria, ten papers did not deal 
with the diseases mentioned above, and in seven articles we were not able to 
derive the number of true positive, false positive, true negative and false 
negative findings. 
In the 35 trials left, either one or several brain structures (SN, LN and RN) were 
investigated. In total, thirty-one dealt with the SN, ten with the LN and seven 
with the RN (See Tables 4.1, 4.2 and 4.3).   
TCD of the substantia nigra  
Results are given in Table 4.1. Only twenty-three of the thirty-one studies 
mentioned the percentage of patients in which the authors experienced 
difficulties judging the SN-TCD, either because of an inappropriate temporal 
bone window or an atypical form of the hyperechointensity. The percentages in 
which the SN-TCD was inconclusive ranged from 0 to 64%.  
In the majority of cases the SN-TCD was regarded as abnormal if the SN 
showed a pathological signal at least at one side. However, some authors 
calculated the mean of both sides.31-33 Mostly, the area of increased signal 
intensity was measured to estimate whether the SN was normal or not.  
The incidence of a pathological SN-TCD varied remarkably between the 
different parkinsonian syndromes as shown in Table 4.1. Of the 1334 IPD 
patients 1167 (87%, range 48-100%) had an increased echointensity of the SN. 
In patients with APS this hyperechointensity was seen less frequently, namely 
in forty-one of the 138 (30%; range 0-100%). In ET, VP and DIP the prevalence 
of a hyperechointense SN was even lower: thirteen of the 112 (12%) ET 
patients, six of the thirty (20%) VP patients and in none of the three DIP 
patients. In healthy controls SN hyperechointensity was found in only 276 of 
the 2340 (12%, range 0-20%) individuals. 
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TCD of the lenticular nucleus  
Results are given in Table 4.2. The investigators of all ten studies mentioned 
the percentage of patients in which they had difficulties to judge the 
echointensity of the LN. The percentages in which the LN-TCD was 
inconclusive ranged from 0 to 24%. Of the 150 APS patients 119 (79%; range 
72-88%) had an increased echointensity of the LN. In IPD patients this 
hyperechointensity was seen less often, namely in 112 of the 493 (23%, range 
11-64%) patients, with the remarkable exception of demented IPD patients: 
64% of these had a pathological LN-TCD.34 In healthy controls this finding was 
seen in only six of 94 subjects (6%, range 0-11%).  
TCD of the Raphe nuclei  
Results are given in Table 4.3. In all seven studies the percentage of patients 
with an inconclusive RN-TCD was mentioned and ranged from 0 to 40%. Fifty-
one of the 111 depressed IPD patients (46%, range 35-89%) had a decreased 
echointensity of the RN in contrast to twenty-three of the 147 non-depressed 
IPD patients (16%, range 0-21%). In patients without IPD this difference was 
more pronounced: in depressed patients without IPD a decreased 
echointensity of the RN was much more common than in non-depressed 
healthy controls: 71% (range 53-100%) versus 5% (range 0-9%), respectively. 
Discussion 
In this review we included thirty-five papers on the diagnostic use of TCD in 
parkinsonian syndromes. The results are discussed separately for: A) the TCD 
technique in general, B) TCD of the substantia nigra, C) the lenticular nucleus, 
D) the Raphe nuclei.  
A. The TCD technique in general 
Studying the literature we found the following differences in TCD technique:  
1) Different research groups use different transducers, different measuring 
methods and cut-off points of normal values, causing variety in sensitivity and 
specificity. To compare the results of these different studies, we applied a 
simplified semi-quantitative scoring system to the original data: abnormal, 
normal, or inconclusive. Consequently, lower sensitivity and higher specificity 
values were obtained than compared to the ones originally reported.  
2) We can not rule out that the same patient(s) that were used in one particular 
study were included in other studies of the same research group, i.e. that there 
is an overlap in patients.  
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B. TCD of the substantia nigra 
Of the 1167 IPD patients examined in thirty-one different clinical studies, 
approximately 90% had an increased echointensity of the SN. The sensitivity 
as compared with the final clinical diagnosis varied from 48 to 100%. The wide 
range can be explained by the different patient population under study, the use 
of various transducers and scorings methods by the different investigators.  
The incidence of a pathological SN-TCD in patients with APS was considerably 
lower than in patients with IPD. Yet, the range was very large between studies 
and also depended on the subtype of APS. All eleven patients with diffuse 
Lewy body disease and seven of the eight patients with corticobasal 
degeneration had a positive SN-TCD.34-39 A positive SN-TCD seemed to be 
more common in PSP (30%, range 8-47%) than in MSA (17%, range 
6-25%).15,25,38-40 
In all patients with APS, the number of inconclusive TCD examinations was 
higher than in patients with IPD. This finding was mostly attributable to 
difficulties in the interpretation of the ultrasound image and rarely due to an 
inappropriate bone window.  
In 12% of 2340 healthy controls SN hyperechointensity was found, suggesting 
a rather large number of false-positive findings. However, there is some 
evidence that the SN hyperechointensity in healthy controls is related to a slight 
motor impairment.41 Additionally, earlier studies showed that  PET or SPECT 
scans are also abnormal in up to 60% of the asymptomatic patients with an 
abnormal TCD.17,18,42,43,44 Long-term follow-up studies are currently underway 
to evaluate if these asymptomatic subjects with an abnormal SN-TCD will 
develop IPD. Furthermore, from literature there is indeed some evidence to 
suggest that a subset of ET patients is predisposed to developing IPD, possible 
explaining the fact that 12% of the ET patients had an abnormal SN-TCD.45  
C. TCD of the lenticular nucleus 
It appears that hyperechointensity of the LN is found quite often in APS (79%), 
but considerably less often in IPD (23%) and healthy controls (6%). These 
findings suggest that TCD of the LN solely will not allow for the discrimination 
between IPD and APS in an individual patient, given the relatively low positive 
and negative predictive values. However, when combining the results of 
different insonated brain structures, the diagnostic accuracy could be improved 
considerably. An increased echointensity of the SN and a normal echointensity 
of the LN is strongly suggestive for the diagnosis of IPD.23,25,46,47 On the 
contrary, a normal SN echointensity and an increased intensity of the LN 
indicates MSA or PSP. Furthermore, a dilation of the third ventricle or the 
frontal horn is postulated to be a predictor of PSP.40 However, these results 
were obtained with post-hoc analyses and their definitive diagnostic value 
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remains to be determined in a long-term follow-up study with an ‘intention-to-
diagnose’ principle. 
D. TCD of the Raphe nuclei  
Seven retrospective studies have been published about the difference of RN 
echointensity between IPD patients and controls with and without depression. 
Decreased RN echointensity was found more often in depressed patients 
(71%) than in healthy controls without depression (5%). Similarly, decreased 
RN echointensity was more common in IPD patients with a depression (46%) 
than in IPD patients without depression (16%).  
Although the diagnostic accuracy of RN-TCD seems to be fairly high in non-
IPD patients, RN-TCD is considerably less accurate in patients with IPD. 
Furthermore, the percentage of patients with doubtful findings or slightly 
decreased echointensity in the latter group is surprisingly high, with a maximum 
of 40% in one study.48 
Conclusion 
Compared to an earlier review considering the literature available until 2003, 
our present up-to-date review confirms the high diagnostic accuracy of SN-
TCD to differentiate patients with IPD from patients with ET and healthy 
controls. This accuracy is less for differentiating patients with IPD from those 
with APS.23 The diagnostic value of LN-TCD and RN-TCD appears to be lower 
than previously assumed.  
We identified several methodological issues: lack of standardized TCD 
techniques, normal values and scoring systems, and the high percentage of 
subjects with an inconclusive TCD. More research is needed, especially in 
patients with as yet undefined parkinsonism. Moreover, these studies should 
ideally include neuropathological post-mortem investigation, or at least 
comparison with follow-up examinations and accepted techniques as SPECT 
or PET.49,50 Without these issues, the clinical significance of SN-TCD would not 
be established. 
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To establish the inter-observer and intra-transducer reliability of “on-line” and “off-line” assessment 
of substantia nigra (SN) and Raphe nuclei (RN) by transcranial duplex scanning (TCD) in a mixed 
study population.   
 
Setting 
Out-patient neurology department of the University Hospital Maastricht 
 
Subjects 
In total 24 subjects were investigated: 9 patients with idiopathic Parkinson’s disease, 10 with 
parkinsonism from yet unclear origin, 1 with essential tremor and 4 healthy volunteers. 
 
Design 
Each patient was assessed four times by two independent experienced sonographers using two 
different ultrasound devices: SONOS 5500 and iU22; both Philips, Eindhoven, The Netherlands. 
The echointensity of the SN is evaluated qualitatively and quantitatively and the RN only 
qualitatively.   
1) In the “on-line” assessment we determined:  
A) the inter-observer agreement of the four possible combinations 
B) the intra-observer agreement of both sonographers using two different ultrasound systems.  
2) In the “off-line” assessment a third sonographer re-examined the stored images. We determined 
the inter-observer agreement of the third sonographer with the “on-line” assessment of the other 2 
sonographers. Cohen’s k value was calculated for the agreement.  
 
Results 
1A. The “on-line” inter-observer agreement of the four possible combinations of sonographer and 
transducer was: kappa 0.23-0.39 for the qualitative evaluation of the SN, kappa 0.31-0.56 for the 
quantitative evaluation of the SN and kappa 0.03-0.15 for the evaluation of the RN. 
1B. The “on-line” intra-observer agreement was: kappa 0.53-0.67 for the qualitative evaluation of 
the SN, kappa 0.55-0.76 for the quantitative evaluation of the SN and kappa 0.45-0.47 for the 
evaluation of the RN 
2. The “off-line” inter-observer agreement was: kappa 0.32-0.67 for the qualitative evaluation of the 
SN, kappa 0.53-0.61 for the quantitative evaluation of the SN and kappa 0.08-0.33 for the 
evaluation of the RN. 
 
Conclusions  
For the SN we found mediocre accordance comparing both observers "on-line" with each other as 
well as comparing an "off-line" observer with both "on-line" observers. Comparing the "on-line" 
observers with themselves, the intra-observer agreement appeared to be moderate to substantial. 
For evaluation of the RN, the concordance between the different observers was apparently low, 
whereas the consistency for a single "on-line" observer using two different ultrasound systems was 
comparable to evaluation of the SN. 
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Introduction 
Transcranial duplex scanning (TCD) of the brainstem is increasingly used in 
the diagnostic work-up of patients who are suspected to suffer from idiopathic 
Parkinson’s disease (IPD). In healthy individuals, the substantia nigra (SN) is 
hardly discernable from the surrounding mesencephalon since the B-mode 
ultrasound image has a predominantly homogeneous aspect. In most cases 
only a small hyperechogenic band can be visualised within the anatomical area 
of the SN. However, in up to 90% of the IPD patients the SN is clearly 
distinguishable due to its large hyperechogenic area as compared to the 
surrounding brainstem tissue.1-4 Contrary to the SN, in healthy individuals the 
Raphe nuclei (RN) can be easily depicted as a hyperechogenic band located in 
the midline of the brainstem extending in an anterior-posterior direction. A 
decreased echogenicity of the RN has been related to depression, which holds 
also true for patients with IPD.5,6 
Since the first report on the use of TCD in IPD patients by Becker and 
colleagues2 in 1995 more than 70 diagnostic trials have been published 
showing that TCD is a useful diagnostic tool for differentiating patients with IPD 
from healthy controls and other parkinsonian syndromes. 
A well-known limitation of TCD can be attributed to an inappropriate temporal 
bone window, which will make intracranial ultrasound examination impossible 
in approximately 10-20%.7 Furthermore, in up to 10% of the patients the B-
mode image might be inconclusive since an increased echogenicity does not 
match with the anatomical area of the SN.8 
Additionally, the widespread use of TCD in clinical practice might be 
questioned if the results obtained vary when different examiners perform the 
test or when using different ultrasound systems. This might especially be the 
case when the sonographers had their ultrasound training at different 
institutions. Previously, excellent values for the inter-observer agreement of SN 
duplex scanning have been reported (intra class correlation coefficients and 
kappa values between 0.80–0.98).3,4,9-11 Yet, in these studies, the evaluation of 
the inter-observer agreement was not the primary objective. So, it was not 
reported how the inter-observer agreement was determined. Furthermore, to 
our knowledge, no data exist on the intra-observer agreement.  
Therefore, the purpose of the present study is to determine the inter-observer 
agreement for the assessment of the echointensity of the SN and RN, but also 
the intra-observer agreement when the same patient is examined by the same 
ultrasonographer, but with different ultrasound systems. 




A mixed population was studied in order to decrease the ‘a priori chance’ of a 
positive finding. Twenty-four volunteers (15 males) were studied. The mean 
age was 60 years (SD: 13; range 28-78). Nine individuals suffered from IPD, 
ten from parkinsonism of unspecified origin, one had an essential tremor and 
four were healthy volunteers. All subjects gave informed consent. The study 
was approved by the local medical ethics committee. 
TCD technique 
Both ultrasonographers used two ultrasound systems to perform TCD (SONOS 
5500 and iU22; both Philips, Eindhoven, The Netherlands). Both devices were 
supplied with a low-frequency phased array transducer with a frequency range 
of 1-4 MHz and 1-3 MHz, respectively, for insonation through the transtemporal 
bone window bilaterally. The focus was set at a depth of 6-8 cm and the depth 
range was chosen to allow for the visualisation of the contralateral side of the 
skull. Overall gain and the degree of compression were visually adapted to 
optimally depict an increased echogenicity of the SN, if present. In practice, a 
relatively high gain setting was used in combination with relatively little 
compression. This combination resulted in an almost homogeneously 
echolucent brainstem in those areas where no increase of the echointensity 
can be expected. The RN, the nucleus ruber and the SN (in case of a positive 
finding) on the other hand were easily distinguishable due to their increased 
echointensity. All other parameters, such as time gain compensation, post-
processing and power settings were kept constant throughout the study. The 
quality of the B-mode images was scored as sufficient or insufficient depending 
on the visibility of the afore mentioned anatomical structures and, hence, the 
possibility to evaluate their echointensity. 
A loop of 64 images was acquired by scanning the brainstem cranio-caudally 
and all images were stored digitally to allow for off-line analysis.  
The echogenicity of the SN was determined following ipsilateral insonation. 
Firstly, the SN echogenicity was quantitatively estimated by manually encircling 
the area of hyperechogenicity, if present. The surface was automatically 
calculated. A hyperechogenic area of at least 0.23 cm2 at one side was 
classified as abnormal and a smaller area at both sides as normal.4,12,13 
Since in our experience it is often difficult to accurately delineate the area of the 
SN hyperechogenicity, we also performed a simplified method using the 
following qualitative scores: “positive”, “negative”, and “inconclusive”. 
Comparable qualitative scoring systems have also been used by other 
investigator groups.11,14,15 The SN-TCD was scored “positive”, when, at least on 
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one side, the SN was clearly visible due to its increased echointensity as 
compared to the surrounding brainstem tissue. Additionally, the 
hyperechogenic area had to correspond with the anatomical site of the SN; 
only if the hyperechogenic area extended as an oblique and continuous band in 
the medial-anterior to lateral-posterior direction, we scored this as a “positive” 
finding.  
If the image quality was sufficient to evaluate the echointensity of the SN, but 
the afore mentioned criteria were not met, the SN-TCD was scored “negative”. 
All other examinations were regarded as “inconclusive”. Firstly, this could be 
either due to an atypical anatomical distribution or only a small area of 
hyperechointensity not extending throughout the whole brainstem in the 
horizontal plane as described above. Secondly, all patients with insufficient 
bone window were scored as “inconclusive”. 
The echointensity of the RN was scored only qualitatively as being either 
“normal” (hyperechogenic from one or both insonation sides), “abnormal” (the 
hyperechogenic line is interrupted or not visible, i.e., hypoechogenic, from both 
insonation sides) or “inconclusive” (when equivocal results from both insonation 
sides were obtained or when the image quality was insufficient.  
Setting 
“On-line” assessment: each individual was scanned by two sonographers 
(1 & 2) both using two different ultrasound systems. So, in total each individual 
underwent four examinations. Several individuals were evaluated at the same 
session, and the examination schedule was set up to avoid that a given 
individual was scanned consecutively by the same sonographer. The 
sonographers were blinded for the clinical diagnosis of the subjects and the 
TCD results of the other sonographer.  
Altogether, four different combinations for the inter-observer agreement 
analysis were possible. Furthermore, the intra-observer agreement of both 
ultrasonographers using two different ultrasound systems was evaluated.  
“Off-line” assessment: two months after data acquisition, a third independent 
observer re-evaluated the ultrasound images that observer 1 and 2 had 
acquired with the SONOS 5500 system, allowing us to calculate an “off-line” 
inter-observer agreement.  
Data analysis 
Cohen’s kappa values were calculated for all inter- and intra-observer 
comparisons of the SN and RN echogenicity. At first, the agreement in 
evaluating the SN was calculated based on the three categories (positive, 
negative, and inconclusive). Previously, we have shown that the presence of a 
pathologically increased echointensity of the SN was highly correlated with an 
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abnormal presynaptic dopaminergic SPECT examination, whereas the 
absence of a positive SN-TCD finding had only little predictive power for the 
SPECT.16 This implies that a positive finding has more impact in daily practice. 
Therefore, in a second step the negative and inconclusive scores were pooled 
and compared with the positive findings. In other words, we evaluated the 
agreement dichotomically, i.e., for the presence of a positive SN-TCD or not. 
We evaluated the data of the RN-TCD likewise. All statistical analyses were 
performed with SPSS 11.0 for Windows.  
Results 
For reasons of clarity, for all studies only the proportion of matching results is 
given as well as the kappa value. Only for the inter-observer agreement study 
on the qualitative analysis of the SN, the detailed scores are presented in order 
to elucidate their distribution.  
”On-line” inter-observer agreement  
Qualitative evaluation of SN-TCD: both observers agreed in approximately 2/3 
of the 24 subjects. The agreement slightly improved if the negative and 
inconclusive TCD’s were pooled, in other words, when the positive findings 
were compared with all other ones. The investigators then agreed in 
approximately 70%, corresponding to kappa values between 0.3 and 0.4. See 
Table 5.1 for all comparisons and results of statistics. The detailed distribution 
of the scores is given in Table 5.2. It appears that the number of positive 
findings for observer 1 is slightly higher when using the SONOS 5500 as 
compared to the iU22, but for the remainder the positive and negative scores 
are evenly distributed. Quantitative evaluation of SN-TCD: with this approach 
results were comparable to those achieved with the qualitative evaluation. The 
agreement also improved when the inconclusive TCD’s were pooled with the 
negative ones. See Table 5.1 for detailed results and the kappa statistics. 
RN-TCD: In approximately half of the patients both sonographers agreed that 
the RN-TCD was normal, abnormal or inconclusive, resulting in very low kappa 
values. On the contrary, if the inconclusive RN-TCD’s were pooled with the 
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Table 5.1 “On-line” inter-observer agreement of two different observers on the echointensity of 
the substantia nigra and Raphe nuclei, when scanning each with two different 
ultrasound systems.  






pooled data (see below) 
(n/24 subjects,%, kappa) 
 1 + SONOS / 2 + SONOS 15/24 (63%), 0.23 16/24 (67%), 0.26 
 1 + iU22 / 2 + iU22 15/24 (63%), 0.31 16/24 (67%), 0.31 




 1 + SONOS / 2 + iU22 15/24 (63%), 0.24 17/24 (71%), 0.37 
 1 + SONOS / 2 + SONOS 16/24 (67%), 0.38 17/24 (71%), 0.40 
 1 + iU22 / 2 + iU 22 15/24 (63%), 0.31 16/24 (67%), 0.31 




 1 + SONOS / 2 + iU22 16/24 (67%), 0.33 18/24 (75%), 0.47 
 1 + SONOS / 2 + SONOS 11/24 (46%), 0.03 19/24 (79%), 0.06 
 1 + iU22 / 2 + iU 22 13/24 (54%), 0.15 21/24 (88%), 0.19 




 1+ SONOS / 2 + iU22 13/24 (54%), 0.15 22/24 (92%), 0.46 
SN: substantia nigra, RN: Raphe nuclei, n: number of subjects. Pooled data: when evaluating the 
SN, negative and inconclusive findings were pooled, when evaluating the RN, normal and 
inconclusive findings were pooled. 
 
 
Table 5.2 “On-line” inter-observer agreement. The scores for both observers on the qualitative 
evaluation of the echointensity of the substantia nigra, when scanning with two different 
ultrasound systems. 
 
a) Observer 1 and 2 both using SONOS 5500 
 
  Obs.2    
  SN-TCD pos. SN-TCD neg. SN-TCD inconcl. Total 
Obs.1 SN-TCD pos. 12 4 1 17 
 SN-TCD neg.   3 2 1   6 
 SN-TCD inconcl.   0 0 1   1 
 Total 15 6 3 24 
 
b) Observer 1 and 2 both using iU22 
 
  Obs.2    
  SN-TCD pos. SN-TCD neg. SN-TCD inconcl. Total 
Obs.1 SN-TCD pos. 10 4 0 14 
 SN-TCD neg.   3 4 0   7 
 SN-TCD inconcl.   1 1 1   3 
 Total 14 9 1 24 
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c) Observer 1 using iU22 and observer 2 using SONOS 5500 
 
  Obs.2    
  SN-TCD pos. SN-TCD neg. SN-TCD inconcl. Total 
Obs.1 SN-TCD pos. 11 2 1 14 
 SN-TCD neg.   4 3 0   7 
 SN-TCD inconcl.   0 1 2   3 
 Total 15 6 3 24 
 
d) Observer 1 using SONOS 5500 and observer 2 using iU22 
 
  Obs.2    
  SN-TCD pos. SN-TCD neg. SN-TCD inconcl. Total 
Obs.1 SN-TCD pos. 12 5 0 17 
 SN-TCD neg.   2 3 1   6 
 SN-TCD inconcl.   0 1 0   1 
 Total 14 9 1 24 
SN: substantia nigra; Obs: observer; pos: positive; neg: negative; inconcl: inconclusive; SN-TCD: 
transcranial duplex scanning of the substantia nigra. 
”On-line” intra-observer agreement 
Qualitative evaluation of SN-TCD: when comparing the results of a single 
observer using both ultrasound systems, observer 1 came to the same 
conclusion in 20 out of the 24 subjects (83%). Observer 2 agreed 18 times 
(75%).  
Quantitative evaluation of SN-TCD: similar results were obtained for both 
observers as compared to the qualitative method.    
RN-TCD: the intra-observer agreement for the evaluation of the RN was slightly 
less than for the evaluation of the substantia nigra.  
For detailed results and kappa values also after pooling the normal scores with 
the inconclusive scores, see Table 5.3. 
 
Table 5.3 Online intra-observer agreement of two different observers on the echointensity of the 
substantia nigra and Raphe nuclei, when scanning with two ultrasound systems.  
 Observer Agreement 
 
(n/24 subjects,%, kappa) 
Agreement on 
pooled data (see below) 
(n/24 subjects,%, kappa) 
observer 1 20/24 (83%), kappa 0.67 21/24 (88%), kappa 0.73 SN; qualitative 
evaluation observer 2 18/24 (75%), kappa 0.53 19/24 (79%), kappa 0.57 
observer 1 21/24 (88%), kappa 0.76 22/24 (92%), kappa 0.82 SN; quantitative 
evaluation observer 2 18/24 (75%), kappa 0.55 19/24 (79%), kappa 0.58 
observer 1 17/24 (71%), kappa 0.47 23/24 (96%), kappa 0.65 RN; qualitative 
evaluation observer 2 16/24 (67%), kappa 0.45 21/24 (88%), kappa 0.51 
SN: substantia nigra, RN: Raphe nuclei, pooled data: when evaluating the SN, negative and 
inconclusive findings were pooled, when evaluating the RN, normal and inconclusive findings were 
pooled. 
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“Off-line” inter-observer agreement 
Qualitative evaluation of SN-TCD: when evaluating the data “off-line”, observer 
3 fairly agreed with the scores that observer 1 had given during the “on-line” 
sessions and to a lesser degree with those from observer 2. Pooling the 
negative and inconclusive findings, the results were identical. For detailed 
results, see Table 5.4.  
Quantitative evaluation of SN-TCD: in contrast to the qualitative analysis, the 
agreement between observer 3 and observers 1 and 2 did not differ. 
RN-TCD: The inter-observer agreement was fair for the comparison between 
observer 3 and 1. Pooling the normal and inconclusive findings resulted in a 
considerable increase of agreement. There was almost no agreement between 
observer 3 and 2.  
 
Table 5.4 Agreement of the “off-line” observer with the "on-line" observers on the echointensity 
of the substantia nigra and Raphe nuclei.  





(n/24 subjects,% , kappa) 
Agreement on 
pooled data (see below) 
(n/24 subjects,%, kappa) 
observer 1 20/24 (83%), kappa 0.67 20/24 (83%), kappa 0.66 SN; qualitative 
evaluation  observer 2 16/24 (67%), kappa 0.32 16/24 (67%), kappa 0.26 
observer 1 18/24 (75%), kappa 0.53 18/24 (75%), kappa 0.50 SN; quantitative 
evaluation  observer 2 19/24 (79%), kappa 0.61 19/24 (79%), kappa 0.66 
observer 1 15/24 (63%), kappa 0.33 23/24 (96%), kappa 0.65 RN; qualitative 
evaluation  observer 2 11/24 (46%), kappa 0.08 18/24 (75%), kappa -0.08 
SN: substantia nigra, RN: Raphe nuclei, Pooled data: when evaluating the SN, negative and 
inconclusive findings were pooled, when evaluating the RN, normal and inconclusive findings were 
pooled. 
Discussion and conclusions 
In the present study we determined the inter-observer and intra-observer 
agreement for the evaluation of brainstem nuclei with the help of TCD. For the 
evaluation of the SN mediocre accordance was found, when comparing the 
results of two observers "on-line" as well as when comparing the results of an 
"off-line" observer with both "on-line" observers. Comparing the "on-line" 
observers with themselves when using an other ultrasound device, the intra-
observer agreement appeared to be moderate to substantial. For the 
evaluation of the RN, the concordance between the different observers was 
apparently low, whereas the consistency for a single "on-line" observer using 
two different ultrasound systems was comparable to the evaluation of the SN. 
 
Previously, considerably higher values for the inter-observer agreement 
evaluating the SN quantitatively have been reported: intra class correlation 
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coefficients and kappa values of 0.80–0.98 were reached instead of kappa 
values ranging between 0.26 and 0.58 in the present study.3,4,9-11 Those 
investigators, however, studied patients already diagnosed with IPD, restless 
legs syndrome or vascular parkinsonism. In contrast, we studied a mixed 
population, including not only patients with IPD and patients with parkinsonism 
of unspecified origin but also healthy volunteers in order to decrease the ‘a 
priori chance’ of a positive finding. Furthermore, our sonographers were 
completely blinded for the clinical diagnoses. Additionally, the sonographers 
had had their training at different institutions and did never work together 
before.  
One might expect that quantitatively evaluating the area of enhanced 
echointensity might be more accurate than qualitatively judging whether the SN 
appears hyperechogenic or not. Hence, the inter-observer agreement might be 
better using the first approach. Our data can not confirm this assumption, 
indicating that measuring the area of increased echointensity does not 
introduce more diagnostic reliability as compared to a more simple, qualitative 
approach.  
The results of the "off-line" assessment were in line with those of the “on-line” 
assessments, which means that reliably estimating the ultrasound properties of 
the SN is not restricted to the "on-line" examination situation. This is important 
with regard to future studies on the inter-observer agreement as well as quality 
control. One should take into account that the "off-line" assessment in the 
present study was performed on a loop of images, and not on one static image, 
allowing a broader view on the surrounding structures and borders of the SN. 
We could previously show that only the presence of a positive SN-TCD was 
highly correlated with an abnormal presynaptic dopaminergic SPECT.12,16 This 
implies that the latter examination might be omitted in those patients with an 
increased echogenicity of the SN, resulting in a considerable reduction of costs 
and patient burden. A negative SN-TCD, on the contrary, was of low predictive 
value. So, for the analysis of the SN, pooling the inconclusive and negative 
findings appears to be clinically warranted. The agreement only slightly 
improved after reducing the findings to two categories, reflecting the low 
proportion of patients with inconclusive TCD findings. Hence, the latter does 
not explain the relatively low kappa values as compared to the data reported by 
others.3,4,9-11 
The highest agreement in our study was achieved when the "on-line" observers 
were compared with themselves using an other ultrasound device, albeit that 
observer 1 showed more consistency than observer 2 (substantial and fair 
agreement, respectively). Evaluating the same patient with two different 
systems did not substantially affect the scores of the intra-observer agreement 
study. However, observer 1 had slightly more positive findings using the 
SONOS 5500 system and observer 2 marginally less negative and more 
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inconclusive findings. This might be explained by the fact that in every day 
practice observer 1 uses the SONOS 5500 system whereas observer 2 is more 
familiar with the iU22 system. Also, for the inter-observer study, the degree of 
agreement between both observers was not affected by the use of a specific 
ultrasound system.  
 
The inter and intra-observer agreement for the evaluation of the RN using TCD 
have not been studied before. We found a very low inter-observer agreement, 
practically not different from chance for the "on-line" comparison and the "off-
line" comparison between observer 3 and 2. On the contrary, the "off-line" 
agreement between observer 3 and 1 was considerably better than the intra-
observer agreement. So, obviously, there was a mismatch between observer 
1 and 2 for the evaluation of the ultrasound properties of the RN despite the 
pre-defined criteria. The meaningfulness of the agreement analysis is, 
however, limited in our study due to the fact that at most two subjects were 
scored "on-line" as abnormal with regard to the RN-TCD.  
 
It is conceivable that the better the quality of the ultrasound images obtained 
the better the intra-and inter-observer agreement will be. Yet the number of the 
included subjects was too small to allow for evaluation of this aspect. It is likely 
that more recent ultrasound devices deliver higher resolution. Technical 
developments like second harmonic imaging possible will possibly influence the 
inter-observer agreement. This has to be tested in further studies. Additionally, 
one has to realise that the image quality cannot be enhanced in a given patient 
for example by the use of contrast agents, which means that a relatively poor 
image quality will occur regularly in daily practice.  
 
Kappa statistics are frequently used for estimating the agreement between two 
observers, for example when evaluating the echogenicity of the SN by means 
of ultrasound.14 Mostly, the strength of agreement is expressed according to a 
classification as proposed by Landis and Koch.17 A kappa value of 0-0.2 is 
commonly interpreted as slight, 0.21-0.4 as fair, 0.41-0.60 as moderate, 
0.61-0.8 as substantial and more than 0.81 as almost perfect. Hence, the 
"on-line" and "off-line" inter-observer agreement for the SN-TCD in this study 
for example can be regarded more or less as moderate, which might be 
interpreted as relatively low for a medical test. Nevertheless, the inter-observer 
agreement for the determination of the vascular territory in patients with a 
recent minor stroke or transient ischemic attack was in the same order of 
magnitude (kappa 0.48-0.54).18     
However, it has to be kept in mind, that several methodological concerns have 
been raised limiting the practical value of this statistic approach.19,20 For 
example, an uneven distribution of the contingency table might affect the kappa 
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statistics, probably being relevant for the part of our study in which the RN were 
evaluated, since the proportion of the pathological findings was very low. But 
also the comparability of kappa values across different studies and the use of 
the aforementioned classification are not unanimously accepted. 
 
The present study has some limitations. Firstly, the total number of subjects 
studied was limited, restricting the significance of our findings especially if the 
distribution between pathological and normal findings was quite asymmetric, 
which was the case for the evaluation of the RN. Secondly, the subjects 
underwent their four TCD examinations on the same day. Although a subject 
was not scanned consecutively by the same sonographer using the two 
different ultrasound systems some memory bias in the intra-observer study can 
not be ruled out. Furthermore, for a true intra-observer agreement study the 
same subject should have been scanned with the same ultrasound system 
twice. Since the subjects were already scanned four times, we decided not to 
perform this test modality.  
The relatively mediocre agreement in our study might be partly explained by  a 
lack of generally accepted criteria for the evaluation of the echointensity of the 
SN and the RN. Possibly, a standardised quantitative measurement of the 
echointensity of the SN and the surrounding tissue might aid in improving the 
uniformity of the results. Additionally, standard settings for the ultrasound 
system used are required. 
 
In this study two observers from different institutions each used two different 
ultrasound systems for the evaluation of the SN and the RN of a mixed 
population. On the whole, the inter-observer and intra-observer agreement 
were moderate to substantial for the evaluation of the SN. "On-line" and "off-
line" comparisons yielded comparable results. The agreement for the 
evaluation of the RN, on the contrary, was considerably lower. TCD of the 
brainstem is a patient friendly and reasonably reliable technique. 
Unambiguously defined and commonly accepted criteria for its evaluation might 
facilitate its clinical implementation. 
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Background 
Transcranial duplex sonography (TCD) of the substantia nigra has emerged as a promising, non-
invasive tool to diagnose idiopathic Parkinson’s disease (IPD). However, its diagnostic accuracy in 
patients with undefined parkinsonism remains to be determined.   
 
Objective 
To determine the predictive value of TCD for the clinical diagnosis in undiagnosed parkinsonian 




We studied 82 patients with an unclassified parkinsonian syndrome. All 82 patients were subjected 
to a TCD, 59 of them underwent a presynaptic SPECT scans and 32 underwent a postsynaptic 
SPECT scan.  
We determined the diagnostic accuracy of TCD and SPECT scans in differentiating:1) IPD patients 
from patients without nigrostriatal degeneration and 2) IPD patients from patients with atypical 
parkinsonian syndromes (APS). To compare the diagnostic accuracy of TCD and SPECT scans, 
we used the clinical diagnosis after follow-up according to generally accepted clinical criteria as the 
gold standard. This clinical diagnosis was determined by a movement disorder specialist. 3) Finally, 
we ascertained the predictive value of TCD for the SPECT result. 
 
Results 
The clinical diagnoses after follow-up resulted in 51 cases of IPD, 7 patients with APS and 17 
patients without nigrostriatal degeneration. In total 7 patients remained undiagnosed. 
1)  The accuracy of TCD, measured by sensitivity and specificity, to differentiate IPD patients from 
patients without nigrostriatal degeneration was 50% and 82% respectively. For the presynaptic 
SPECT scans sensitivity was 97% and specificity 100%.  
2)  In differentiating IPD patients from APS patients, the sensitivity and specificity of TCD was 50% 
and 43% respectively. For presynaptic SPECT scans this was 97% and 0%. For the 
postsynaptic SPECT scans the sensitivity was 75% and the specificity 81%.  
3)  The positive predictive value (PPV) of an abnormal TCD for an abnormal presynaptic SPECT 
scan was 88%. 
 
Conclusions 
Presynaptic SPECT scanning has a higher predictive value for the clinical diagnosis than TCD. 
However, since the PPV of an abnormal TCD for parkinsonism with nigrostriatal degeneration is 
high, TCD might be used as screening tool, before ordering a presynaptic SPECT. 
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Introduction 
The diagnosis of idiopathic Parkinson’s disease (IPD) is based on clinical 
criteria. When cardinal clinical signs and symptoms as bradykinesia, rigidity, 
and resting tremor are present, the diagnosis of IPD is straightforward.1 
However, the differentiation between IPD and other parkinsonian syndromes 
can be difficult, especially in the early stages of the disease.  
Diseases which might resemble early-stage IPD are atypical parkinsonian 
syndromes (APS, i.e. multiple system atrophy [MSA], progressive supranuclear 
palsy [PSP], diffuse Lewy body disease [DLBD], and corticobasal degeneration 
[CBD]), but also vascular parkinsonism (VP), drug induced parkinsonism (DIP) 
and essential tremor (ET). Clinico-pathological studies show that 2-25% of the 
patients with IPD are classified incorrectly in the final stage of their disease, 
even by specialists in movement disorders.2-6 Because the prognosis and 
medical treatment differ between various parkinsonian syndromes, an accurate 
and early diagnosis is essential for optimal treatment and counselling. 
Single Photon Emission Computer Tomography (SPECT), with presynaptic and 
postsynaptic radiotracers, is widely used in the diagnostic work-up of patients 
with parkinsonian syndromes. Despite its widespread use, the exact diagnostic 
accuracy of this technique in parkinsonian syndromes remains somewhat 
controversial.7,8 
Becker and colleagues were first to report hyperechointensity of the substantia 
nigra (SN) in patients with IPD by using transcranial duplex sonography 
(TCD).9 Several studies found that this increased SN echointensity is present in 
90% of IPD patients9-12, presumably caused by a local increased iron 
content.13,14 In healthy individuals this increased SN echointensity is found in 
only 9%.15 Since Becker’s first report, roughly 70 studies on the diagnostic 
accuracy of TCD in parkinsonian syndromes have been published. Most 
studies on TCD and IPD have been done on later-stage, well-diagnosed 
patients. However, this does not resemble the situation in clinical practice, 
where the neurologist would want to use TCD to reach a diagnosis in patients 
with a clinically unclear parkinsonism. 
In the present study we assessed  the diagnostic accuracy of SN-TCD with that 
of SPECT scan, which was performed simultaneously in most of these patients. 
We also calculated the  predictive value of the SN-TCD for the results of the 
SPECT scans.   
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Patients and methods 
Patients 
We retrospectively studied 82 consecutive patients with a parkinsonism of yet 
unknown origin. All of these patients were subjected to a SN-TCD between 
2004 - 2006 after giving their informed consent. The study was approved by the 
Institutional Review Board (committee for Medical Ethics) of the University 
Hospital Maastricht. We initially studied 95 patients, of whom we had to 
exclude 13 (15%) with inconclusive SN-TCD’s because of an inappropriate 
temporal bone window (i.e. insufficient to acquire a 2-dimensional image of the 
intracranial structures). This percentage of inconclusive results is within the 
normal range.15-17 
Of the 82 patients, fifty-nine underwent presynaptic-SPECT imaging and thirty-
two postsynaptic SPECT imaging depending on the personal judgement of the 
























Figure 6.1 Flowchart 
n=number of subjects, TCD transcranial duplex scanning, SPECT single photon 
emission computer tomography, IPD idiopathic Parkinson’s disease, APS atypical 
parkinsonian syndromes, ET essential tremor, VP vascular parkinsonism, DIP drug 
induced parkinsonism.  
n=95
























Diagnosis after follow-up: 75 patients diagnosed: 51 IPD 5 VP
7 APS 4 DIP
2 ET 6 restgroup
7 patients undiagnosed
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To come to a clinical diagnosis (the surrogate gold standard in this study) the 
patients were re-examined by an independent neurologist specialized in 
movement disorders. This happened after a follow-up interval of at least six 
months. 
A total of 52 patients (63%) gave consent to be re-examined (twenty-one 
refused re-examination, five patients died, and four were lost to follow-up). 
However, the clinical records of the 30 patients that were not re-examined, 
were studied by the experts (WW, AW) to see if it was possible draw a 
conclusion on the final diagnosis of these patients, according to generally 
accepted clinical criteria.1,3,18-21 If there was clinical doubt between different 
parkinsonian disorders a patient was called “undiagnosed”.  
SN-TCD 
We used a 2-4 MHz phased array transducer on a commercially available 
ultrasound system (SONOS 5500; Philips, Eindhoven, the Netherlands). The 
transducer was placed over the transtemporal bone window and focussed at a 
depth of 6-8 cm to allow for optimal image quality of the brainstem. Overall gain 
and the degree of compression were visually adapted to optimally depict an 
increased echointensity of the SN, if present. In practice a relatively high gain 
setting was used in combination with relatively little compression. This 
combination resulted in an almost homogeneously echolucent brainstem for the 
areas where no increase of the echointensity can be expected. The Raphe 
nuclei, the nucleus ruber and the SN (in case of a positive finding) on the other 
hand were easily distinguishable due to their increased echointensity. All other 
parameters like time gain compensation, post processing and power settings 
were kept constant throughout the study. 
Initially were performed also second harmonic imaging (insonation frequency 
1.8 MHz). Yet it appeared, that with our ultrasound system we were able to 
visualize the brainstem only in a minority of patients. Since it is also well-known 
(personal conversation with Prof. D. Berg, Tübingen), that second harmonic 
imaging will lead to an increase of the hyperechointense area of the SN if 
compared to images based on the basal frequency content, we decided to use 
only primary images in this study. 
A loop of 64 images was acquired by scanning the brainstem cranio-caudally 
through the pre-auricular bone window on the both sides. The images were 
stored digitally to allow for off-line analysis by a second sonographer. Both 
sonographers were blinded for the SPECT results and the clinical diagnoses. 
The echointensity of the SN was evaluated by ipsilateral insonation.  
 
The SN echointensity can be estimated semi-quantitatively by manually 
encircling the area of hyperechointensity and having the ultrasound system 
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measuring the area.10,15 in our experience it is often difficult to accurately 
delineate the area of the SN hyperechointensity (if present), which would lead 
to inconsistent results. Therefore, we used a simplified and more practical 
method using the following qualitative scores: “positive”, “negative”, 
“inconclusive”. Comparable qualitative scoring systems have also been used 
by other investigator groups.22-24  
The SN-TCD is scored “positive”, when, at least on one side, the SN is clearly 
visible due to its large hyperechointense area as compared to the surrounding 
brainstem tissue. Additionally, the hyperechointense area has to correspond 
with the anatomy of the SN. Only if the hyperechointense area extends as an 
oblique and continuous band in the medial-anterior to lateral-posterior direction, 
we scored this as a “positive” finding. We could show that such an echo 
intensity increase always corresponded to an area larger than 0.2 cm2 
(unpublished data; currently under review). 
If the image quality is sufficient to evaluate the echointensity of the SN, but the 
above mentioned criteria are not met, then the SN-TCD is scored “negative”. 
This implies, that an SN-TCD is also called “negative” if there is a doubtful 
hyperechointensity. This could be either due to an atypical anatomical 
distribution or only a small area of hyperechointensity not extending throughout 
the whole brainstem in the horizontal plane as described above. 
An “inconclusive” SN-TCD is a measurement where visualization of the 
intracranial structures is not or only partly possible due to insufficient temporal 
bone windows on both sides.    
SPECT 
In this study we used the presynaptic radiotracer FP-CIT (123I-Ioflupane, 
General Electrics Health, Eindhoven, The Netherlands) and the postsynaptic 
tracer IBZM (123I-iodobenzamide, General Electrics Health, Eindhoven, The 
Netherlands). Medication which could interfere with the radiotracer was 
stopped at least 5 half-life times before the SPECT scan was made. SPECT 
scans were performed with a triple head camera (MultiSPECT3, Siemens, 
Ohio, USA) equipped with high-resolution collimators. A semi-automatic 
template model programme was used to calculate the ratios between left 
striatal and right striatal and occipital regions, respectively. Total time of 
acquisition was 30 minutes (45 seconds per frame for 40 views per detector), 
zoom factor: 1.00 and the matrix size: 128x128. Filtered back-projection 
acquisition was performed. Images were filtered using a Butterworth filter with a 
cut-off value of 0.4-0.5 and an order of 5. The ratios were corrected using 
Alderson's brain phantom with known activities in the caudate nucleus and 
putamen.  
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A binding of two standard deviations below healthy controls was considered as 
abnormal (FP CIT 8.25, sd 1.85 for putamen and 7.76, sd 1.77 for caudate 
nucleus. IBZM for striatum 3.58, sd 0.18). The scans were analysed by a 
nuclear medicine specialist who was  blinded for the clinical diagnosis and the 
SN-TCD results.  
Statistics 
The diagnostic accuracy of SN-TCD, presynaptic and postsynaptic SPECT 
scintigraphy was determined by comparing their results to the surrogate gold 
standard: the clinical diagnosis after follow-up. Diagnostic accuracy is defined 
as the sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV).  
The accuracy was determined for: 1) IPD patients and patients without 
nigrostriatal degeneration (ET, DIP, VP, restgroup) and 2) IPD and APS 
patients.   
And finally, we calculated the predictive value of SN-TCD for the presynaptic 
and postsynaptic SPECT result. SPSS (SPSS, Chicago, IL) was used for 
statistical analysis.  
Results 
Descriptives 
The mean (SD) age of the eighty-two patients was 69 (10) years, and the 
majority (65%) was male. The mean (SD) Hoehn and Yahr score was 2.4 (1.1). 
The follow-up duration after the SN-TCD was on average 17 (10) months.   
In seventy-five (91%) of the eighty-two cases, it was possible for the MD-
specialist to come to a definite clinical diagnosis. In total seven cases stayed 
undiagnosed after follow-up, because they did not fulfil the generally accepted 
clinical criteria.1,3,18-21 For an overview of all the clinical diagnoses after follow-
up see Table 6.1.  
Accuracy of SN-TCD and pre- and post-synaptic SPECT in 
predicting the clinical diagnosis after follow-up 
For the complete overview of the results of the SN-TCD, presynaptic and 
postsynaptic SPECT in each subgroup of patients, see Table 6.1.  
The first thing we looked at was the sensitivity of the SN-TCD in differentiating 
patients with IPD (n=51)  from patients with ET, VP, DIP or the rest group 
(n=17). This sensitivity was 50%, while the specificity was 82%, the PPV 89% 
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and the NPV 35%. For the presynaptic SPECT scans these values were 
respectively 97%, 100%, 100% and 92%.   
SN-TCD could differentiate IPD patients (n=51) from patients with APS (n=7) 
with a sensitivity of 50% and a specificity of 43%; the PPV and NPV were 86% 
and  10% respectively. For the presynaptic SPECT scans, these values were 
97%, 0%, 86% and 0% respectively, while for the postsynaptic SPECT the 
were 75%, 81%, 43% and 94%.  
Of the seven APS patients, four had a positive SN-TCD, while all seven had an 
abnormal presynaptic SPECT scan. Further all seven IPD and APS patients 
with an abnormal postsynaptic SPECT also had a significantly lowered 
presynaptic SPECT scan.  
When the second sonographer (ST) assessed the SN-TCD, she obtained 
similar results in the vast majority of the patients (92%).  
 
Table 6.1 Results of SN-TCD and presynaptic and postsynaptic SPECT imaging for each patient 
subgroup. 




(=abnormal) of total 
Presynaptic SPECT 
number abnormal  
of total 
Postsynaptic SPECT 
number abnormal  
of total 
IPD n=51 25 of 51 37 of 38 4 of the 21 
APS n=7 4 of 7 6 of 6 3 of 4 
    MSA  n=2 2 of 2 1 of 1 1 of 1 
    PSP n=2 1 of 2 2 of 2 1 of 1 
    CBD  n=2 0 of 2 2 of 2 1 of 1 
    DLBD n=1 1 of 1 1 of 1 0 of 1 
ET n=2 0 of 2 0 of 2 - 
VP n=5 2 of 5 0 of 4 2 (visually 0) of 3 
DIP n=4 0 of 4 0 of 1 - 
rest group n=6a 1 of 6 0 of 4 0 of 1 
undiagnosed n=7b 3 of 7 3 of 4 1 of 3 
n= 82 n= 82 n= 59 n= 32 
n: number of patients, SN-TCD: transcranial duplex of the substantia nigra, SPECT: Single Photon 
Emission Computer Tomography, IPD: idiopathic Parkinson’s disease, APS: atypical parkinsonian 
syndromes, MSA: multiple system atrophy, PSP: progressive supranuclear paralysis, CBD: cortical 
basal degeneration, DLBD: diffuse Lewy body disease, ET: essential tremor, VP vascular 
parkinsonism, DIP: drug induced parkinsonism,  
a restgroup: 4 patients had spontaneous disappeared parkinsonism, 1 normal pressure 
hydrocephalus, 1 frontotemporal dementia.  
b undiagnosed: a patient was called undiagnosed if it was not possible draw a conclusion on the 
final diagnosis from these, according to generally accepted clinical criteria the patient.1,3,18-21 
 
Predictive value of SN-TCD for the results of the SPECT scan 
Fifty-nine patients underwent presynaptic SPECT imaging (see Table 6.2). In 
33 patients (56%), the result of the SN-TCD was in line with the result of the 
presynaptic SPECT scan. The PPV of a positive SN-TCD for an abnormal 
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SPECT was high: 88%. However, the NPV of a negative SN-TCD for a normal 
presynaptic SPECT was only 30%.  
Thirty-two patients underwent postsynaptic SPECT imaging (see Table 6.3). In 
fourteen (44%) of the thirty-two cases, the result of the SN-TCD was in line with 
the result of the postsynaptic SPECT scan. The PPV of a positive SN-TCD for 
an abnormal postsynaptic SPECT was 29% and the NPV 73%.  
 








SN -TCD positive (= abnormal) 23 a   3 c 
SN -TCD negative (= normal)  23 b 10 d 
SN: substantia nigra, TCD: transcranial duplex, SPECT: Single Photon Emission Computer 
Tomography, n: number of subjects 
a n= 23 (19 IPD, 3 APS, 1 undiagnosed); b n= 23 (18 IPD, 3 APS [2 CBD, 1 PSP], 2 undiagnosed); 
c n= 3 (2 VP, 1 spontaneous disappeared parkinsonism); d n=10 (1 IPD, 2 VP, 2 ET, 1 DIP, 3 rest 
group, 1 undiagnosed). 
 
 








SN-TCD positive (= abnormal) 6 a 15 c 
SN-TCD negative (= normal) 3 b   8 d 
SN: substantia nigra, TCD: transcranial duplex, SPECT: Single Photon Emission Computer 
Tomography, n: number of subjects 
a n=6 (IPD 2, APS 2, inconclusive 2); b n=3 (2 IPD, 1 APS); c n=15 (13 IPD, 1 APS, inconclusive 1); 
d n=8 (4 IPD, 3 VP, 1 restgroup) 
Discussion 
Since the first report by Becker et al. in 1995, SN hyperechogenicity in patients 
with IPD has been confirmed by many researchers.9,16,25-28 These investigators 
have suggested that SN-TCD is an accurate instrument in discriminating IPD 
patients from normal healthy subjects, and from patients with other types of 
parkinsonism. However, most studies on TCD of the SN involve groups of well-
diagnosed IPD patients, in the latter stages of the disease. The diagnostic 
accuracy of SN-TCD in early-stage patient populations, with less well-defined 
clinical syndromes, thus remains to be determined. In an effort to investigate 
the diagnostic accuracy of SN-TCD in early-stage patients we performed an 
SN-TCD in 82 undiagnosed parkinsonian patients. As the gold standard for the 
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patient’s final diagnosis, we chose the clinical diagnosis after follow-up. This is, 
of course, not as good as post-mortem neuropathological analysis, but the best 
possible alternative at present.  
In our study, the diagnostic accuracy of presynaptic SPECT imaging is superior 
to that of SN-TCD. Especially the sensitivity and NPV in differentiating patients 
with parkinsonism with nigrostriatal degeneration (IPD, MSA, PSP, DLBD, 
CBD), from other causes of parkinsonism, are remarkably higher in presynaptic 
SPECT than in SN-TCD. However, the PPV of a positive SN-TCD for 
parkinsonism with nigrostriatal degeneration is high. This means that, although 
not all patients with nigrostriatal degeneration have a positive SN-TCD, a 
positive SN-TCD is a good predictor in diagnosing parkinsonism with 
nigrostriatal degeneration. 
In our study, we also investigated the similarity in results between SN-TCD and 
presynaptic SPECT. We found a high PPV (88%) of a positive SN-TCD for an 
abnormal SPECT result, confirming other reports.29 For clinical practice, this 
would imply that a positive SN-TCD in a patient with an early-stage, recently 
diagnosed parkinsonian syndrome, would reduce the added diagnostic value of 
a presynaptic SPECT scan. 
A striking difference between ours and other studies, is the percentage of false-
negative IPD patients diagnosed by SN-TCD. Our 50% is much higher than the 
0-20% reported by other investigators.9,16,25-28 There are several explanations 
for our lower sensitivity rate. Firstly, we used a broad spectrum of parkinsonian 
patients, which is representative for the diagnostic problem that one wants to 
solve. Other studies with similarly mixed patient groups also found a lower 
accuracy of the SN-TCD.22,23,30 Secondly, our sonographers were blinded to 
the results of the clinical diagnosis. This might also have led to a decreased 
sensitivity of the SN-TCD, since we considered the SN-TCD negative in cases 
where we had doubts about the level of hyperechointensity. Thirdly, our patient 
population had a relatively large number of patients in the early stages of their 
disease. Although Berg et al. reported SN echointensity to be stable during 
follow-up, the question remains whether this is also the case in early-stage 
patient populations.31 Fourthly, the quality of the ultrasound system is a non-
neglectable variable, since in our pilot experiments, we found that the newest 
ultrasound systems will reveal hyperechointensity of the SN in more patients.32 
Finally, the TCD technique itself can provide an explanation. One needs 
considerable personal expertise to perform and interpret a TCD correctly. Since 
the pioneering research group in Tübingen has built up an enormous amount of 
expertise, it will be difficult for other groups to reproduce their excellent 
diagnostic results.25,32-37  
 
In summary, our study with early-stage parkinsonian patients, shows that the 
specificity and the PPV of SN-TCD for the final clinical diagnosis is just as high 
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as it is for the SPECT scans. The sensitivity of the SN-TCD in our patient 
population is significantly lower than that of presynaptic SPECT scans. So in 
this population, the SN-TCD might be used as screening instrument: one could 
argue that in patients where the SN-TCD is compatible with parkinsonism with 
nigrostriatal degeneration, a presynaptic SPECT is no longer necessary in the 
diagnostic work-up. Applying this strategy, in our group of patients, 35% 
SPECT scans could have been omitted, resulting in a significant reduction in 
costs. Besides this, SN-TCD is also a more patient-friendly technique than 
SPECT scans.   
Conclusion 
Our study with early-stage parkinsonian patients shows that the diagnostic 
accuracy of presynaptic SPECT scans is higher than that of SN-TCD. 
However, the specificity and the PPV of SN-TCD for the final clinical diagnosis, 
are almost as high as for presynaptic SPECT scans. So in this population, the 
SN-TCD might be used as screening instrument: patients with a SN-TCD 
compatible with parkinsonism with nigrostriatal degeneration would not need a 
presynaptic SPECT.  
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Parkinson’s disease (IPD) is the second most common neurodegenerative disorder. As there is no 
definitive diagnostic test, its diagnosis is based on clinical criteria. Recently transcranial duplex 
scanning (TCD) of the substantia nigra in the brainstem has been proposed as an instrument to 
diagnose IPD. We and others have found that TCD scanning of substantia nigra duplex is a 
relatively accurate diagnostic instrument in patients with parkinsonian symptoms. However, all 
studies on TCD so far have involved well-defined, later-stage IPD patients, which will obviously 
lead to an overestimate of the diagnostic accuracy of TCD.  
We have therefore set out to conduct a prospective study testing the diagnostic accuracy of TCD in 
patients with a parkinsonism of unclear origin. 
 
Methods/Design 
We will enrol 250 consecutive patients, who are referred to neurology outpatient clinics of two 
teaching hospitals, for analysis of clinically unclear parkinsonism. Patients, whose parkinsonism is 
clearly diagnosable at the first visit, will be excluded from the study. All patients will undergo a TCD 
of the substantia nigra. As a surrogate gold standard we will use the consensus clinical diagnosis 
reached by two independent, blinded, movement disorder specialist neurologists after two years 
follow-up. At the time of TCD, patients will also undergo a SPECT scan of the brain.  
 
Discussion 
As this prospective trial enrols only patients with an early-stage parkinsonism, it will yield data on 
the diagnostic accuracy of TCD that is relevant to daily clinical practice: The neurologist needs a 
diagnostic tool that provides additional information in patients with a clinically indefinable 
parkinsonian syndrome. The above described observational longitudinal study was designed to 
explicitly study this aspect in the diagnostic process.  
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Introduction 
Parkinson’s disease (IPD) is the second most common neurodegenerative 
disorder with a life-time risk of 2 percent in males and 1.3 percent in females.1 
Diagnosis is based on clinical criteria. In most cases the diagnosis of IPD is 
straightforward when cardinal clinical signs and symptoms as bradykinesia, 
rigidity, and resting tremor are present.2 However, these main features of IPD 
are shared, at least in part, by atypical parkinsonian syndromes (APS i.e. 
multiple system atrophy [MSA], progressive supranuclear palsy [PSP],  
corticobasal degeneration and dementia with Lewy bodies), secondary 
parkinsonisms like vascular parkinsonism (VP) and drug induced parkinsonism 
(DIP). Besides delineating IPD from the above parkinsonian syndromes, 
distinguishing IPD from normality and essential trermor (ET) can also be 
difficult, especially in early stage of the disease.3 
The gold standard for the diagnosis of IPD is post-mortem neuropathological 
examination. Clinicopathological studies show that 2-25% of the patients with 
IPD are classified incorrectly in the final stage of their disease, even by 
specialists in movement disorders, with MSA and PSP accounting for most 
false positives.2,4,5 Diagnostic accuracy is certainly less than 90% in earlier 
disease, as Litvan et al. found that the median sensitivity for the diagnosis of 
IPD increased from 73% at the first visit to 80% to the last visit after a mean 
follow-up of 9 years, and the median positive predictive value increased from 
46 to 64%.6  
A reliable test to diagnose IPD is important for two reasons. Prognosis and 
medical treatment in the various parkinsonian syndromes differ considerably 
and an objective disease marker would facilitate the development of 
neuroprotective therapies.7,8 Several procedures have been proposed to 
diagnose IPD: functional imaging with Positron Emission Tomography (PET)-
scan or Single Photon Emission Computer Tomography (SPECT), olfactory- 
and neuropsychological tests, and DNA tests.9-12 
 
At the moment neuro-imaging techniques like PET and SPECT are the most 
widely used diagnostic tools.8 PET is at least as reliable as SPECT, but its use 
in routine clinical practice is limited by high costs and a relative short half-life of 
its radioactive tracers.13-16 Despite its widespread use, there is no consensus 
about the value of SPECT scintigraphy in the differential diagnosis of IPD.8,17-19 
The ability of SPECT scanning to discriminate IPD from normality and other 
parkinsonian syndromes varies greatly among different studies. A major issue 
here is that many studies use well-defined later-stage patients that are 
obviously not representative for the diagnostic problem that one wants to solve 
with a SPECT. 
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A more recent addition to the diagnostic armamentarium of the neurologist is 
transcranial duplex scanning (TCD) of the substantia nigra (SN) in the 
brainstem. In 1994 Becker discovered that patients with IPD had bilateral 
hyperechogenicity of the SN, probably caused by iron deposition.12,20,21 Several 
publications confirmed this observation that up to 90% of IPD patients have 
increased echo-intensity of the SN. In healthy subjects and in patients with ET 
or VP this hyperintensity of the SN is only found in 10-25%.20,22-29  
This technique has high inter-observer reliability.22,25,29 In a pilot study with 45 
patients with IPD or APS who underwent SPECT and TCD we found a positive 
predictive value of 95% of an abnormal TCD for an abnormal FP-CIT SPECT 
scan.30 
Based on this study we hypothesized that TCD of SN is a tool deserving a 
place in the diagnostic work-up of parkinsonian patients. TCD is less costly and 
less invasive than SPECT.31 Since a diagnostic test for parkinsonian 
syndromes is especially valuable in the early stage of disease(s), we devised a 
prospective diagnostic study with a clinical follow-up after two years as 
surrogate gold standard. As SPECT is currently the most widely used 
diagnostic tool in parkinsonian syndromes we included this in the study to 
directly compare the two techniques as to their diagnostic capacities in this 
field. 
Methods and design 
Design  
Observational, prospective, longitudinal study. 
Setting  
Consecutive patients will be recruited from the Neurology Outpatient Clinic of 
two hospitals: the University Hospital Maastricht in Maastricht and the 
Maasland Hospital in Sittard, The Netherlands. TCD will be done in the 
departments of Clinical Neurophysiology of the two above mentioned hospitals. 
SPECT scanning will be done in the departments of Nuclear Medicine of the 
two hospitals 
Ethical approval   
The Institutional Review Board (IRB) of the University Hospital Maastricht has 
approved the study (MEC 05-228, 4 April 2006). (This IRB also functions as 
IRB for the Maasland Hospital in Sittard, The Netherlands). All patients will be 
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asked for informed consent through a standardised information form that is also 
approved by the Institutional Review Board. 
Participants 
250 consecutive patients with new parkinsonian signs and symptoms (of 
unclear origin at the time of visit) referred to the Neurology Outpatient Clinics of 
the University Hospital Maastricht (n=150) and the Maasland Hospital Sittard, 
(n=100).    
Inclusion criteria  
1. Patients with parkinsonian signs and symptoms of unclear origin at the time 
of visit at the Neurology Outpatient Clinic. In his/her differential diagnosis 
the treating neurologist should be considering one of the following 
conditions: IPD, MSA, PSP, VP or DIP.  
2. Age older than 18 years.  
Exclusion criteria  
1. Patients presenting with a clear unequivocal diagnosis of their 
parkinsonism. 
2. Patients whose life expectancy is less than the required follow-up of two 
years.  
Methods 
After informed consent all subjects will undergo a structured interview, 
neurological examination, TCD and SPECT within six weeks of the initial visit at 
the Outpatient Clinic. After two years all patients are re-examined by two 
movement disorder specialist neurologists for a final clinical diagnosis. This 
diagnosis serves as a surrogate gold standard to calculate the accuracy of 
SPECT and TCD to differentiate between IPD and other types of parkinsonism.  
A. Interview and neurological examination 
After informed consent the patient is seen on the outpatient clinic for the 
inclusion interview and neurological examination by a third party physician (i.e. 
a physician not treating the patient, and blinded for information in the routine 
clinical records). In the structured interview a standard form with the following 
items are discussed: medical history, used drugs and effect, intoxications, 
duration of complaints, and most affected body- side (See appendix E). The 
following clinimetric scales are scored: UPDRS (parts I, III and IV), Hoehn and 
Yahr score, Hamilton Rating Scale for depression and the SCOPA cognition 
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scale.32-35 The Sniffin Sticks smell test is done according to a standardised 
protocol.36,37  
Finally, the including physician will try to reach a probable diagnosis, strictly 
applying the UK Parkinson’s Disease Society Brain Bank criteria and the 
generally accepted criteria for the other parkinsonian disorders.2,38-44 For the 
used clinimetric scales and clinical criteria see appendix A en B. 
B. SPECT 
All subjects will undergo SPECT scanning within six weeks of inclusion in the 
study. In this study FP-CIT (123I-ioflupane, Nycomed, Amersham, U.K.) is used 
as presynaptic radiotracer. Medication (amphetamine, citalopram, fentanyl, 
cocaine, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine) which 
could interfere with the radiotracer is discontinued at least 5 half life times. After 
intravenous injection of the tracer, SPECT measures baseline dopamine 
transporter integrity in the brain. SPECT is performed with a triple head camera 
(MultiSPECT3, Siemens, Ohio, USA) equipped with high-resolution collimators. 
A semi-automatic template model programme is used to calculate the ratios 
between left striatal and right striatal and occipital regions respectively. Total 
time of acquisition is thirty minutes (45 seconds per frame for 40 views per 
detector). Zoom factor: 1.00 and the matrix size: 128x128. Filtered back-
projection acquisition is performed. Images are filtered using a Butterworth filter 
with a cut-off value of: 0.4-0.5 and an order of 5. A division between the 
caudate nucleus and putamen is made. The ratios are corrected using 
Alderson's brain phantom, with known activities in the caudate nucleus and 
putamen. A binding of two standard deviations below healthy controls is 
considered as abnormal (FP-CIT 8.25+-1.85 for putamen and 7.76+-1.77 for 
caudate nucleus). Beside quantitative the scans will be also judged visually by 
the same nuclear specialist blinded for the final clinical diagnosis. If quantitative 
and visual judgments do not agree the conclusion of visual judgment is taken 
(unpublished data).  
C. Transcranial Duplex Scanning (TCD) 
TCD investigation is performed bilaterally through the pre-auricular bone 
window with a 2-4 MHz phased array transducer (SONOS 5500; Philips, 
Eindhoven, the Netherlands) by an experienced sonographer, blinded for the 
clinical data and SPECT results. The quality of the temporal bone window, the 
SN and Raphe nuclei (RN) of all subjects are scored directly by the 
sonographer blinded for the final clinical diagnosis and SPECT result. The 
quality of the bone window is scored as good, moderate or inconclusive.  
Two different methods are applied for the evaluation of the echointensity of the 
SN. Firstly, the presence or absence of an obviously visible bilateral 
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hyperechogenic SN is scored (qualitative method). The SN are scored as 
hyperechointens, not hyperechointens or inconclusive (=no typical 
configuration of hyperechointensity or low quality of the temporal bone 
window). Secondly, the area of an eventually hyperechogenic SN will be 
measured quantitatively (quantitative method). Both the right and left SN are 
measured from both sides, i.e. both temporal bone windows. After encircling, 
the area is automatically calculated. A hyperechogenic area of at least 0.2 cm2 
is classified as characteristic for IPD. The RN are scored as: invisible (=iso-
intense), just visible, visible (=hyper-intense) or inconclusive (=doubtful 
echointensity or low quality temporal bone window). 
To determine inter-observer variability and to increase the power of the study a 
second sonographer will also judge the acquired echo data. A loop of 64 
images of each patient will be acquired scanning the brainstem cranio-caudally 
and will be stored in order to allow for off-line analysis. Off-line the quality of the 
temporal bone window, SN and RN will scored by the second sonographer. 
D. Regular outpatient follow-up 
The initial treating neurologist will remain responsible for the regular outpatient 
management of the patient included in the study. He or she will discuss the test 
results with the patient, and base his/her treatment plan on these. All further 
clinical decisions will be made by the treating neurologist. 
E. Re-examination at two-year follow-up 
Two years after inclusion, all patients will be re-examined separately by two 
independent movement disorder specialist neurologists blinded for the tests 
results. They will also be blinded for the clinical records of the treating 
neurologist. The same standard form as in the first visit is filled in (See 
appendix E) and the clinimetric tests are repeated. The neurologists will be 
asked to reach a clinical diagnosis, independently from each other, according 
to generally accepted clinical criteria.38-44 If these two diagnoses are not 
identical, the final diagnosis of this patient will be coded as inconclusive.  
Data analysis 
Our main hypothesis is that TCD is as sensitive as SPECT to differentiate IPD 
from other parkinsonian disorders. For the power analyses we assumed a 
sensitivity of SPECT of 90%, based on the analysis of our own data on 248 
consecutive patients.19 Assuming this 90% for TCD sensitivity we can accept 
as lowest border of the 95% confidence interval, 86% or higher:  
SD = (√ (p1 (1-p1)) / n Æ p1 = 0.9, sd 0.02, implying n=190 patients, needed 
who have the hyperintensity of SN with TCD scanning.  
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In our pilot study 15% of the patients had an insufficient temporal bone window, 
so 224 patients are needed to compensate for the amount of inconclusive 
TCDs.28 Based on this study we expect that 90% of all patients with 
inconclusive parkinsonism will ultimately have IPD, so we set a target of initial 
250 patients with unclear parkinsonism needed for this trial. 
We will calculate the sensitivity and specificity, positive predictive value, 
negative predictive value and diagnostic odd’s ratio (OR) with its 95% 
confidence intervals (95% CI) of the first clinical judgment, TCD, FP-CIT 
SPECT scan and smell tests to predict the clinical diagnosis after two year 
follow-up. Accuracy is determined for all parkinsonian subgroups separately 
(IPD versus APS, IPD versus ET, and IPD versus VP, IPD versus DIP, and IPD 
versus all other types of parkinsonism). For expected SPECT, TCD and smell 
tests scores for each parkinsonian disorder, see Table 7.1. 
Additionally we will determine the predictive value of TCD compatible with IPD 
for an abnormal FP-CIT SPECT scan. Finally the inter-observer reliability for 
SN and RN judgement by TCD will be determined (Cohen’s kappa test). SPSS 
11.0 for windows (SPSS, Chicago, IL, USA) and StataSE9 (Stata corporation, 
Texas, USA) will be used for statistical analysis.  
 
Table 7.1 Expected TCD, FP-CIT SPECT and odour recognition results for all parkinsonian 








 IPD + + + ± 
 ET normal normal normal normal 
 VP normala normal normal ± 
 DIPb normal (±) normal (±) normal (±) normal (±) 
 MSA +c ± + ± 
 PSP +c ± normal (±) + 
 DLBD + + + + 
 CBD + + ± + 
Frequency of abnormal findings: + = frequently found, ± = sparsely found, normal =rarely or not 
found.  
IPD idiopathic Parkinson’s disease; ET essential tremor; VP vascular parkinsonism; DIP drug 
induced parkinsonism; MSA multiple system atrophy; PSP progressive supranuclear palsy  
a Especially visual judgement together with CT or MRI. 
b At least 10% percent of the patients with DIP will develop IPD.48 Berg et al. investigated the 
correlation between the echointensity of the SN on TCD and DIP after starting the patients on 
antipsychotic drugs. Patients with serious parkinsonism showed higher echointensity than patients 
with mild or no parkinsonism.47  
c In our retrospective trial, 76% of the 27 patients with APS had FP-CIT binding lower than two 
standard deviations below healthy controls. In the eleven studies included in our meta-analysis, this 
percentage varies from 67 to 100%.19,46 
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Discussion 
The hitherto published literature on TCD in parkinsonian syndromes are cross-
sectional studies on clinically well-defined patient populations.20-30,45 Although 
one has to start with these to study the diagnostic potential of a new technique, 
these kind of studies are obviously not representative of the clinical problem 
that one wants to solve with a TCD in parkinsonian syndromes. The treating 
neurologist wants a diagnostic tool that provides additional information in 
patients with a clinically indefinable parkinsonian syndrome.  
The above described observational longitudinal study was designed to explicitly 
study this aspect in the diagnostic process. We arbitrarily choose the clinical 
diagnosis after two years as the surrogate gold standard. This is, of course, not 
ideal, as there will always remain a small proportion of patients that is not 
definitely diagnosable after two years, and misdiagnoses (as opposed to the 
ultimate gold standard the post-mortem pathological analysis) are still possible. 
In an effort to tackle this last obstacle we require the final diagnosis to be 
shared by two independent, blinded, experienced movement disorders 
specialist neurologists. 
We included SPECT scans in the study to enable us to make a direct 
comparison between SPECT and TCD as to their diagnostic accuracy. 
Although the use of SPECT scans in the diagnostic work-up of parkinsonian 
patients is still debated, it is widely used.8,19,46 We feel that this will add to the 
clinical relevancy of our study results. Additionally, we also included tests on 
smell, depression and cognition, in the diagnostic process.  
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General discussion 
The diagnosis Idiopathic Parkinson’s disease (IPD) is based on the clinical 
finding of bradykinesia combined with rigidity, resting tremor and postural 
instability.1 Yet, it can be difficult to diagnose the disease in a considerable 
proportion of patients. Two major problems are responsible for this dilemma. 
Firstly, in the early stages of the disease, the typical symptoms may only partly 
be present or to a very subtle degree. Secondly, IPD’s main symptoms are 
nonspecific meaning that they do occur in other movement disorders as well. 
These disorders are characterised by tremor (particularly essential tremor [ET]) 
or bradykinesia and rigidity, such as atypical parkinsonian syndromes (APS, 
i.e. multiple system atrophy [MSA], progressive supranuclear palsy [PSP], 
diffuse Lewy body disease and corticobasal degeneration) and secondary 
parkinsonism (i.e. vascular parkinsonism [VP] and drug induced parkinsonism 
[DIP]).  
An accurate diagnosis in early stages of the disease is essential for optimal 
treatment and counselling since the prognosis and medical treatment differ 
between various parkinsonian syndromes. Hence, to enable early diagnosis, 
the development of objective diagnostic markers to aid in the differentiation 
between these syndromes has gained considerable research interest.  
 
Currently, there is no test available that reliably allows for diagnosing IPD. The 
available diagnostic tools are not included in the internationally accepted 
diagnostic criteria for IPD. Therefore, although frequently used, these tests do 
not belong to the regular diagnostic work-up of a patient suspected of IPD.1  
What should be the requirements for the ideal clinical diagnostic test for IPD? 
Along with the obvious need for a high sensitivity in diagnosing IPD, it also 
should be able to separate IPD from the other parkinsonian disorders. The tool 
should, therefore, display a high sensitivity, specificity and positive predictive 
value (PPV). The values for sensitivity and specificity should be at least 85% 
and that for the PPV at least 80%.2 Further requirements would be the ability to 
monitor disease progression as well as to detect presymptomatic changes, 
which in case of IPD might in the future offer fascinating possibilities for 
neuroprotective intervention. Furthermore, a clinical diagnostic test should be 
minimally invasive, of low costs and widely available, which would all favour its 
use in everyday clinical practice. 
 
Despite the shortcomings mentioned above, various tests are currently 
employed in the diagnostic work-up of the parkinsonian patient: Single Photon 
Emission Computer Tomography (SPECT), Positron Emission Tomography 
(PET), magnetic resonance imaging, biochemical tests, genetic analyses, 
neuropsychological and depression scales, smell tests, autonomic function 
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tests and sleep disorder analyses.3-5 SPECT is the most commonly used 
technique. It visualises the integrity of the dopaminergic pathways in the brain. 
Despite of its widespread use, the exact diagnostic accuracy of this technique 
in parkinsonian syndromes remains controversial. A relatively new method to 
visualise alterations in structures involved in the cerebral dopaminergic 
pathways is transcranial duplex scanning (TCD).6 
 
In this thesis, two of the aforementioned imaging techniques are discussed with 
regard to their value in the diagnostic work-up of undiagnosed parkinsonian 
patients: the widely available and frequently used SPECT and the promising 
TCD, which has only lately been added to the armamentarium of the 
neurologist. Although PET is at least comparable with SPECT in terms of 
diagnostic accuracy we have chosen not to include this modality in our study 
due to its inherent practical disadvantages.7 The relatively short half-life of its 
radioactive tracers, its high costs and its sporadic availability are very likely to 
prevent this technique from widespread clinical use.  
Single Photon Emission Computer Tomography 
By using SPECT, the uptake of a radiotracer can be measured quantitatively, 
and the absolute and percentual difference from the normal uptake can be 
determined. Different tracers can be used to visualise the function of the 
dopaminergic system: presynaptic tracers are used to visualise the dopamine 
transporter density, and postsynaptic radiotracers to assess the dopamine 
receptor density. The highest tracer uptake in both pre- and postsynaptic 
SPECT scans takes place in the striatum, an area representing the terminal 
projections of nigral dopaminergic neurons.  
 
It has consistently been shown by several research groups, as well as in our 
retrospective study, that presynaptic SPECT imaging is very accurate in 
discriminating patients with IPD from patients suffering from disorders without 
nigrostriatal degeneration, such as ET, DIP and VP.  
However, accurately differentiating IPD from APS is not possible. Especially 
the specificity (24%) and predictive value (15%) of a normal presynaptic 
SPECT scan for APS is relatively low, since the majority of both IPD and APS 
patients show a decreased presynaptic striatal tracer binding.8  
 
It is a matter of debate whether a normal presynaptic SPECT scan completely 
excludes a diagnosis of IPD.9-11 Recent clinical trials using presynaptic SPECT 
scans and PET as surrogate markers for disease progression have found that 
a proportion of patients diagnosed as early IPD have normal presynaptic 
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SPECT scans. These have been termed subjects with “scans without evidence 
of dopaminergic deficit (SWEDD)" and represented from 5.7 to 14.7% of all 
patients clinically diagnosed as having early IPD in different studies.9,10,12  
In our study even 19.6% of the 112 IPD patients had a normal initial 
presynaptic SPECT scan. 
Possible explanations for a discrepancy between clinical diagnosis and SPECT 
findings are, firstly, that the patient is wrongly diagnosed as having IPD, or, 
secondly, that the reduction in striatal radioactive tracer uptake is so low that is 
escapes detection. Of course, the latter is dependent on the evaluation method 
(cut-off values, quantitative or visual analysis) used. 
Since the tracer-uptake in both healthy and parkinsonian patients declines 
during follow-up the presynaptic SPECT result theoretically can change from 
normal to abnormal during follow-up.13 In our sample of 12 IPD patients who 
underwent a second SPECT scan during follow-up, accordance with the 
ultimate clinical diagnosis rose from 4 (33%) to 10 (83%) patients. According to 
our results, a normal initial presynaptic SPECT scan makes IPD highly unlikely, 
but not completely excludes the diagnosis of IPD. 
 
There is also discussion about the diagnostic value of postsynaptic SPECT 
scintigraphy. In our meta-analysis as well as in our retrospective trial, it 
appeared that the ability to discriminate patients with IPD from those with APS 
patients is relatively low. Although a normal postsynaptic SPECT scan is found 
in 80% of the IPD patients, the sensitivity (62%) and positive predictive value 
(50%) of an abnormal scan for APS is relatively low, mainly since (especially 
advanced) IPD patients can also have an abnormal postsynaptic scan.  
 
In conclusion, presynaptic SPECT scans can provide valuable support in the 
diagnosis of dopamine deficiency related parkinsonian syndromes like IPD and 
APS. So, albeit the result of a SPECT scan is not part of the internationally 
accepted criteria for IPD, a presynaptic SPECT scan has an additional 
diagnostic value if there is a certain level of clinical uncertainty.1 However, 
accurate differentiation between IPD and APS is not possible with presynaptic 
nor with postsynaptic SPECT scans. As a consequence we no longer use 
postsynaptic SPECT scans in our clinic.  
Transcranial duplex scanning 
In 1995, Becker and colleagues reported for the first time that IPD patients 
have a characteristic finding on intracranial B-mode imaging. The area of the 
substantia nigra (SN) can show a hyperechointensity as compared to the 
adjacent brainstem tissue.6 Up to 90% of the IPD patients have such an SN 
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hyperechointensity.14-17 On the contrary, we found that only 50% of the IPD 
patients had an abnormal SN-TCD despite the fact that 97% of the IPD patients 
in our study had an abnormal presynaptic SPECT scan. However, our study 
confirmed the finding of other investigators of a high PPV (88%) of an abnormal 
SN-TCD for an abnormal presynaptic SPECT scan.18,19 
Some studies reported that the area of SN-hyperechointensity in IPD patients 
was larger as compared to APS patients. Yet, in other studies both patient 
groups had a similar SN hyperechointensity area. Therefore, it remains 
indefinite, whether or not it is not possible to differentiate between both groups 
by solely using SN-TCD.16,17,20,21  
 
The echointensity of the SN can be judged qualitatively (i.e. whether or not a 
typical hyperechointensity is present) as well as quantitatively (i.e. encircling 
the hyperechogenic area). In addition to the SN, TCD can also be used to 
visualise other brain structures such as the lenticular nucleus (LN) and the 
Raphe nuclei (RN). 
 
Visualisation of the LN has been described to differentiate IPD from APS. The 
LN is only discernable when its echointensity is abnormally increased 
compared to the surrounding brain parenchyma. Finding a marked SN 
hyperechogenicity in combination with a normal aspect of the LN might 
discriminate IPD from APS (especially MSA, PSP and CBD). By combining SN- 
and LN-TCD, a PPV of more than 90% can be achieved.22,16,17,23 However, the 
reliability of sonographic visualisation of the LN appeared in our hands to be 
technically more challenging than the insonation of the SN, which might partly 
be due to the use of different equipment. Consequently, we do not expect that 
in the short term insonation of the LN will be implemented into the routine 
clinical work-up of the patient with suspected IPD or APS. 
  
A diminished echointensity of the RN has been reported to be associated with 
depression in subjects with and without parkinsonism.24,25 However, according 
to our systematic review, the RN-TCD has only marginal diagnostic accuracy in 
diagnosing depression in IPD patients.21  
 
Other research groups described excellent inter-observer agreement for SN-
TCD14,26,27, in our hands mediocre accordance was found for the inter-observer 
agreement. The agreement of the quantitative evaluation of the SN-TCD was 
comparable to the qualitative judgement. The results of the “off-line” 
assessment were in line with those of the “on-line” assessments, which means 
that reliably estimating the ultrasound properties of the SN is not restricted to 
the “on-line” situation. The intra-observer agreement appeared to be 
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considerably better, namely moderate to substantial according the commonly 
used classification by Landis and Koch.28  
Furthermore, we found the inter-observer agreement of the RN-TCD (which 
was not studied by other investigators before) to be rather low, whereas the 
intra-observer agreement of the RN-TCD was comparable to the sonographic 
evaluation of the SN. The impact of these findings for further TCD research will 
be discussed later. 
 
The relatively mediocre inter-observer agreement in our study might be partly 
explained by a lack of generally accepted criteria for the evaluation of the 
echointensity of the SN and the RN. A more standardised method of 
qualitatively and quantitatively measuring the echointensity of the respective 
anatomical areas is needed to improve the uniformity of the results.  
 
Several reasons might account for the relatively low diagnostic accuracy of 
TCD in our studies. Firstly, we used a broad spectrum of undiagnosed 
parkinsonian patients. In most of the studies included in our systematic review 
the involved patients were already diagnosed. Secondly, our patient population 
to a considerable degree comprised patients in early stages of their disease. 
Although Berg and colleagues reported SN echointensity to be stable during 
follow-up, the question remains whether this is also the case in early-stage 
patient populations.29 Thirdly, the type and quality of the ultrasound system 
might be a non-neglectable variable. So far, no systematic comparison 
between different ultrasound systems used in the same patient has been done 
except for our intra-observer agreement study. Finally, it is commonly agreed 
upon that considerable experience both in terms of performance and 
interpretation of TCD is needed to obtain optimal results. The latter might partly 
explain why we were not able to reproduce the excellent results that were 
obtained for example by the research group in Tübingen with a more than 10 
year history of ultrasound examination of the brainstem.  
 
Nevertheless, in our opinion TCD might be used in the diagnostic work-up of 
the undiagnosed parkinsonian patient. 
Firstly, although diagnostic tools such as SPECT and SN-TCD are not 
completely accurate, they definitely do have additional diagnostic value 
supporting the initial clinical opinion of the clinician. Cost effectiveness studies 
showed that it is economically worth considering to include presynaptic SPECT 
scans in the regular diagnostic work-up of patients with uncertain 
parkinsonism.30-32 By estimation, in roughly 30% of the 13.000 new patients 
with parkinsonism in the Netherlands a SPECT scan is performed, leading to 
about 4.000 presynaptic SPECT scans every year. This number of presynaptic 
SPECT scans can be decreased if SN-TCD is used as a screening tool. Since 
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its high PPV (88%) for an abnormal presynaptic SPECT, a presynaptic SPECT 
scan can be considered unnecessary in case the SN-TCD is compatible with 
IPD. In our study 78% of the patients referred for a presynaptic SPECT had an 
abnormal scan, 14% of all patients had an inconclusive SN-TCD and 50% of 
the patients with an abnormal presynaptic SPECT had an abnormal SN-TCD. 
Applying this strategy, at least 35% of the presynaptic SPECT scans could 
have been omitted. This will mean a reduction of 800 SPECT scans in the 
current situation and more than 4.000 presynaptic scans if presynaptic SPECT 
scans will become part of the regular diagnostic work-up. The policy outlined 
above could lead to a considerable reduction of health care costs if the huge 
difference of the price tag for TCD (about 80 Euros) and SPECT (about 900 
Euros) is considered. 
Secondly, TCD is far more patient-friendly. The examination can be performed 
within ten minutes, with the patient sitting in a comfortable chair, while a 
presynaptic SPECT scan requires an injection of a radioactive tracer, then 
three hours of waiting and thereafter twenty minutes lying on a stretcher in the 
scanner.  
Ongoing TCD research in our clinic 
Two years ago, we started a prospective trial with undiagnosed parkinsonian 
patients.33 We planned to include 250 patients and currently these 250 patients 
have all been included in the trial. All patients underwent TCD and presynaptic 
SPECT scintigraphy. Additionally, their olfactory function, cognition, motor 
function and emotional state were tested. All patients will be re-examined by 
two independent movement disorder specialists after a follow-up of two years 
in order to make the final clinical diagnosis. At this moment the first 60 patients 
are re-examined. This study will provide information on the additional value of 
the aforementioned examinations with respect to their capability of predicting 
the natural course of the patient with parkinsonism of unclear origin. Another 
ongoing study is aimed to find out whether the SN echointensity will remain 
stable in 100 early stage patients during the follow-up period of two years. 
TCD in the future 
Although TCD is an attractive diagnostic tool there are also shortcomings that 
we need to consider and for which improvements or further research are 
needed.  
 
Thesis_Vlaar_v3.pdf   128 26-6-2009   9:23:33
 General discussion⏐129 
 
1) TCD has to be tested against a reference standard by truly blinded 
investigators to accurately establish its value. In all studies TCD was 
compared against clinical criteria or functional neuro-imaging. As outlined in 
the introduction, the definite diagnosis is still made neuropathologically. 
Therefore, in order to determine the true meaning of the ultrasound 
examination of the SN, a comparison with post-mortem studies is definitely 
needed.  
 
2) To determine if SN-TCD can be applied on a large scale, the reliability must 
be assessed more extensively, especially in an environment outside the 
expert use in a clinical research setting.    
The relatively mediocre inter-observer agreement in our study might be 
partly explained by a lack of generally accepted criteria for the evaluation of 
the echointensity of the SN and the RN. Possibly, a standardised 
quantitative and qualitative measurement of the echointensity of the SN and 
the surrounding tissue might aid in improving the uniformity of the results. 
Additionally, standard settings for the ultrasound system used might be 
required.  
 
3) Widespread application of TCD is hindered by the fact that the investigator 
needs extensive experience with ultrasound and has to be trained by an 
expert. Possibly, a training course might be a good starting point, whereas 
later on a discussion on the acquired data would be feasible via the 
internet. 
 
4) In our systematic review we could confirm that in approximately 10% of the 
patients the temporal bone window is inappropriate to visualise the 
intracranial brain structures. Contrary to the evaluation of the intracranial 
vasculature, which has been established as a clinically relevant method that 
is applied on a large scale, the visibility of the brainstem can not be 
enhanced by the use of ultrasound contrast agents. Hence, in 1 out of 10 
patients, the temporal bone window will be inappropriate to visualise the SN 
and other brain structures. This failure rate has to be taken into account 
when implementing TCD in daily clinical practice. Whether this percentage 
can be lowered, for instance by applying a lower insonation frequency has 
to be determined.  
 
5) If healthy people are subjected to TCD, approximately ten percent will show 
a SN hyperechointensity. Despite being apparently healthy, Berg and 
colleagues found that 60% of the asymptomatic subjects with SN 
hyperechointensity also had decreased nigrostriatal dopaminergic function 
when PET scans were performed. Longitudinal follow-up studies on these 
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asymptomatic subjects are currently under way to investigate whether they 
will develop IPD.34 These findings may suggest that TCD as well as PET 
and SPECT scans might be helpful in identifying individuals potentially at 
risk to develop IPD.35,15  
 
If in the future imaging techniques will allow for diagnosing IPD 
presymptomatically, this will not only enable the neurologist to advise the 
patient much earlier in the course of the disease but the targeted use of 
preventive drugs will also be feasible. TCD would be the preferred screening 
technique for large scale studies and not SPECT and PET scans, since it is 
more patient-friendly, less costly and readily available. Due to recent technical 
developments, it is now even possible to carry a duplex system in a briefcase 
to almost any location.  
Conclusion 
Diagnosing IPD is most challenging in the early stages of the disease. If there 
is a need for a diagnostic tool in an individual patient the first choice is still a 
presynaptic SPECT scan since this technique is well investigated and still more 
accurate than TCD. With a presynaptic SPECT the diagnostic accuracy of 
differentiating neurodegenerative parkinsonian syndromes from healthy 
controls, patients with ET, DIP and VP is excellent. However, differentiation of 
IPD from APS is relatively inaccurate with presynaptic as well as with 
postsynaptic SPECT scans. 
 
The SPECT scans display higher diagnostic accuracy than TCD. However, the 
PPV of an abnormal TCD for an abnormal SPECT finding as well as for the 
clinical diagnosis of IPD is high, implying that TCD can be used as a screening 
tool. If the TCD results are indicative for IPD, a SPECT scan can be considered 
unnecessary.  
 
Longitudinal studies are under way to show if TCD has the ability to diagnose 
IPD in a presymptomatic stage, leading to exciting possibilities to develop 
neuroprotective, or even curative drugs.  
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Idiopathic Parkinson’s disease (IPD) is the second most common 
neurodegenerative disorder. Since there is no definitive diagnostic test, the 
diagnosis of IPD is based on clinical criteria. When cardinal clinical signs and 
symptoms, such as bradykinesia, rigidity, and resting tremor are present, the 
diagnosis of IPD is straightforward. However, in the early stages of the disease, 
when symptoms are mild and non-specific, differentiation between IPD and 
other parkinsonian syndromes can be difficult. Diseases which might resemble 
early-stage IPD are the atypical parkinsonian syndromes (APS, e.g. multiple 
system atrophy [MSA] and progressive supranuclear palsy [PSP]) or secondary 
parkinsonisms (e.g. vascular parkinsonism [VP] and drug induced 
parkinsonism [DIP]) and essential tremor (ET). Clinical criteria at best lead to a 
diagnosis of probable IPD, while a definite diagnosis requires post-mortem 
confirmation. Neuropathological studies have shown that even in the final 
stages of the disease, the clinical diagnostic accuracy for IPD varies between 
75-90%.1-5 
An accurate diagnosis in the early stages of the disease is essential for giving 
patients optimal treatment and counselling, since the prognosis and treatment 
differ between various parkinsonian syndromes. Hence, to enable early 
diagnosis, the development of diagnostic tools is an important research topic. 
Examples of techniques widely studied, but not yet incorporated in the regular 
diagnostic work-up of the parkinsonian patient, are single photon emission 
computer tomography (SPECT), positron emission tomography (PET), 
magnetic resonance imaging (MRI), transcranial duplex scanning (TCD), smell 
tests, neuropsychological tests and genetic analyses.  
Of the above mentioned techniques, SPECT scans are most frequently 
employed when diagnosing patients with parkinsonism of unclear origin. 
SPECT scans are used to visualise the integrity of the dopaminergic pathways 
in the brain. There are several SPECT radiotracers available to be used to 
investigate different parts of the dopaminergic systems. A SPECT scan with 
radioactive isotopes binding to presynaptic dopamine transporters has been 
shown to be a good predictor of the existence of IPD as underlying mechanism 
of the parkinsonism. The most widely used presynaptic radiotracers are 123I-
ioflupane and 99mCT-TRODAT-1.  
A SPECT scan with tracers binding to postsynaptic dopamine receptors 
provides information on the postsynaptic level of the nigro-striatal circuitry. 
Postsynaptic SPECT scans seem to be helpful to discriminate patients with IPD 
from those with APS. The most used postsynaptic radiotracer is 
123I-iodobenzamide.  
Despite its widespread use, the exact diagnostic accuracy of this technique in 
parkinsonian syndromes remains controversial.  
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A relatively new diagnostic method in parkinsonian patients is transcranial 
duplex scanning (TCD).6 This technique is different from SPECT, since it 
visualises structural changes while SPECT visualises the function of a 
particular system. A TCD can reveal increased echointensity of the substantia 
nigra (SN). It is still a research tool, but since TCD is widely available and a 
simple and non-expensive method, it seems to be a promising technique. 
However, before TCD can be implemented in daily clinical practice, it is 
desirable to investigate its reliability and attributive diagnostic value in 
comparison with already existing techniques like SPECT scintigraphy.  
 
In this thesis we started with exploring and investigating the diagnostic 
accuracy of SPECT in parkinsonian patients. Secondly, we assessed the 
accuracy of TCD in the differential diagnosis of IPD. Finally, we studied the 
combination of both techniques in the diagnostic work-up of patients with 
clinical parkinsonism of unclear origin.  
 
In chapter 2 the existing literature regarding the diagnostic accuracy of both 
pre- and post-synaptic SPECT imaging in the differential diagnosis of IPD is 
reviewed and presented in a meta-analysis. Relevant studies were searched in 
Medline, EMBASE and Cochrane databases with back-searching of their 
reference lists. The search resulted in 185 articles, of which we deemed 32 
suitable for our analysis. From these we recalculated the diagnostic odds ratio 
(OR) with 95% confidence interval of SPECT for the clinical questions above. 
We found a high diagnostic accuracy for the presynaptic SPECT scan to 
distinguish patients with IPD in an early stage from normalcy (OR 60 [13-277]), 
patients with IPD from those with ET (OR 210 [78-563]) and patients with IPD 
from those with VP (OR 105 [32-348]). The accuracy to differentiate between 
patients with IPD and those with APS was low for the presynaptic (OR 2 [1-4]) 
as well as the postsynaptic (OR 19 [10-36]) SPECT scans.  
In conclusion, SPECT with presynaptic radiotracers is relatively accurate to 
differentiate patients with IPD in an early phase from normalcy, or from patients 
with ET or VP. This meta-analysis also confirmed that presynaptic tracers 
cannot accurately differentiate between patients with IPD and those with APS. 
Neither is the SPECT with postsynaptic tracers highly accurate in distinguishing 
patients with IPD from those with APS. 
Until now, most studies have been performed using late-stage, well-diagnosed 
patients. However, this does not resemble the situation in clinical practice, 
where one seeks to find the cause of the parkinsonian disorder in a given 
patient in a rather early stage by using a diagnostic tool such as SPECT.  
 
In chapter 3 we retrospectively determined the predictive value of presynaptic 
and postsynaptic SPECT scans for the clinical diagnosis after follow-up in 248 
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parkinsonian patients with initially unclassified parkinsonism. Gold standard in 
this study was the clinical diagnosis derived from the latest available clinical 
record, or, when this was not possible, a new complete physical and 
neurological examination by a blinded neurologist specialised in movement 
disorders. We found a relatively high diagnostic OR for presynaptic SPECT 
scans to differentiate patients with IPD from patients with ET (OR 82 [11-674]), 
from those with VP (OR 61 [8-490]) and from those with DIP (OR 33 [2-697]). 
The accuracy to discriminate between patients with IPD and those with APS 
was relatively low for both presynaptic (OR 1 [0-4]) and postsynaptic (OR 7 
[2-17]) SPECT scans. This study is the largest diagnostic retrospective study 
which included as yet undiagnosed parkinsonian patients. The conclusions of 
this study were similar to the results of our meta-analysis discussed in 
chapter 2.  
 
Chapter 4 reviews the literature regarding transcranial duplex scanning (TCD) 
in parkinsonian disorders. TCD is a non-invasive, fast, and patient-friendly 
technique, which is employable at the bedside. With TCD several brain 
structures like the substantia nigra (SN) can be visualised. TCD is performed 
by placing the ultrasound transducer on the temporal bone in front of the ear. 
Usually, the mesencephalon has a predominantly homogeneous aspect; in 
most cases a small hyperechogenic zone can be discerned within the area of 
the SN. However, in the majority of patients with IPD the SN is clearly visible 
due to its large hyperechointense area, which is presumably caused by an 
increased iron content. Also other brain structures like the lenticular nucleus 
(LN) and the Raphe nuclei (RN) can be visualised by TCD. Usually, the LN is 
only discernable when hyperintense, and this increase in echointensity of the 
LN might differentiate between IPD and APS, such as MSA and PSP.7,8 A 
decrease in the echointensity of the Raphe nuclei (RN) is reported to be 
associated with depression in patients with or without parkinsonism.8,9 For 
detailed technical aspects of TCD see appendix C.  
Numerous studies on the diagnostic accuracy of TCD in parkinsonian 
syndromes have already been published and several research groups are 
currently studying TCD. To get a clear overview of the results so far we 
performed a systematic review. We found 35 eligible studies. Of the 1534 
patients with IPD 200 (13%) had an inconclusive SN-TCD since the 
investigators experienced difficulties judging the SN-TCD, either because of an 
inappropriate temporal bone window or an atypical form of the 
hyperechointensity. An increased echointensity of the SN was seen in 1167 
(87%) of the 1334 patients with IPD. In comparison, an abnormal SN-TCD was 
only found in 12% of the healthy controls, 12% of the patients with ET, 20% of 
the patients with VP, 0% of the patients with DIP and 30% of the patients with 
APS. On the contrary, a significantly increased LN echointensity was found in 
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79% of the patients with APS, in 23% of the patients with IPD and in 6% of the 
healthy controls. A decreased echointensity of the RN was found in 46% of 
depressed and in 16% of the non-depressed patients with IPD. 
The conclusion of our systematic review was that SN-TCD accurately 
differentiates between patients with IPD and healthy controls, or patients with 
ET, DIP and VP, but not between patients with IPD and those with APS. Also 
TCD of the LN solely will not allow for the discrimination between IPD and APS 
in an individual patient. The diagnostic value of RN-TCD to diagnose 
depression in patients with IPD was low. Unfortunately the SN-TCD was 
inconclusive in more than 10% of the patients. In addition, approximately 1 out 
of 10 apparently healthy individuals appear to have an increased SN 
echointensity. Long-term follow-up studies are currently underway to assess 
whether this finding on TCD indicates an increased susceptibility for IPD.  
  
Although TCD is used since 1995, its use is mainly limited to research settings 
and as a diagnostic tool in parkinsonian patients TCD is not widely employed 
yet. One of the possible explanations is that there are several methodological 
issues: lack of standardised TCD techniques, normal values and scoring 
systems, and the high percentage of subjects with an inconclusive TCD.  
Currently, the inter-observer and intra-observer variability of SN-TCD is studied 
by German and Taiwanese research groups. They report excellent agreement 
values in their diagnostic studies, although the methods behind these inter-
observer sub-analyses are not elaborated on. Before implementation of TCD in 
daily clinical practice its methodological aspects should be investigated more in 
detail. 
 
Therefore, in chapter 5 we determined the inter-observer and intra-observer 
reliability of “on-line” and “off-line” assessment of the echointensity of the SN 
and RN. The echointensity of the SN was judged qualitatively and quantitatively 
and the RN only qualitatively. Each patient was assessed four times by two 
independent experienced sonographers using two different transducers. In the 
“off-line” assessment a third independent experienced sonographer re-
assessed the stored images. 
Concerning the qualitative SN-TCD judgement we found a moderate 
agreement for the “on-line” inter-observer, “on-line” intra-observer and the “off-
line” inter-observer agreement. By example, kappa values of 0.23-0.39 were 
obtained for “on-line” inter-observer agreement, 0.53-0.67 for the “on-line” intra-
observer agreement and 0.32-0.67 for “off-line” inter-observer variability. The 
results of the quantitative SN judgement were comparable to those of the 
qualitative SN judgement. The kappa values for judging the RN-TCD were low. 
We concluded that the “on-line” as well as the “off-line” inter-observer 
agreement of the SN-TCD evaluation is moderately reliable and of the RN-TCD 
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it is relatively low. Quantitative judgement of the SN-TCD was not more 
accurate than qualitative judgement. The results of the “off-line” assessment 
were in line with those of the “on-line” assessments. For the intra-observer 
agreement of both the SN-TCD and the RN-TCD we found mediocre 
accordance.  
Previously, considerably higher values for the inter-observer agreement 
evaluating the SN quantitatively have been reported: kappa values of 0.80–
0.98 were obtained.10-14 Those investigators, however, studied already 
diagnosed patients. In contrast, we investigated a mixed population in order to 
decrease the ‘a priori chance’ of a positive finding. Furthermore, our 
sonographers were completely blinded for the clinical diagnoses. Additionally, 
our sonographers had had their training at different institutions and did never 
work together before. The relatively mediocre agreement in our study might be 
partly explained by a lack of generally accepted criteria for the evaluation of the 
echointensity of the SN and the RN. Possibly, a standardised quantitative 
measurement of the echointensity of the SN and the surrounding tissue might 
aid in improving the uniformity of the results. Additionally, standard settings for 
the ultrasound system used are required. 
 
Similar to the diagnostic studies using SPECT scans, most of the diagnostic 
studies using TCD included late-stage, well-diagnosed patients. Therefore, we 
assessed in chapter 6 the diagnostic accuracy of SN-TCD in unclear 
parkinsonism, and compared it with presynaptic and postsynaptic SPECT 
examinations being already part of our workup protocol. We studied 82 patients 
with an unclassified parkinsonian syndrome. The clinical diagnosis after follow-
up determined by an independent neurologist specialised in movement 
disorders was used as gold standard.  
Firstly, we investigated the diagnostic accuracy to differentiate between 
patients with IPD and patients without nigrostriatal degeneration like ET, VP, 
DIP. For SN-TCD we found a sensitivity of 50%, a specificity of 82%, a positive 
predictive value (PPV) of 89% and a negative predictive value (NPV) of 35%. 
For presynaptic SPECT scans these values were 97%, 100%, 100% and 92%, 
respectively.  
Secondly, we studied the accuracy to differentiate patients with IPD from 
patients with APS. For SN-TCD the sensitivity was 50%, the specificity 43%, 
the PPV 86% and the NPV 10% and for postsynaptic SPECT scans 75%, 81%, 
43% and 94%, respectively. The PPV of an abnormal SN-TCD for an abnormal 
presynaptic SPECT scan was 88%.  
We concluded that the diagnostic accuracy of presynaptic SPECT scan for the 
clinical diagnosis is higher than the accuracy of TCD. However, since an 
abnormal SN-TCD is highly predictive for an abnormal presynaptic SPECT 
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scan, SN-TCD can be used as screening tool before ordering a presynaptic 
SPECT scan.  
 
In chapter 7 we describe the protocol of the prospective diagnostic study we 
started in August 2006. In this study we enrolled 250 consecutive patients, who 
were referred to neurology outpatient clinics of two teaching hospitals, for 
analysis of clinically parkinsonism of unclear origin. All patients underwent 
TCD, presynaptic SPECT imaging, cognitive tests, motor tests and a smell test. 
As gold standard we use the clinical diagnosis as agreed upon by two 
independent, blinded neurologists specialised in movement disorders after a 
follow-up period of two years. In August 2008 inclusion was finished and we 
started re-examining the patients. In the coming years, we will continue with the 
follow-up of the 250 patients in our prospective trial. We expect the final results 
of this trial to be published by the end of 2010.  
 
In conclusion, diagnosing IPD can be difficult, especially in the early stages of 
the disease. Therefore, finding a reliable diagnostic test will have a positive 
effect on clinical patient care. As yet, there is no perfect test to diagnose 
Parkinson’s disease. Only the presynaptic SPECT scan is sufficiently studied 
and deemed reliable to use it in clinical diagnostic workup. Using the 
presynaptic SPECT scan, patients with IPD can be distinguished from healthy 
controls and from patients with VP and ET. Unfortunately, both post- and 
presynaptic SPECT scans are not suitable to differentiate patients with IPD 
from those with APS. Likewise, TCD is also not accurate in the differentiation 
between patients with IPD and those with APS. Nevertheless, SN-TCD seems 
to be a good alternative diagnostic tool, since an abnormal SN-TCD is an 
accurate predictor for the diagnosis of IPD. Although in our studies TCD is less 
reliable than SPECT scans, the PPV of an abnormal SN-TCD for IPD is very 
high. The fact that SN-TCD is less costly and less invasive for the patient in 
comparison with SPECT, makes it very worthwhile to study its true potential 
further.  
Although SN-TCD and SPECT can be helpful in the diagnostic process, they 
can never replace careful neurological examination since false positives do 
exist: the diagnosis of parkinsonian disorders continues to be based primarily 
on the demonstration of the characteristic neurological features.  
In our view the future role of SN-TCD is mainly being a screening instrument in 
two ways. Firstly, in daily clinical practice in selected patients with unclear 
parkinsonism a TCD can be ordered before a SPECT scan. In case of an 
abnormal SN-TCD a presynaptic SPECT scan can be considered unnecessary. 
Secondly, as soon as predictive or curative drugs are available SN-TCD may 
be an ideal tool for screening large populations to help identify subpopulations 
at risk. 
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1A. Idiopathic Parkinson’s Disease 
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of 
idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J 
Neurol Neurosurg Psychiatry 1992;55:181-4. 
1. Diagnosis of Parkinsonian syndrome 
- bradykinesia (slowness of initiation of voluntary movement with progressive 
reduction in speed and amplitude of repetitive actions)  
- and at least one of the following: a) muscular rigidity, b) 4-6 Hz tremor, c) 
postural instability not caused by primary visual, vestibular, cerebellar or 
proprioceptive dysfunction. 
 
2. Exclusion criteria for Parkinson’s disease 
- history of repeated strokes with stepwise progression of parkinsonian 
features 
- history of repeated head injury 
- history of definite encephalitis 
- oculogyric crises 
- neuroleptic treatment at onset of symptoms 
- more than one affected relative 
- sustained remission 
- strictly unilateral features after 3 years 
- supranuclear gaze palsy 
- cerebellar signs 
- early severe autonomic involvement 
- early severe dementia with disturbances of memory, language or praxis 
- Babinski sign 
- presence of cerebral tumour or communicating hydrocephalus on CT scan 
- negative response to large doses of Levodopa (if malabsorption excluded) 
- MPTP exposure 
3. Supportive prospective positive criteria for Parkinson’s disease 
(> 3 required for diagnosis of definite Parkinson’s disease) 
- unilateral onset 
- rest tremor present 
- progressive disorder 
- persistent asymmetry affecting side of onset most 
- excellent response (70-100%) to Levodopa 
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- severe Levodopa induced chorea 
- Levodopa response for 5 years of more 
- clinical course of 10 years of more 
1B. Diagnostic Criteria for Multiple System Atrophy 
(MSA) 
Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, 
Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver 
E, Robertson D, Schatz I, Wenning GK. Consensus statement on the diagnosis 
of multiple system atrophy. J Neurol Sci 1999;163:94-8. 
Clinical domains, features, and criteria used in the diagnosis of 
MSA 
Feature (A) is a characteristic of the disease 
Criterion (B) is a defining feature or composite of features required for 
diagnosis 
I Autonomic and urinary dysfunction 
A. Autonomic and urinary features: 
1. orthostatic hypotension (by 20 mmHg systolic or 10 mmHg 
diastolic) 
2. urinary incontinence or incomplete bladder emptying 
B. Criterion for autonomic failure or urinary dysfunction in MSA: 
Orthostatic fall in blood pressure (by 30 mmHg systolic or 15 mmHg 
diastolic) or urinary incontinence (persistent, involuntary partial or total 
bladder emptying, accompanied by erectile dysfunction in men) or both 
II Parkinsonism 
A. Parkinsonian features: 
1. bradykinesia (slowness of voluntary movement with progressive 
reduction in speed and amplitude during repetitive actions) 
2. rigidity 
3. postural instability (not caused by primary visual, vestibular, 
cerebellar, or proprioceptive dysfunction) 
4. tremor (postural, resting or both) 
B. Criterion for parkinsonism in MSA: 
 Bradykinesia plus at least 1 of items 2 to 4 
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III Cerebellar dysfunction 
A. Cerebellar features: 
 1. gait ataxia (wide based stance with steps of irregular length and 
direction) 
 2. atactic dysarthria 
 3. limb ataxia 
 4. sustained gaze-evoked nystagmus 
B. Criterion for cerebellar dysfunction in MSA: 
 gait ataxia plus at least 1 of items 2 to 4 
IV Corticospinal tract dysfunction 
A. Corticospinal tract features:   
 Extensor plantar responses with hyperreflexia 
B. Corticospinal tract dysfunction in MSA:  
 No corticospinal tract features are used in defining the diagnosis of 
 MSA 
Exclusion criteria for the diagnosis of MSA 
I. History: 
- symptomatic onset under 30 years of age 
- family history of a similar disorder- systemic diseases or other 
identifiable causes for clinical features- hallucinations unrelated 
to medication 
II. Physical examination: 
- DSM criteria for dementia 
- prominent slowing of vertical saccades or vertical supranuclear gaze 
palsy* 
- evidence of focal cortical dysfunction such as aphasia, alien limb 
syndrome, and parietal dysfunction 
III. Laboratory investigation: 
- metabolic, molecular genetic, and imaging evidence of an alternative 
cause of clinical features 
*mild limitation of upward gaze alone is non-specific, whereas a prominent 
(>50%) limitation of upward gaze or any limitation of downward gaze suggests 
progressive supranuclear palsy 
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Diagnostic categories of MSA 
Possible MSA 
1 criterion plus 2 features from separate domains 
When the criterion is parkinsonism, a poor Levodopa response qualifies as 1 
feature (hence only 1 additional feature is required) 
Probable MSA 
Criterion for autonomic failure/urinary dysfunction plus poor Levodopa-
responsive parkinsonism or cerebellar dysfunction 
Definite MSA 
Pathologically confirmed by the presence of a high density of glial cytoplasmic 
inclusions in association with a combination of degenerative changes in the 
nigrostriatal and olivopontocerebellar pathways 
1C Diagnostic Criteria for Progressive Supranuclear 
palsy (PSP) 
National Institute of Neurological Disorders and Stroke (NINDS)/Society for 
PSP (NINDS-SPSP); Neurology 1996; 47(1):1-9 
Possible PSP 
- gradually progressive disorder  
- onset at age 40 or later 
- either vertical supranuclear palsy or both slowing of vertical saccades and 
prominent postural instability with falls in the first year of disease onset 
- no evidence of other diseases that could explain the foregoing features, as 
indicated by mandatory exclusion criteria 
Probable PSP 
- gradually progressive disorder  
- onset at age 40 or later 
- vertical (upward or downward gaze) supranuclear palsy and prominent 
postural instability with falls in the first year of disease onset 
- no evidence of other diseases that could explain the foregoing features, as 
indicated by mandatory exclusion criteria 
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Definite 
- clinically probable or possible PSP and histopathologic evidence of typical 
PSP 
Exclusion criteria 
- recent history of encephalitis 
- alien limb syndrome, cortical sensory deficits, focal frontal or 
temporoparietal atrophy 
- hallucinations or delusions unrelated to dopaminergic therapy 
- cortical dementia of Alzheimer type (severe amnesia or aphasia or agnosia, 
according to NINCDS-ADRA criteria) 
- prominent early cerebellar symptoms or prominent, early, unexplained 
dysautonomia (marked hypotension and urinary disturbances) 
- severe asymmetric parkinsonian signs (i.e. bradykinesia) 
- neuroradiologic evidence of relevant structural abnormality (i.e. basal 
ganglia or brainstem infarcts, lobar atrophy) 
- whipple’s disease, confirmed by PCR, if indicated 
Supportive criteria 
- symmetric akinesia or rigidity, proximal more than distal 
- abnormal neck posture, especially retrocollis 
- poor or absent response of parkinsonism to levodopa therapy 
- early dysphagia and dysarthria 
- early onset of cognitive impairment including at least two if the following: 
apathy, impairment in abstract thought, decreased verbal fluency, utilisation 
or imitation behaviour, frontal release signs 
 
NB. Upward gaze is considered abnormal when pursuit or voluntary gaze, or 
both, have a restriction of at least 50% of the normal range 
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1D (Revised) Diagnostic Criteria for Dementia with 
Lewy Bodies (DLB) 
McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al. 
Consensus guidelines for the clinical and pathologic diagnosis of dementia with 
Lewy bodies (DLB): report of the consortium on DLB international workshop. 
Neurology 1996,47:1113-24. 
 
1. Central features  
 (Essential for a diagnosis of possible or probable DLB) 
- dementia defined as progressive cognitive decline of sufficient 
magnitude to interfere with normal social or occupational function 
- prominent or persistent memory impairment may not necessarily occur 
in the early stages but is usually evident with progression 
- deficits on tests of attention, executive function, and visuospatial ability 
may be especially prominent 
2. Core features  
 (2 core features are sufficient for a diagnosis of probable DLB, 1 for 
possible DLB) 
- fluctuating cognition with pronounced variations in attention and 
alertness 
- recurrent visual hallucinations that are typically well formed and 
detailed 
- spontaneous features of parkinsonism 
3. Suggestive features  
 (If one or more of these is present in the presence of one or more core 
features, a diagnosis of probable DLB can be made. In the absence of 
any core features, one or more suggestive features is sufficient for 
possible DLB)  
- REM sleep behaviour disorder 
- severe neuroleptic sensitivity 
- low dopamine transporter uptake in basal ganglia demonstrated by 
SPECT or PET imaging 
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4. Supportive features  
 (commonly present but not proven to have diagnostic specificity) 
- repeated falls and syncope 
- transient unexplained loss of consciousness 
- severe autonomic dysfunction, e.g. orthostatic hypotension, urinary 
incontinence 
- hallucinations in other modalities 
- systematized delusions 
- relatively preservation of medial temporal lobe structures on CT/MRI 
- generalized low uptake on SPECT/PET perfusion scan with reduced 
occipital activity 
- abnormal (low uptake) MIBG myocardial scintigraphy 
- prominent slow wave activity on EEG with temporal lobe transient 
sharp waves 
5. A diagnosis of DLB is less likely 
- in the presence of cerebrovascular disease evident as focal neurologic 
signs or on brain imaging 
- in the presence of any other physical illness or brain disorder sufficient 
to account in part or in total for the clinical picture 
- if parkinsonism only appears for the first time at a stage of severe 
dementia 
6. Temporal sequence of symptoms 
DLB should be diagnosed when dementia occurs before or concurrently 
with parkinsonism (if it is present). The term Parkinson disease dementia 
(PDD) should be used to describe dementia that occurs in the context of 
well-established Parkinson’s disease. In a practice setting the term that is 
most appropriate to the clinical situation should be used and generic 
terms such as LB disease are often helpful. In research studies in which 
distinction needs to be made between DLB and PDD, the existing 1-year 
rule between the onset of dementia and parkinsonism DLB continues to 
be recommended.  
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1E Corticobasal degeneration 
Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to 
progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 
2003;54 Suppl 5:S15-9. 
Core features 
1) iInsidious onset and progressive course 
2) no identifiable cause 
3) cortical dysfunction as reflected by at least one of the following: 
- focal or asymmetric ideomotor apraxia 
- alien limb phenomenon 
- cortical sensory loss 
- visual or sensory hemi-neglect 
- constructional apraxia 
- focal or asymmetric myoclonus 
- apraxia of speech/ nonfluent aphasia 
4) extrapyramidal dysfunction as reflected by at least one of the following: 
- focal or asymmetric appendicular rigidity lacking prominent and  
  sunstained L-dopa response 
- focal or asymmetric appendicular dystonia 
Supportive investigations 
1) variable degrees of focal or lateralized cognitive dysfunction, with relative 
preservation of learning and memory, on neuropsychometric testing 
2) focal or asymmetric atrophy 
3) focal or asymmetric hypoperfusion on SPECT and hypometabolism on PET, 
typically maximal in parietofrontal cortex +/- basal ganglia +/- thalamus 
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1F Vascular parkinsonism 
Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ: Clinicopathological 
investigation of vascular parkinsonism, including clinical criteria for diagnosis. 
Movement Disorders 2004;19:630-40. 
1. Parkinsonism 
A. Bradykinesia (slowness of initiation of voluntary movement with 
progressive reduction in speed and amplitude of repetitive actions in 
either upper limb or lower limb, including the presence of reduced step 
length)  
B. At least one of the following: rest tremor, muscular rigidity, or postural 
instability not caused by primary visual, vestibular, cerebellar or 
proprioceptive dysfunction. 
2. Cerebrovascular disease 
Definition: evidence of relevant cerebrovascular disease by brain imaging 
(CT or MRI) or the presence of focal signs or symptoms that are consistent 
with stroke. 
3. A relationship between the above two disorders.  
A. An acute or delayed progressive onset with infarcts in or near areas 
that can increase the basal ganglia motor output (external globus 
pallidus or substantia nigra pars compacta) or decrease the 
thalamocortical drive directly (ventral lateral nucleus of the thalamus, 
large frontal lobe infarct). The parkinsonism at onset consists of a 
contralateral bradykinetic rigid syndrome or shuffling gait, within one 
year after a stroke.  
B. An insidious onset of parkinsonism with extensive subcortical white 
matter lesions, bilateral symptoms at onset, and the presence of early 
shuffling gait or early cognitive dysfunction. 
Exclusion criteria:  
- history of repeated head injury 
- definite encephalitis 
- neuroleptic treatment at onset of symptoms 
- presence of cerebral tumor or communicating hydrocephalus on CT or 
MRI scan 
- other alternative explanation for parkinsonism 
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1G Essential tremor  
Deuschl G, Bain PG, Brin M, and an Ad Hoc Scientific Committee. Consensus 
statement of the Movement Disorder Society on tremor. Movement Disorders 
1998;13:2–23 
 
The following clinical criteria are used to make the diagnosis of classical 
essential tremor:  
1. Inclusion criteria:  
- the presence of bilateral, largely symmetrical postural or kinetic tremor 
involving hands and forearms that is visible and persistent 
- additional or isolated tremor of the head may occur but in the absence 
of abnormal posturing  
2. Exclusion criteria:  
- other abnormal signs, especially dystonia  
- the presence of known causes of enhanced physiological tremor, 
including current or recent exposure to tremorgenic drugs or a drug 
withdrawal state  
- historic or clinical evidence for a psychogenic origin of tremor  
- convincing evidence of sudden onset or evidence of stepwise 
deterioration of tremor  
- primary orthostatic tremor  
- isolated voice tremor  
- isolated position specific or task specific tremors, including 
occupational tremors and primary writing tremor  
- isolated tongue or chin tremor  
- isolated leg tremor  
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Gestandaardiseerde Parkinsonschaal (UPDRS) 
Fahn S, Elton RL. The Unified Parkinson's Disease Rating Scale. In: Recent developments in 
Parkinson's disease. Edited by M Goldstein. pp. 153-64. Florham Park, NJ: Marcmillan Health Care 
Information. 1987:153-64. 
I. Geestestoestand, gedrag en stemming 
1. Cognitieve stoornis 
0 = Geen. 
1 = Licht. Constante vergeetachtigheid met gedeeltelijke herinnering van 
gebeurtenissen zonder andere moeilijkheden. 
2 = Matig geheugenverlies met desoriëntatie en matige moeite met complexe 
probleemhantering. Lichte maar duidelijke functiezwakte in geval van incidenteel op 
te roepen herinneringen in de thuissituatie. 
3 = Ernstig geheugenverlies met desoriënatie in tijd en vaak in plaats. Ernstige zwakte 
in probleemhantering. 
4 = Ernstig geheugenverlies met enkel oriëntatie in persoon. Niet in staat inschattingen 
te maken of probleemoplossend te denken. Grote hulpbehoefte bij persoonlijke 
verzorging. Kan geenszins alleen gelaten worden. 
2. Denkstoornis (t.g.v. dementie of geneesmiddelintoxicatie) 
0 = Geen. 
1 = Levendige dromen, nachtmerries. 
2 = Pseudohallucinaties met ziekte-inzicht. 
3 = Incidenteel tot frequent hallucinaties of waanideeën; zonder ziekte-inzicht; mogelijk 
belemmerend voor dagelijkse activiteiten. 
4 = Persisterende hallucinaties, waanideeën of ernstige psychose. Niet in staat voor 
zichzelf te zorgen. 
3. Depressie 
0 = Niet aanwezig. 
1 = Perioden van somberheid of schuldgevoel meer dan normaal, nooit dagen of weken 
aanhoudend. 
2 = Aanhoudende depressie (één week of langer). 
3 = Aanhoudende depressie met vitale symptomen (slapeloosheid, gebrek aan eetlust, 
gewichtsverlies, interesseverlies). 
4 = Aanhoudende depressie met vitale symptomen en zelfmoordgedachten of -
neigingen. 
4. Motivatie/ondernemingszin 
0 = Normaal. 
1 = Minder assertief dan normaal; passiever. 
2 = Verlies van ondernemingszin of desinteresse in voorkeursactiviteiten (niet 
routinematig). 
3 = Verlies van van ondernemingszin of desinteresse in dagelijkse activiteiten 
(routinematige). 
4 = Teruggetrokken, volledig verlies van motivatie. 
II. Activiteiten dagelijks leven 
5. Spraak 
0 = Normaal. 
1 = Licht aangedaan. Geen moeilijkheden ondervindend. 
2 = Matig aangedaan. Soms gevraagd uitspraken te herhalen. 
3 = Ernstig aangedaan. Regelmatig gevraagd uitspraken te herhalen. 
4 = Meestal onverstaanbaar. 
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6. Speekselvloed 
0 = Normaal. 
1 = Onbeduidende maar duidelijke overmaat aan speeksel in de mond; mogelijk 
nachtelijk kwijlen. 
2 = Matige overmaat aan speeksel; mogelijk overdag minimaal kwijlen. 
3 = Uitgesproken overmaat aan speeksel met enig kwijlen. 
4 = Uitgesproken kwijlen, constant een zakdoek nodig. 
7. Slikken 
0 = Normaal. 
1 = Zelden verslikkend. 
2 = Incidenteel verslikkend. 
3 = Zacht voedsel noodzakelijk. 
4 = (PEG-) of sondevoeding noodzakelijk. 
8. Handschrift 
0 = Normaal. 
1 = Iets  traag of klein. 
2 = Matig traag of klein; alle woorden zijn leesbaar. 
3 = Ernstig aangedaan; niet alle woorden zijn leesbaar. 
4 = De meerderheid van de woorden zijn niet leesbaar. 
9. Snijden van voedsel en gebruik van werktuigen 
0 = Normaal. 
1 = Ietwat traag en onhandig, maar geen hulp nodig. 
2 = Kan het meeste voedsel snijden, echter onhandig en traag; enige hulp nodig. 
3 = Voedsel moet door iemand gesneden worden, maar kan nog altijd traag eten. 
4 = Moet gevoerd worden. 
10. Aankleden 
0 = Normaal. 
1 = Ietwat traag, maar geen hulp nodig. 
2 = Incidenteel hulp nodig bij dichtknopen en armen in mouwen steken. 
3 = Aanzienlijke hulp nodig, maar kan enkele dingen zelf. 
4 = Geheel afhankelijk. 
11. Hygiène 
0 = Normaal. 
1 = Ietwat traag, maar geen hulp nodig. 
2 = Hulp nodig bij douchen of baden; of erg traag in hygiënische verzorging. 
3 = Hulp vereist bij wassen, tandenpoetsen, haar kammen en toiletbezoek. 
4 = Cathether of andere mechanische hulpmiddelen. 
12. Omdraaien in bed en rechttrekken beddegoed 
0 = Normaal. 
1 = Ietwat traag en onhandig, maar geen hulp nodig. 
2 = Kan zelfstandig draaien of lakens rechttrekken, maar met grote moeite. 
3 = Kan het intiatief nemen, maar niet zelfstandig omdraaien of de lakens rechttrekken. 
4 = Geheel afhankelijk. 
13. Vallen (Niet gerelateerd aan blokkeren) 
0 = Niet. 
1 = Valt zelden. 
2 = Valt soms, minder dan één keer per dag. 
3 = Valt gemiddeld één keer per dag. 
4 = Valt vaker dan één keer per dag. 
14. Blokkeren bij lopen 
0 = Niet. 
1 = Zelden blokkeren bij lopen; mogelijk 'startproblemen'. 
2 = Soms blokkeren bij lopen. 
3 = Regelmatig blokkeren. Valt soms t.g.v. blokkeren. 
4 = Valt frequent t.g.v. blokkeren. 
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15. Lopen 
0 = Normaal. 
1 = Lichte moeite. Mogelijk afwezige armzwaai of neiging tot sloffen. 
2 = Matige moeite, maar weinig tot geen hulp vereist. 
3 = Ernstige loopstoornis, hulp vereist. 
4 = Kan in het geheel niet lopen, zelfs niet met hulp. 
16. Tremor (Symptomatische klachten van tremor in een willekeurig deel van het lichaam.) 
0 = Afwezig. 
1 = Onbeduidend en onregelmatig aanwezig. 
2 = Matig; hinderlijk voor de patiënt. 
3 = Ernstig; belemmerend voor veel activiteiten. 
4 = Uitgesproken; belemmerend voor de meeste activiteiten. 
17. Gevoelsklachten gerelateerd aan parkinson. 
0 = Geen. 
1 = Incidenteel last van doof gevoel, tintelingen of lichte pijn. 
2 = Regelmatig last van doof gevoel, tintelingen of pijn; niet kwellend. 
3 = Vaak pijnlijke sensaties. 
4 =  Ondraaglijke pijn. 
III. Motorisch onderzoek 
18. Spraak 
0 = Normaal. 
1 = Onbeduidend verlies van uitdrukkingskracht, articulatie en/of volume. 
2 = Monotoon en mompelend, maar begrijpelijk; matig gestoord. 
3 = Uitgesproken gestoord, moeilijk te begrijpen. 
4 = Onbegrijpelijk. 
19. Gezichtsuitdrukking 
0 = Normaal. 
1 = Minimaal verminderde mimiek, zou een normaal 'poker face' kunnen zijn. 
2 = Lichte, maar duidelijk abnormale vermindering van mimiek. 
3 = Matig verminderde mimiek; af en toe open mond.  
4 = Maskergelaat met ernstig of volledig verlies van mimiek; mond meer dan een halve 
centimeter open. 
20. Rusttremor 
0 = Afwezig. 
1 = Onbeduidend en onregelmatig aanwezig. 
2 = Kleine amplitude en persisterend. Of matige amplitude, maar intermitterend. 
3 = Matige amplitude en meestal aanwezig. 
4 = Grote amplitude en meestal aanwezig. 
21. Actietremor van de handen 
0 = Afwezig. 
1 = Onbeduidend; aanwezig bij actie. 
2 = Matige amplitude, aanwezig bij actie. 
3 = Matige amplitude, zowel bij statische houding als bij intentie. 
4 = Grote amplitude; belemmerend bij eten. 
22. Rigiditeit (Beoordeeld bij passief bewegen grote gewrichten terwijl de patiënt ontspannen 
zit; niet verwarren met tandradfenomeen.) 
0 = Afwezig. 
1 = Onbeduidend of enkel waarneembaar indien geactiveerd door 'mirror movements' 
of andere bewegingen. 
2 = Licht tot matig. 
3 = Uitgesproken, maar volledige bewegingsuitslagen worden gemakkelijk bereikt. 
4 = Ernstig, bewegingsuitslagen worden moeizaam bereikt. 
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23. Vingertikken (Patiënt tikt duim en wijsvinger snel opeenvolgend met de grootst mogelijke 
amplitude, elke hand afzonderlijk.) 
0 = Normaal. 
1 = Lichte vertraging en/of verminderde amplitude. 
2 = Matig gestoord. Duidelijk en snel vermoeid. Eventueel incidentele onderbreking van 
de beweging. 
3 = Ernstig gestoord. Frequente aarzeling in het initiëren van bewegingen of 
onderbreking van herhaalde beweging. 
4 = Kan de taak nauwelijks uitvoeren. 
24. Handbewegingen (Patiënt opent en sluit de hand snel opeenvolgend met de grootst 
mogelijke amplitude, elke hand afzonderlijk.) 
0 = Normaal. 
1 = Lichte vertraging en/of verminderde amplitude. 
2 = Matig gestoord. Duidelijk en snel vermoeid. Eventueel incidentele onderbreking van 
de beweging. 
3 = Ernstig gestoord. Frequente aarzeling in het initiëren van bewegingen of 
onderbreking van een herhaalde beweging. 
4 = Kan de taak nauwelijks uitvoeren. 
25. Snel alternerende handbewegingen (Pro-/ supinatiebewegingen van de hand, vertikaal 
en horizontaal, met de grootst mogelijke amplitude, elke hand afzonderlijk.) 
0 = Normaal. 
1 = Lichte vertraging en/of verminderde amplitude. 
2 = Matig gestoord. Duidelijk en snel vermoeid. Eventueel incidentele onderbreking van 
de beweging. 
3 = Ernstig gestoord. Frequente aarzeling in het initiëren van bewegingen of 
onderbreking van een herhaalde beweging. 
4 = Kan de taak nauwelijks uitvoeren. 
26. Beweeglijkheid van de benen (Patiënt tikt de hiel snel opeenvolgend tegen de grond, het 
hele been optillend. Amplitude ca. 7,5 cm.) 
0 = Normaal. 
1 = Lichte vertraging en/of verminderde amplitude. 
2 = Matig gestoord. Duidelijk en snel vermoeid. Mogelijk incidentele onderbreking van 
de beweging. 
3 = Ernstig gestoord. Frequente aarzeling in het initiëren van bewegingen of 
onderbreking van een herhaalde beweging. 
4 = Kan de taak nauwelijks uitvoeren. 
27. Opstaan uit stoel (Patiënt tracht op te staan uit een houten of metalen stoel met rechte 
rugleuning, met de armen gekruist voor de borst.) 
0 = Normaal. 
1 = Traag; of heeft meer dan één poging nodig.  
2 = Duwt zichzelf op vanuit de armleuning. 
3 = Neigt terug te vallen in de stoel en moet mogelijk meer dan één keer proberen, 
maar kan opkomen zonder hulp. 
4 = Niet in staat zonder hulp op te staan. 
28. Houding 
0 = Normaal rechtop. 
1 = Niet volledig rechtop, enigszins gebogen houding; zou normaal kunnen zijn voor 
een ouder iemand. 
2 = Matig gebogen houding, duidelijk afwijkend; mogelijk iets naar één kant neigend. 
3 = Ernstig gebogen houding met een kyfose; mogelijk matig naar één kant neigend. 
4 = Uitgesproken flexie met extreme houdingsafwijking. 
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29. Gang 
0 = Normaal. 
1 = Loopt traag, mogelijk schuifelend met korte pasjes, maar geen festinatie (snelle 
pasjes) of propulsie. 
2 = Moeite met lopen, maar weinig tot geen hulp nodig; mogelijk enige festinatie, korte 
pasjes of propulsie. 
3 = Ernstige gangstoornis, hulp vereist. 
4 = Totaal niet in staat te lopen, zelfs niet met hulp. 
30. Houdingsstabiliteit (Reactie op plotselinge, krachtige achterwaartse verplaatsing 
veroorzaakt door een ruk aan de schouders terwijl de patiënt rechtop staat met 
geopende ogen en de benen iets gespreid. De patiënt is voorbereid en heeft mogelijk 
wat oefenpogingen gehad.) 
0 = Normaal. 
1 = Retropulsie, maar herstelt zich zonder hulp. 
2 = Afwezigheid van de houdingsreflex; zou vallen indien niet opgevangen door de 
onderzoeker. 
3 = Erg instabiel, neigt spontaan het evenwicht te verliezen. 
4 = Niet in staat te staan zonder hulp. 
31. Algehele brady- en hypokinesie (Traagheid, aarzeling, afgenomen armzwaai, kleine 
bewegingsuitslagen en bewegingsarmoede in het algemeen.) 
0 = Geen. 
1 = Minimale traagheid, wat het bewegen een bedachtzaam karakter geeft; zou voor 
sommige personen normaal kunnen zijn. Mogelijk afgenomen bewegingsuitslagen. 
2 = Lichte mate van traagheid en duidelijke bewegingsarmoede. Ofwel wat afgenomen 
bewegingsuitslagen. 
3 = Matige traagheid, bewegingsarmoede of kleine bewegingsuitslagen. 
4 = Uitgesproken traagheid, bewegingsarmoede of kleine bewegingsuitslagen. 
IV. Complicaties van de therapie (In de voorgaande week.) 
A Dyskinesieën 
32. Duur: welk percentage van de dag zijn dyskinesieën aanwezig? [Anamnestisch.] 
0 = Niet. 
1 = 1-25% van de dag. 
2 = 26-50% van de dag. 
3 = 51-75% van de dag. 
4 = 76-100% van de dag. 
33. Handicap: in welke mate vormen de dyskinesieën een handicap? 
0 = Niet invaliderend. 
1 = Licht invaliderend. 
2 = Matig invaliderend. 
3 = Ernstig invaliderend. 
4 = Volledig invaliderend. 
34. Pijnlijke dyskinesieën: hoe pijnlijk zijn de dyskinesieën? 
0 = Geen pijnlijke dyskinesieën. 
1 = Licht. 
2 = Matig. 
3 = Ernstig. 
4 = Zeer ernstig. 
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35. Aanwezigheid van ochtendkramp 
0 = Nee. 
1 = Ja. 
B. Klinische schommelingen 
36. Zijn er voorspelbare 'off'-perioden, samenhangend met tijdstip van medicatie-inname? 
0 = Nee. 
1 = Ja. 
37. Zijn er onvoorspelbare 'off'-perioden, dus niet samenhangend met het tijdstip na 
medicatie-inname? 
0 = Nee. 
1 = Ja. 
38. Komen de 'off'-perioden plotseling op, bijvoorbeeld na een paar seconden? 
0 = Nee. 
1 = Ja. 
39. Welk percentage van de dag is de patiënt gemiddeld 'off'? 
0 = Geen. 
1 = 1-25% van de dag. 
2 = 26-50% van de dag. 
3 = 51-75% van de dag. 
4 = 76-100% van de dag. 
C. Andere complicaties 
40. Heeft de patiënt last van gebrek aan eetlust, misselijkheid of braken? 
0 = Nee. 
1 = Ja. 
41. Heeft de patiënt last van slaapstoornissen, bijvoorbeeld slapeloosheid of overmatige 
slaperigheid? 
0 = Nee. 
1 = Ja. 
42. Heeft de patiënt last van symptomatische bloeddrukdaling? 
0 = Nee. 
1 = Ja. 
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Hoehn and Yahr Scale for Parkinson’s disease  
Brandt T, Caplan LR, Dichgans J, Diener C, Kennard C. Neurological disorders. Course and 
treatment. In. San Diego, California: Academic press; 1996. 
 
 
Stage   
1 unilateral disease 
1.5 unilateral plus axial involvement 
2 bilateral disease without impairment of balance 
2.5 mild bilateral disease, with recovery on pull test 
3 mild to moderate bilateral disease, some postural instability, physically
independent 
4 severe disability, still able to walk or to stand unassisted 
5 wheelchair bound or bedridden unless aided 
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Hamilton Rating Scale for Depression 
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 
 
De HDRS is een vragenlijst met 17 items. Optelling van de eerste 17 items 
geeft een maat voor de ernst van een al vastgestelde depressie. Score van de 
eerste 17 items: mild = 10 - 13; mild tot matig = 14-17; >17 = matig tot ernstig. 
1. Depressieve stemming 
Heeft betrekking op de verbale en non-verbale uitingen van een depressieve stemming, 
gekarakteriseerd door verschijnselen als: neerslachtigheid, bedroefdheid, moedeloosheid, 
hopeloosheid, hulpeloosheid en pessimisme. 
0 = afwezig 
1 = twijfelachtig (patiënt vertelt alleen als er naar gevraagd wordt) 
2 = duidelijk (patiënt vertelt er spontaan over) 
3 = non-verbale tekenen van depressie en/ of soms er door overweldigd 
4 = niet er van af te leiden, uitgesproken non-verbale tekenen van depressie 
2. Zelfverwijt 
Inhoudelijke denkstoornissen met als thema's: zelfverwijt, schuldgevoel, falen, verminderd 
zelfrespect et cetera. 
0 = afwezig 
1 = twijfelachtig (alleen m.b.t. familie en collega's) 
2 = duidelijk (kleine tekortkomingen, falen, verzaken plicht et cetera) 
3 = ernstig (waandenkbeelden zoals de huidige ziekte is een soort straf) 
4 = stemmingscongruente wanen 
3. Suïcidaliteit 
0 = afwezig 
1 = het leven is niet de moeite waard, maar geen doodswens 
2 = geen zelfmoordplannen, maar wel doodswens 
3 = overweegt zich te suïcideren 
4 = zelfmoordpoging, opgenomen en gevaar voor eigen leven 
4. Inslaapstoornissen 
0 = afwezig 
1 = afgelopen 3 nachten duurde inslapen 1 à 2 maal langer dan 1½ uur 
2 = afgelopen 3 nachten duurde inslapen elke nacht langer dan 1½ uur 
5. Doorslaapstoornissen 
0 = afwezig 
1 = afgelopen 3 nachten één à twee maal (onrustige nacht, lichte slaap) 
2 = afgelopen 3 nachten elke nacht tenminste eenmaal (lang) wakker 
6. Vroeg (voortijdig) ontwaken 
0 = afwezig 
1 = afgelopen 3 nachten minder dan een uur, kan weer inslapen 
2 = afgelopen 3 nachten constant (meer dan een uur, kan niet meer inslapen) 
7. Werk en belangstelling 
Heeft betrekking op verrichte werkzaamheden, motivatie.  
0 = normaal 
1 = moeite met dagelijkse werkzaamheden, wordt wel gedaan 
2 = uitgesproken tekortschieten, gereduceerd niveau en tempo 
3 = werkt hooguit 3 à 4 uur per dag 
4 = inactief, doet vrijwel niets 
8. Retardatie (vertraging, remming) 
Heeft op betrekking op de psychomotoriek (onder andere mimiek) en formele denkstoornissen 
(aandacht, concentratie,denkremming, besluiteloosheid, geheugenstoornissen) 
0 = afwezig 
1 = twijfelachtig, licht vertraagd 
2 = duidelijk vertraagd 
3 = gesprek zeer moeizaam, uitermate trage bewegingen 
4 = stupor (bewegingloosheid), spraakarmoede, zegt vrijwel niets meer 
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9. Agitatie (opwinding) 
Heeft op betrekking op de psychomotoriek. 
0 = afwezig 
1 = twijfelachtige of lichte opwinding, onrust en gejaagdheid 
2 = duidelijke onrust (handen wringen, voortdurend veranderen houding) 
3 = kan niet blijven zitten, steeds opstaan om te lopen 
4 = voortdurend heen en weer lopen, haren plukken 
10. Angst 
Heeft betrekking op het gevoel, omvat gespannenheid, prikkelbaarheid, tobben, onveiligheid, 
angst tot paniek 
0 = afwezig 
1 = twijfelachtig of licht gespannen, prikkelbaar 
2 = duidelijk angstig, prikkelbaar, maar zonder invloed op dagelijks leven 
3 = paniek, (soms interfererend met dagelijks leven) en anticipatie-angst 
4 = vaak angst en paniek, interfereert duidelijk met dagelijks leven 
11. Angst (lichamelijke) 
Omvat alle fysiologische (lichamelijke) begeleidende symptomen van angst zoals: droge 
mond, diaree, krampen, misselijk, hartkloppingen, pijn op de borst, versnelde hartactie, 
duizelig, wazig zien, ademnood, hyperventilatie, transpireren, trillen 
0 = afwezig 
1 = twijfelachtig of lichte verschijnselen  
2 = duidelijk verschijnselen, maar zonder invloed op dagelijks leven 
3 = uitgesproken, soms zorgwekkend, soms invloed op het dagelijks leven  
4 = veel, hardnekkige verschijnselen, ernstige invloed op dagelijks leven 
12. Gastro-intestinaal (maag-darm) 
Gebrek aan eetlust, droge mond, obstipatie et cetera 
0 = afwezig 
1 = eten smaakt niet, verlies eetlust, eet wel vrijwel normaal  
2 = eet duidelijk minder, meestal duidelijke obstipatie 
13. Lichamelijk (algemeen) 
Moe, geen energie, initiatiefverlies, krachteloos, vage spierpijnen, et cetera 
0 = afwezig 
1 = twijfelachtig of vage klachten van vermoeidheid in spieren et cetera  
2 = duidelijk of constant vermoeid en uitgeput en spierpijnen 
14. Seksuele stoornissen 
0 = normaal 
1 = twijfelachtig of licht verminderde seksuele belangstelling  
2 = duidelijk verlies seksuele belangstelling, vaak impotentie klachten 
15. Hypochondrie 
Preoccupatie met lichamelijke verschijnselen en functies 
0 = afwezig 
1 = lichte of twijfelachtige bezorgdheid  
2 = duidelijk bezorgd omtrent lichamelijke gezondheid  
3 = preoccupatie met angst of overtuiging ernstige lichamelijke ziekte te hebben  
4 = hypochondrische wanen 
16. Gewichtsverlies 
0 = afwezig 
1 = 1 - 1½ kg/ week  
2 = 3 kg/ week of meer  
17. Ziekte-inzicht 
0 = erkent depressief te zijn 
1 = erkent depressief te zijn, wijdt het aan andere omstandigheden, bijv. klimaat, werk 
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SCOPA-COG  
Marinus J, Visser M, Verwey NA, Verhey FRJ, Middelkoop HAM, Stiggelbout AM, van Hilten JJ. 
Assessment of cognition in Parkinson’s disease. Neurology 2003;61:1222-1228.  
The mean SCOPA-COG for controls (n=75) in this study was 30.7 (standard deviation 5.6). Lower 
scores indicate more severe impairment. 
Geheugen en leren  
1. woordherinneringstaak 
(N.B. elk woord staat gedrukt op een los vel. De 10 woorden worden steeds minimaal 4 
seconden aangeboden; hardop door de patiënt laten voorlezen, geen tijdslimiet aan het 
herinneren)  
Instructie:“Lees de woorden hardop. Het zijn tien woorden, waarvan u er zoveel  
mogelijk moet proberen te onthouden! Na het oplezen van alle woorden, probeert u er zoveel op 
te noemen”.  
(10 goed= 5, 8-9 goed= 4, 6-7 goed= 3, 5 goed= 2, 4 goed= 1, 3 goed= 0)  
 
groenteboer  prikkeldraad  boter  koffie  gordijn  hand  krant  mond  trein  muur  
 
aantal woorden goed:  /10 
score:  /5  
2. spanne achterwaarts  
(NB: patiënt vragen de cijfers in omgekeerde volgorde te herhalen; cijfers worden afzonderlijk 
opgelezen, 1 seconde per cijfer; indien niet correct wordt herhaald, het alternatief in de 2e kolom 
aanbieden; doorgaan totdat tweemaal hetzelfde aantal digits is gemist; noteer hoogste reeks die 




2-4   5-8   = 1  
6-2-9   4-1-5   = 2  
3-2-7-9   4-9-6-8   = 3  
1-5-2-8-6   6-1-8-4-3  = 4  
5-3-9-4-1-8   7-2-4-8-5-6  = 5  
8-1-2-9-3-6-5   4-7-3-9-1-2-8  = 6  
9-4-3-7-6-2-5-8   7-2-8-1-9-6-5-3  = 7  
 
score:…………../7  
3. blokjes aanwijzen (vier blokjes staan in een rij naast elkaar afgebeeld) 
(NB: blokjes in aangegeven volgorde aanwijzen; patiënt dient dit te herhalen; langzaam 
uitvoeren; patiënt bepaalt zelf met welke hand dit gedaan wordt)  
 
a. 1-2-4-2  
b. 1-2-3-4-3  
c. 3-4-2-1-4  
d. 1-4-2-3-4-1  
e. 1-4-2-3  
 
aantal goed:……/5  
 
Aandacht  
Thesis_Vlaar_v3.pdf   166 26-6-2009   9:23:36
 Appendix B⏐167 
167 
Aandacht  
4. terugtellen (30 naar 0)  
(NB: fout kan óf de volgorde, óf het overslaan / niet weten van het getal, óf het niet afmaken van 
de reeks betreffen)  
Instructie: "Wilt u van de 30 drie aftrekken, dan van de uitkomst weer 3 aftrekken en daarmee 
doorgaan tot 0?"  
(0 fout= 2, 1 fout= 1, 2 of meer fouten= 0) 
 
aantal goed:  /10  
score: /2 
5. maanden achterwaarts  
(NB: fout kan óf de volgorde, óf het overslaan / niet weten van maanden, óf het niet afmaken van 
de reeks betreffen)  
Instructie: "Noem de maanden van het jaar in omgekeerde volgorde op, beginnend bij de laatste 
maand van het jaar”  
 
(dec – nov – okt – sept – aug – juli – juni – mei – april – maart – febr – jan)  
(0 fout= 2, 1 fout= 1, 2 of meer fouten= 0)  
 
aantal goed: /12  
score: /2 
Executieve functies  
6. fist-edge-palm  
(NB: 1.vuist met ulnaire zijde naar beneden, 2. gestrekte vingers, ulnaire zijde beneden, 3. 
gestrekte vingers, palm naar beneden); eerst 5 series oefenen met verbale ondersteuning, bv 
door VUIST-STREK-PALM; noteer aantal goede triades uit totaal van 10; patiënt kiest welke 
hand gebruikt wordt)  
(10 goed= 3, 9 goed= 2, 8 goed= 1, 7 of minder goed= 0)  
 
aantal fout:......... aantal goed:  /10  
score:……..…… /3  
7. semantic fluency  
(NB: 1 minuut; geen woordherhalingen of woordvariaties, zoals aap-apin, beer-berin etc.; ook 
categorieën zijn toegestaan, zo zijn ‘vogel’ en ‘merel’ beiden goed; noteer zowel het aantal 
goede dieren als de namen van alle genoemde dieren)  
(25 goed= 6, 20-24= 5, 15-19= 4, 10-14= 3, 5-9= 2, 1-4= 1, 0= 0)  
 
aantal dieren goed: …………  
score:…          …..……/6  
8. dobbelstenen  
(NB: gebruik 2 kaartjes, een met JA = EVEN, NEE = ONEVEN; een met JA = HOGER, NEE = 
LAGER. Leg het correcte plaatje bij de uitleg van de test neer en zorg dat het andere, niet 
relevante plaatje, niet zichtbaar is.  
De patient krijgt een aantal bladzijden te zien met dobbelstenen.  
De eerste testreeks (conditie 1) wordt niet gescoord. Verbeter de patiënt als deze een fout 
maakt).  
 
Conditie 1: JA = EVEN  
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Instructie: "Zeg JA tegen een even aantal ogen op de dobbelsteen en NEE tegen een oneven 
aantal ogen".  
 
Hierna wordt de patiënt gevraagd te antwoorden volgens het principe JA = HOGER, NEE = 
LAGER. Het gaat hierbij steeds om de eerste respons. Corrigeren is in conditie 2 niet 
toegestaan.  
Conditie 2: JA = HOGER  
 
Instructie: Zeg JA indien het aantal ogen op de dobbelsteen hoger is dan op de vorige en NEE 
als dit aantal lager is.  
 
1  2  3  4  5  6  7  8  9  10  
(10 goed= 3, 9 goed=2, 8 goed=1, 7 of minder goed= 0)  
 
aantal goed: …./10  
score:……..……/3  
Visuospatiële functies  
9. figuren completeren  
NB: patiënt krijgt 5 incomplete figuren te zien en moet steeds 2 of 3 vormen uit 4 of 5 mogelijke 
alternatieven kiezen om het figuur te completeren. Eerst 2 oefen voorbeelden  
 
 a.  b.  c.  d.  e.  aantal goed:……..……/5  
Geheugen  
10. delayed recall  
Instructie: "Kunt u de 10 woorden die u in het begin uit uw hoofd hebt moeten leren nog een 
proberen op te noemen?"  
 
(10 goed= 5, 8-9 goed= 4, 6-7 goed= 3, 5 goed= 2, 4 goed= 1, 3 goed= 0)  
groenteboer prikkeldraad boter koffie gordijn hand krant mond trein muur  
 
aantal woorden goed: /10  
score: /5 
 
Totale COG score: /43  
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Sniffin Smell tests 
Kobal G, Hummel T, Sekinger B, Barz S, Roscher S, Wolf S. "Sniffin' sticks": screening of olfactory 
performance. Rhinology 1996, 34:222-6. 
 
- Hoe is uw reuk?: 0 normaal    
 0 verminderd 
 0 versterkt 
 0 weet ik niet 
- Uitgeoefend beroep?:   
- Roken? 0 rookt nog  
 0 in verleden gerookt 
 0 nooit gerookt 
 
- Doorgemaakt hersenletsel/ ernstige hoofdtrauma? 0 nee   0 ja 





































Vis Ham  
Thesis_Vlaar_v3.pdf   169 26-6-2009   9:23:36
170⏐ 
               






Appendix C  
 























Chapter 10C v9.pdf   1 2-7-2009   8:50:56
172⏐ 
Chapter 10C v9.pdf   2 2-7-2009   8:50:56
 Appendix C⏐173 
 
Praktische handleiding transcraniële echografie 
Inleiding 
Sedert ruim 10 jaar wordt transcraniële duplex (TCD) in het kader van 
wetenschappelijk onderzoek gebruikt bij patiënten met een parkinsonistische 
aandoening.1 Met behulp van deze techniek kunnen veranderingen in de echo-
intensiteit van hersenstructuren gevisualiseerd worden. Veranderingen in echo-
intensiteit worden veroorzaakt door veranderingen in weefsel impedantie ten 
gevolge van gliale reactie, verandering in celdichtheid en het gehalte aan 
metalen zoals ijzer en koper.2  
Inmiddels zijn circa 70 studies verricht naar de diagnostische waarde van TCD 
bij parkinsonistische aandoeningen en steeds meer onderzoeksgroepen zijn de 
techniek gaan gebruiken. Voor het implementeren van de techniek als 
diagnosticum in de klinische praktijk is het allereerst van belang om ervaring op 
te doen bij patiënten met verschillende aandoeningen. Hierbij kan deze 
praktische handleiding als een soort leidraad gebruikt worden. 
In deze handleiding worden namelijk de technische aspecten met betrekking 
tot het benaderen van de te onderzoeken structuren met behulp van TCD 
beschreven, alsmede een overzicht van de betekenis van afwijkende TCD 
bevindingen bij de ziekte van Parkinson (ZvP) en overige extrapiramidale 
aandoeningen.3  
Technische aspecten 
TCD is een elegante, niet-invasieve, goedkope en snelle techniek welke 
gebruikt kan worden voor verscheidene onderzoeksdoeleinden waaronder het 
afbeelden van de intracraniële vaten. Sinds 1995 wordt TCD ook gebruikt om 
de substantia nigra (SN) en verschillende andere hersenstructuren in beeld te 
brengen.1 De techniek is eenvoudig te leren mits men TCD ervaring heeft. Wel 
is, om een goed oordeel te kunnen geven of de te onderzoeken 
hersenstructuur een normaal of afwijkend aspect heeft, specifieke ervaring van 
enkele maanden nodig.  
 
TCD wordt over het algemeen verricht bij een patiënt in rugligging. De 
onderzoeker zit bij het hoofdeind en plaatst een ultrageluid transducer voor het 
oor op het os temporale (Figuur 1). Bij de meeste mensen (circa 85%) is dit 
botvenster toegankelijk genoeg om zo een tweedimensionaal beeld van de 
intracraniële structuren te verkrijgen.4,5 Daarvoor wordt een laagfrequente 
transducer gebruikt (1-4 MHz). De diepte range wordt ingesteld op 12 tot 16 
cm, zodat de contralaterale zijde van de schedel in beeld komt. In een latere 
instantie wordt verder ingezoomd.   

















Figuur 1 Plaatsing van de ultrageluid transducer over het transtemporale schedelvenster. 
 
 
Substantia nigra (SN) 
De rechter en linker SN gelegen in het mesencephalon worden tegelijk in beeld 
gebracht door te scannen in het axiale vlak dat parallel loopt aan de 
zogenaamde orbitomeatale lijn (Figuur 2A en 2B). Het mesencephalon is 
zichtbaar als een echo-arme, vlindervormige structuur, omringd door de basale 














Figuur 2A Schematisch overzicht van de axiale TCD sneden die gebruikt kunnen worden bij 
bewegingsstoornissen. 1 = mesencephale vlak (orbitomeatale vlak) , 2 = derde 
ventrikel-vlak (nadat de transducer vanuit het orbitomeatale vlak circa 10% naar 
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Figuur 3 Een normale hersenstam toont zich in het axiale vlak als een homogeen echoarme en 
vlindervormige structuur. De substantia nigra (SN) is niet tot nauwelijks zichtbaar. De 
raphe kernen (RN) daarentegen imponeren als relatief echorijke structuur in de 
middellijn. Een SN-TCD wordt als normaal beschouwd als de echo-intensiteit van 
beide SN normaal (hypo-echogeen) zijn. Een RN-TCD wordt normaal beschouwd als 




Normaal gesproken is het mesencephalon vrij homogeen. In veel gevallen kan 
wel een aanduiding van de SN gezien worden in het mediale gebied. Van een 
afwijkende  SN wordt gesproken als er een grote duidelijke hyperechogene 
zone zichtbaar is op de plaats van de SN (Figuur 4). Deze hyperechogene 
zone kan streepvormig zijn (overeenkomstig met de anatomie van de 




































































































































Figuur 4 Bij een patiënt met de ziekte van Parkinson kan ter plaatse van de substantia nigra 
(SN) een gebied met verhoogde echo-intensiteit herkend worden. Als aan één zijde of 
beide zijden ter plaatse van de SN een hyperecho-intensiteit zichtbaar is wordt de SN-
TCD als afwijkend beschouwd.3 
 
De SN wordt beoordeeld vanuit de ipsilaterale zijde. 
De hyperecho-intensiteit kan op twee manieren beoordeeld worden (Tabel 1): 
• Visuele (kwalitatieve) methode. Hierbij wordt een 2-, 3- of 4-deling 
toegepast, van een afwezige of twijfelachtige tot een duidelijk afgetekende 
hyperechogene zone.  
• Semi-kwantitatieve methode. Hierbij wordt de hyperechogene zone ter 
plaatse van de SN handmatig omcirkeld, zodat de oppervlakte berekend 
kan worden (Figuur 5). Gebruikmakend van deze laatste methode werd bij 
de meeste vergelijkende onderzoeken tussen gezonde vrijwilligers en 
patiënten met de ZvP gevonden dat een oppervlakte van <0.2 cm2 als 
normaal, 0.2-0.25 cm2 als licht afwijkend en >0.25 cm2 als fors afwijkend 
kan worden beschouwd.4 
 
Tabel 1 Beoordeling van de substantia nigra en Raphe nuclei. 
 
substantia nigra - beoordelen vanuit ipsilaterale zijde 
- kwalitatief (visuele) beoordeling of semi-kwantitatief (inzoomen en het 
gebied omcirkelen voor oppervlakte meting (>0.2 cm2 passend bij een 
hyper-echointensiteit) 
Raphe nuclei - beoordelen vanuit beide zijden 
- kwalitatieve beoordeling; afwijkend indien vanuit beide zijden niet zichtbaar 
of onderbroken (hypo-echointens) 
derde ventrikel - diameter beoordelen vanuit één of beide zijden;  
- normaal: <60 jaar tot 7 mm, >60 jaar tot 10 mm 
thalamus,  
n. caudatus en  
n. lentiformis 
- het beste te beoordelen vanuit contralaterale zijde 
- normaal niet te onderscheiden, afwijkend indien zichtbaar (hyper-echo-
intens) 




























Figuur 5 Door het gebied met verhoogde echo-intensiteit te omcirkelen (gestippelde lijn) kan de 
oppervlakte kwantitatief bepaald worden (in cm2).3 
 
 
Idealiter moeten voor elk transducer type de normaalwaarden afzonderlijk 
bepaald worden, aangezien de mogelijkheden om de basale kernen af te 
beelden per type aanzienlijk verschillen. Zelf gebruiken wij de kwalitatieve 
indeling (normaal, afwijkend, inconclusief, niet te beoordelen) in combinatie 
met de semi-kwantitatieve methode.  
 
De echo-intensiteit ter plaatse van de SN is niet altijd eenvoudig te beoordelen. 
Soms is de echo-intensiteit slechts licht verhoogd of heeft de hyperecho-
intensiteit een atypische vorm. Bij twijfel scoren wij de SN-TCD inconclusief 
(Figuur 6). Indien de beeldkwaliteit onvoldoende is scoren wij de SN-TCD als 
niet te beoordelen (Figuur 7).  
 
Om achteraf ook nog een goede beoordeling van de structuur te kunnen laten 
plaatsvinden, is het raadzaam een serie images op te slaan waarbij de 
transducer langzaam van craniaal naar caudaal wordt gedraaid. Voor de 
uiteindelijke beoordeling van de SN wordt de image genomen waarop het 
gebied met een verhoogde echo-intensiteit het grootst en het duidelijkst is.  
 























Figuur 6 Bij deze twee personen is de beeldkwaliteit vanuit rechts slechts matig. In het gebied 
van de rechter substantia nigra (SN) is bij beide personen een relatief groot gebied 
van slechts een licht toegenomen echo-intensiteit zichtbaar met een niet typische 
configuratie. In een dergelijk geval van twijfel scoren we de SN inconclusief (voor de 
klinische praktijk negatief). Als de contralaterale SN wel betrouwbaar te beoordelen is 














Figuur 7 Bij deze patiënt is het temporale botvenster niet voldoende om de echo-intensiteit van 
de substantia nigra en andere hersenstructuren te beoordelen gezien het 
mesencephalon en de omgevende structuren (epifyse, basale cisternen) niet 
geïdentificeerd kunnen worden. 
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Raphe kernen  
De Raphe nuclei (RN) bevinden zich in hetzelfde axiale vlak als de SN, maar in 
de midline van het mesencephalon en dienen vanaf beide zijden kwalitatief te 
worden beoordeeld. Gewoonlijk zijn de RN zichtbaar als een zeer 
hyperechogene lijn (als het ware als het lijfje van de vlinder; zie figuur 3). Als 
deze lijn niet zichtbaar is, dat wil zeggen dezelfde echo-intensiteit heeft als het 
omringende mesencephale weefsel, of als deze lijn onderbroken is, wordt deze 
als afwijkend beschouwd (Tabel 1).  
Pas als de echo-intensiteit van de RN verminderd is vanuit beide zijden wordt 
de TCD van de RN als afwijkend beschouwd.4 
Derde ventrikel 
Vanuit het voornoemde vlak waarin het mesencephalon goed te beoordelen is, 
wordt de ultrageluid transducer zodanig van positie veranderd (gekanteld) dat 
het insonatie vlak een hoek van 10o naar boven maakt (Figuur 2). In dit vlak 
komt het typische patroon van twee parallelle hyperechogene lijnen van de 
derde ventrikel à vue en kan de grootste diameter van de 3e ventrikel goed 
worden gemeten. Deze diameter wordt bepaald door de afstand vanaf de 
ipsilaterale tot de contralaterale binnenste laag van het hyperechogene 
ependym te meten (Figuur 8). Deze diameter is in de leeftijdsgroep van 20-60 
jaar <7 mm en voor 60 jaar of ouder <10 mm. 
 
 
Figuur 8 Diameterbepaling van de derde ventrikel.  
 De diameter wordt bepaald door de afstand tussen de binnenste lagen te meten (wit 
balkje). Links is een normale bevinding weergegeven, rechts een relatief wijde derde 
ventrikel, waarbij de gemeten waarde grensnormaal is. (E) is de epifyse, zichtbaar als 
een hyperechogene structuur.3 
 
 

















Thalamus, nucleus lentiformis en nucleus caudatus 
In hetzelfde insonatie vlak als de derde ventrikel kan de echo-intensiteit van de 
contralaterale thalamus, nucleus lentiformis (NL) en/of nucleus caudatus 
worden beoordeeld. Normaal gesproken zijn deze structuren niet te 
onderscheiden omdat zij iso-echogeen zijn aan het omliggende 
hersenparenchym. Een matige of forse hyperecho-intensiteit van deze 




Figuur 9 De ipsilaterale wand van de derde ventrikel is als hyperintense lijn zichtbaar (witte 
pijlpunten). Contralateraal van de zijde van insonatie is in het gebied van de nucleus 
lentiformis een groot echorijk gebied aanwijsbaar (witte cirkel).  
 Deze figuur werd door Prof.dr. D. Berg uit Tübingen ter beschikking gesteld. 
 
 
Betekenis van afwijkende bevindingen in het kader van de 
differentiële diagnostiek van parkinsonisme 
In Tabel 2 vindt u de percentages van de afwijkende TCD bevindingen van de 
substantia nigra (SN) en de nucleus lentiformis (NL) bij patiënten met 
verschillende parkinsonistische aandoeningen, patiënten met een essentiële 
tremor en bij gezonde controles. Achter de percentages staan het aantal 
personen waarop het percentage gebaseerd is. Uit de tabel blijkt dat een 
afwijkende SN-TCD heel sensitief is voor de ZvP. Echter een abnormale SN-
TCD wordt niet exclusief bij de ZvP gezien, en eveneens sluit een normale SN-
TCD de ZvP niet uit. Hetzelfde geldt voor de voorspellende waarde van een 
abnormale NL-TCD voor atypische parkinsonistische syndromen.  
In de laatste kolom is de diagnostische bijdrage van de wijdte van de derde 
ventrikel te vinden. Een verwijde derde ventrikel schijnt specifiek (en sensitief) 
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voor progressieve supranucleaire paralyse te zijn.4,6 Echter naar de 
diagnostische betrouwbaarheid is nog maar zeer weinig onderzoek verricht. 
 
 
Tabel 2 Percentage van afwijkingen ter plaatse van de substantia nigra, de nucleus lentiformis 
en de derde ventrikel voor gezonde controles, patiënten met een essentiële tremor of 
een parkinsonistische aandoening. Achter het percentage staat het patiëntenaantal 










Ziekte van Parkinson 87% (n=1334) 23% (n=493) laag? 
Atypische parkinsonistische 
syndromen: 
 - MSA 
 - PSP 
 - CBD 



















Vasculair parkinsonisme 20% (n=30) middelmatig? sporadisch? 
Medicatie geïnduceerd 
parkinsonisme 
  0% (n=3) sporadisch? sporadisch? 
Essentiële tremor 11% (n=112) sporadisch? sporadisch? 
Gezonde controles 12% (n=2340) 6% (n=94) sporadisch? 
n: aantal personen, MSA: multipele systeem atrofie, PSP: progressieve supranucleaire paralyse, 
CBD: corticobasale degeneratie, DLBD: diffuse Lewy body dementie 
 
 
Een aantal onderzoeksgroepen bereikten een hogere sensitiviteit en 
specificiteit door het maken van subgroepen. Bijvoorbeeld door een hyperecho-
intensiteit ter plaatse van de SN in te delen in een matig en zeer duidelijk 
verhoogde echo-intensiteit. Ook wordt een hogere betrouwbaarheid gehaald 
door het combineren van de bevindingen van de SN, NL en de derde 
ventrikel.4,6  
Zoals eerder genoemd is het visualiseren afhankelijk van de ervaring en de 
gebruikte apparatuur. In onze kliniek meten we standaard de echo-intensiteit 
van de SN en de RN en de wijdte van de derde ventrikel. Echter onze 
ervaringen met het betrouwbaar visualiseren van de NL, thalamus en de 
nucleus caudatus vallen enigszins tegen.   
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    ANTI-PARKINSONIAN DRUGS IN THE PAST:      
     
    RESPONSE TO ANTI-PARKINSONIAN DRUGS:     
       POSITIVE – NEGATIVE – RESPONSE TO LARGE DOSES OF LEVODOPA UNKNOWN  
     
          
3. INTOXICATIONS: (ALCOHOL, SMOKING, DRUGS): 
 
4. DURATIONS OF COMPLAINTS: 
 
5. MOST AFFECTED SIDE: 
 
CLINIMETRIC SCALES (SEE APPENDIX B): 
 
UNIFIED PARKINSON’S DISEASE RATING SCALE  
HOEHN AND YAHR SCALE FOR PARKINSON’S DISEASE 
SCOPA COGNITION SCALE: 
HAMILTON RATING SCALE FOR DEPRESSION: 
 
MOST PROBABLE CLINICAL DIAGNOSIS (SEE APPENDIX A): 
1  IDIOPATHIC PARKINSON’S DISEASE 
2 VASCULAR PARKINSONISM 
3 PROGRESSIVE SUPRANUCLEAR PALSY 
4 MULTIPLE SYSTEM ATROPHY 
5 ESSENTIAL TREMOR 
6 DRUG INDUCED PARKINSONISM 
7 CORTICOBASAL DEGENERATION 
8  DIFFUSE LEWY BODY DISEASE 
9  OTHER: 
DEGREE OF CONFIDENCE: 
 
CERTAIN (POSSIBLE) /  NOT CERTAIN (PROBABLE) 
 
STANDARD FORM PROSPECTIVE TRIAL 
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De ziekte van Parkinson (ZvP) is na de ziekte van Alzheimer de meest 
voorkomende neurodegeneratieve aandoening. Aangezien er geen 
betrouwbare test bestaat, die de aanwezigheid van de ziekte bevestigt, is de 
diagnose gebaseerd op klinische criteria. Indien de hoofdsymptomen, zoals 
bradykinesie, rigiditeit en tremor aanwezig zijn, is de diagnose vaak eenvoudig 
te stellen. Echter, in het beginstadium, wanneer de symptomen nog mild en 
aspecifiek zijn, is het niet altijd mogelijk onderscheid te maken tussen de ZvP 
en andere parkinsonistische syndromen. Aandoeningen, die in een vroeg 
stadium op de ZvP kunnen lijken, zijn: atypische parkinson syndromen (APS, 
bijv. multiple systeem atrofie [MSA], progressieve supranucleaire paralyse 
[PSP]) of secundair parkinsonisme (vasculair parkinsonisme [VP], 
medicamenteus geïnduceerd parkinsonisme [DIP]) en essentiële tremor. Met 
behulp van de klinische criteria kan de ZvP alleen als "waarschijnlijke" 
diagnose gesteld worden. Een “zekere” ZvP vereist een neuropathologische 
diagnose na obductie. Neuropathologische studies tonen aan, dat zelfs in het 
eindstadium van de ziekte de diagnostische betrouwbaarheid voor de ZvP op 
basis van klinische symptomen varieert tussen de 75-90%.1-5 
 
Het stellen van een vroege en juiste diagnose is van belang, omdat de 
prognose en behandeling verschillen tussen de verschillende parkinsonistische 
aandoeningen. Het ontwikkelen van aanvullende diagnostische technieken, die 
de diagnose in een vroeger stadium en betrouwbaarder kunnen stellen, is dan 
ook een belangrijk onderzoeksdoel. Voorbeelden van technieken, die veel 
gebruikt worden, maar niet zijn opgenomen in de reguliere diagnostiek, zijn: 
single photon emmission computer tomography (SPECT), positron emission 
tomography (PET), magnetic resonance imaging (MRI), transcraniële 
echografie (TCD), reuktesten, neuropsychologische testen en genetisch 
onderzoek. 
 
De SPECT scan is momenteel de meest toegepaste aanvullende 
onderzoekstechniek bij patiënten, bij wie onduidelijkheid bestaat over de aard 
van hun parkinsonistische aandoening. De SPECT scan kan worden gebruikt 
om de integriteit van het dopaminerge systeem te visualiseren. Verscheidene 
radioactieve isotopen zijn verkrijgbaar om verschillende delen van het 
dopaminerge systeem af te beelden. Uit eerder onderzoek blijkt dat een 
afwijkende SPECT scan met isotopen, die binden aan de presynaptische 
dopamine transporters, een goede voorspeller is voor een onderliggend 
degeneratief lijden, zoals bijvoorbeeld de ZvP en APS. De meest gebruikte 
presynaptische isotopen zijn 123I-ioflupane and 99mCT-TRODAT-1. 
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Een SPECT scan met radioactieve isotopen, die binden aan de 
postsynaptische dopamine receptors, geeft informatie over het postsynaptische 
deel van het nigro-striatale circuit. Postsynaptische SPECT scans worden met 
name gebruikt om te differentiëren tussen de ZvP en APS. De meest gebruikte 
postsynaptische isotoop is 123I-iodobenzamide. Ondanks veel onderzoek is er 
nog steeds discussie over de precieze diagnostische bijdrage van 
presynaptische en postsynaptische SPECT scans bij de differentiatie tussen 
verschillende parkinsonistische syndromen.  
 
Een relatief nieuwe onderzoekstechniek bij patiënten met een 
parkinsonistische aandoeningen is TCD.6 Deze techniek verschilt van de 
SPECT in die zin, dat TCD structurele afwijkingen visualiseert en SPECT 
veranderingen in de functie van een bepaald systeem. TCD kan een 
verhoogde echo-intensiteit ter plaatse van de substantia nigra (SN) laten zien. 
Tot nu toe wordt deze techniek voor deze indicatie alleen gebruikt in het kader 
van onderzoek, maar het feit, dat het een elegante, niet-invasieve, relatief 
goedkope en snelle onderzoeksmethode is, maakt TCD tot een veelbelovende 
techniek. Voordat TCD in de dagelijkse klinische praktijk toegepast kan 
worden, moet de betrouwbaarheid en toegevoegde diagnostische waarde ten 
opzichte van de reeds bestaande technieken goed onderzocht zijn. 
In dit proefschrift hebben we allereerst de diagnostische waarde van SPECT 
scans bij patiënten met een parkinsonistisch beeld onder de loep genomen. 
Verder hebben we de diagnostische waarde van TCD in de differentiaal 
diagnose van de ZvP onderzocht. Tenslotte hebben we de combinatie van 
beide technieken in de diagnostiek van patiënten met een nog niet 
gediagnosticeerd parkinsonistisch beeld onderzocht. 
  
In Hoofdstuk 2 wordt een meta-analyse gepresenteerd van de klinische 
studies, waarin de betrouwbaarheid van de presynaptische en postsynaptische 
SPECT scans in het differentiëren van de verschillende parkinsonistische 
aandoeningen onderzocht werd. Relevante studies zijn gezocht in Medline, 
EMBASE en de Cochrane databases, waarbij de referentielijsten van de 
geschikte artikelen handmatig zijn nagezocht. De zoektocht leverde 185 
artikelen op, waarvan er 32 geschikt waren voor de analyse. Uit deze studies 
herberekenden we de diagnostische odds ratio (OR) met een 95% 
betrouwbaarheids interval. Voor de presynaptische SPECT was de 
diagnostische waarde om patiënten met de ZvP in een vroeg stadium te 
differentiëren van gezonde controles hoog (OR 60 [13-277], evenals voor het 
onderscheid tussen patiënten met de ZvP en een essentiële tremor (210 
[78-563] en voor het onderscheid tussen patiënten met de ZvP en VP (OR 105 
[32-382]. De betrouwbaarheid om patiënten met de ZvP en APS van elkaar te 
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onderscheiden was laag, zowel voor de presynaptische scan (OR 2 [1-4]) als 
voor de postsynaptische SPECT scan (OR 19 [10-36]). 
Uit deze meta-analyse kan geconcludeerd worden, dat de SPECT scan met 
presynaptische radioactieve isotopen nauwkeurig is in het differentiëren tussen 
patiënten met de ZvP in een vroeg stadium en gezonde controles, danwel 
patiënten met een ET of VP. Het blijkt niet mogelijk betrouwbaar onderscheid 
te maken tussen patiënten met de ZvP en patiënten met APS. Dit geldt voor 
zowel de presynaptische als de postsynaptische SPECT .  
Tot op heden werden in de meeste studies alleen reeds gediagnosticeerde 
patiënten geïncludeerd. Deze groep patiënten is echter geen goede 
representatie van de klinische praktijk, waarbij men een patiënt met een 
parkinsonistisch beeld vaak in een vroeg stadium probeert te diagnosticeren.  
 
In Hoofdstuk 3 beschrijven we de diagnostische waarde van de presynaptische 
en postsynaptische SPECT scan in ons eigen ziekenhuis. Deze retrospectieve 
studie bevatte gegevens van 248 patiënten, die in de periode 2000-2006 een 
SPECT scan ondergingen vanwege onduidelijkheid over de origine van hun 
parkinsonisme. Als gouden standaard werd de klinische diagnose na follow-up 
gebruikt. De diagnostische OR voor de presynaptische SPECT scans was 
relatief hoog voor de differentiatie tussen patiënten met de ZvP en patiënten 
met een ET (OR 82 [11-674]). Ook het onderscheiden van patiënten met de 
ZvP en patiënten met VP (OR 61 [8-490]) of patiënten met DIP (OR 33 [2-697]) 
was goed mogelijk middels een presynaptische SPECT scan. Daarentegen 
was de nauwkeurigheid om patiënten met de ZvP te differentiëren van 
patiënten met APS relatief laag. Dit gold zowel voor presynaptische (OR 1 [0-
4]) als postsynaptische (OR 7 [2-17] SPECT scans.  
De conclusies van dit hoofdstuk komen overeen met de eerder genoemde 
resultaten van de meta-analyse in hoofdstuk 2.  
 
In Hoofdstuk 4 beschrijven we onze literatuurstudie over het gebruik van TCD 
bij parkinsonistische aandoeningen. Deze patiëntvriendelijke techniek is 
beschikbaar in veel klinieken en kan tegenwoordig zelfs aan het bed van de 
patiënt uitgevoerd worden. Door de transducer op het temporale botvenster te 
plaatsen kunnen meerdere hersenstructuren, waaronder de substantia nigra 
(SN), gevisualiseerd worden. Voor een gedetailleerde beschrijving van de TCD 
techniek zie appendix C. 
Normaal gesproken is het mesencephalon een vrij homogene echo-arme 
vlindervormige structuur. Bij de meeste patiënten met de ZvP is de SN duidelijk 
zichtbaar als een grote echo-intense zone. De verhoogde echo-intensiteit 
berust waarschijnlijk op een toegenomen ijzergehalte. Ook andere 
hersenstructuren zoals de nucleus lentiformis (NL) en Raphe nuclei (RN) zijn af 
te beelden met behulp van TCD. De NL is bij gezonde personen niet te 
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onderscheiden. Het vinden van een NL en dus een verhoogde echo-intensiteit 
van de kern is mogelijk van belang bij het differentiëren tussen patiënten met 
de ZvP en patiënten met APS.7, 8 
Een afname van de echo-intensiteit van de RN wordt geassocieerd met een 
depressie bij zowel patiënten met als zonder de ZvP.8,9  
 
Omdat er inmiddels vele studies zijn verschenen over de diagnostische waarde 
van TCD bij parkinsonistische aandoeningen, hebben wij een systematisch 
literatuuronderzoek verricht. In totaal waren 35 studies volgens onze criteria 
geschikt om op te nemen in het onderzoek.  
De resultaten van dit onderzoek kunnen als volgt worden samengevat: van de 
1534 patiënten met de ZvP hadden 200 patiënten (13%) een inconclusieve SN-
TCD, omdat men moeite had de SN-TCD te beoordelen, vanwege een 
ontoegankelijk botvenster of een atypische vorm van de hyperecho-intensiteit. 
Een verhoogde echo-intensiteit ter plaatse van de SN werd gevonden bij 1167 
(87%) van de 1334 patiënten met de ZvP. Diezelfde verhoogde echo-intensiteit 
werd ook aangetoond bij 12% van de gezonde controles, 12% van de patiënten 
met een ET, 20% van de patiënten met VP, 30% van de patiënten met een 
APS, maar bij geen van de patiënten met DIP. 
Daarentegen hadden 79% van de patiënten met APS, slechts 23% van de 
patiënten met de ZvP en 6% van de gezonde controles een verhoogde echo-
intensiteit ter plaatse van de NL. Een verlaagde echo-intensiteit van de RN was 
aanwezig bij 46% van de patiënten met de ZvP en een depressie en bij 16% 
van de patiënten met de ZvP zonder depressie. 
De conclusie van dit literatuuroverzicht is, dat de SN-TCD nauwkeurig kan 
differentiëren tussen patiënten met de ZvP en patiënten met ET, DIP of VP en 
gezonde controles, maar niet tussen patiënten met de ZvP en APS. 
Ook de NL-TCD alleen kan in een individuele patiënt niet differentiëren tussen 
de ZvP en APS. De diagnostische waarde van de RN-TCD om een depressie 
in patiënten met de ZvP aan te tonen is laag. Helaas was de SN-TCD in meer 
dan 10% van de onderzochte patiënten inconclusief. Verder heeft bij 
benadering 1 op de 10 ogenschijnlijk gezonde individuen een verhoogde echo-
intensiteit ter plaatse van de SN. Momenteel lopen er vervolgstudies met een 
langdurige follow-up om uit te zoeken of deze bevinding een teken is voor een 
toegenomen vatbaarheid voor de ZvP. 
 
Ondanks een hoge mate van patiëntvriendelijkheid en – voor zover op basis 
van de bestaande literatuur te beoordelen – betrouwbaarheid wordt TCD 
momenteel klinisch niet op brede schaal toegepast. Eén van de mogelijke 
verklaringen is, dat er meerdere methodologische onduidelijkheden zijn: het 
ontbreken van een gestandaardiseerde TCD techniek, scoringssysteem en 
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normaalwaardes, en het hoge percentage van personen met een inconclusieve 
TCD.  
 
Tot op heden is de inter-observer en intra-observer betrouwbaarheid van de 
SN-TCD alleen bestudeerd door Duitse en Taiwanese onderzoeksgroepen.10-14 
Zij rapporteren hiervoor uitstekende waardes in hun diagnostische studies. 
Helaas is niet gepubliceerd, welke methoden zijn gebruikt voor het bepalen van 
deze inter-observer subanalyses. Voordat de TCD techniek geïmplementeerd 
kan worden in de klinische praktijk, moeten de methologische aspecten 
uitgebreider bestudeerd worden.    
 
In Hoofdstuk 5 wordt een studie beschreven, waarin de inter-observer en inter-
transducer betrouwbaarheid van TCD wordt onderzocht. De echo-intensiteit 
van de SN is zowel kwalitatief als kwantitatief beoordeeld, de echo-intensiteit 
van de RN enkel kwalitatief. Elke patiënt werd viermaal onderzocht door twee 
onafhankelijke ervaren onderzoekers, die twee verschillende echosystemen 
gebruikten. In de “off-line” beoordeling scoorde een derde onafhankelijke 
ervaren echografist de opgeslagen beelden.  
De resultaten waren als volgt: wij vonden een matige overeenstemming voor 
de kwalitatieve SN-TCD beoordeling; dit geldt zowel voor de “on-line” inter-
observer, de “on-line” intra-observer en de “off-line” inter-observer 
overeenstemming. Zo werden kappa-waardes van 0.23-0.39 voor de “on-line” 
inter-observer, 0.53-0.67 voor de “on-line” intra-observer en 0.32-0.67 voor de 
“off-line” inter-observer overeenstemming berekend. De resultaten voor de 
kwantitatieve SN beoordeling waren vergelijkbaar en niet wezenlijk verschillend 
van de kwalitatieve SN beoordeling. De kappa-waardes voor de RN-TCD 
waren laag. 
De conclusie van deze studie is, dat de betrouwbaarheid van zowel de “on-line” 
als “off-line” inter-observer overeenstemming van de SN-TCD evaluatie matig 
is en die van de RN-TCD relatief laag. De intra-observer overeenstemming van 
zowel de SN-TCD als de RN-TCD was matig. De kwantitatieve beoordeling van 
de SN-TCD was even nauwkeurig als de kwalitatieve. Verder stemmen de 
resultaten, die “off-line” verkregen waren overeen met die van de “on-line” 
beoordelingen.  
 
Andere onderzoeksgroepen rapporteerden met kappa-waardes van 0.80 – 0.98 
een aanzienlijk grotere inter-observer overeenstemming van de kwantitatieve 
SN-TCD beoordeling.10-14 Deze onderzoekers includeerden echter patiënten 
met een reeds bekende diagnose. Daarentegen kozen wij voor een gemengde 
populatie, om de a priori kans op een positieve bevinding te verkleinen. Ook 
waren onze echografisten geheel geblindeerd voor de klinische diagnoses. 
Tenslotte hadden onze echografisten hun training in een ander ziekenhuis 
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genoten en nooit eerder samengewerkt. De relatief matige overeenstemming in 
onze studie kan deels verklaard worden door het ontbreken van criteria voor de 
evaluatie voor de echo-intensiteit van de SN en de RN. Mogelijk kan een 
gestandaardiseerde kwantitatieve beoordeling van de echo-intensiteit van de 
SN en het omliggende weefsel bijdragen aan uniformiteit van de resultaten. 
Verder zijn standaard instellingen voor het echosysteem vereist.  
 
Net als bij de diagnostische SPECT studies zijn de meeste studies over TCD 
gedaan bij patiënten met een reeds bekende diagnose. Daarom hebben wij in 
Hoofdstuk 6 verder onderzoek verricht naar de betrouwbaarheid van TCD bij 
82 patiënten met nog onduidelijkheid over de oorzaak van hun parkinsonisme. 
De betrouwbaarheid van de SN-TCD hebben we vergeleken met die van 
presynaptische en postsynaptische SPECT scans. De klinische diagnose na 
follow-up diende daarbij als gouden standaard; deze diagnose werd gesteld 
door een onafhankelijke neuroloog gespecialiseerd in bewegingsstoornissen.  
Allereerst onderzochten we de diagnostische betrouwbaarheid van TCD om 
patiënten met de ZvP te onderscheiden van patiënten zonder nigrostriatale 
degeneratie (oa. ET, VP, DIP). SN-TCD bereikte hiervoor een sensitiviteit van 
50%, een specificiteit van 82%, een positief voorspellende waarde (PPV) van 
89% en een negatief voorspellende waarde (NPV) van 35%. Voor de 
presynaptische SPECT scan daarentegen vonden we waardes van 
respectievelijk 97%, 100%, 100% en 92%. 
Vervolgens onderzochten we de betrouwbaarheid van TCD om patiënten met 
de ZvP te onderscheiden van patiënten met APS. SN-TCD bereikte hiervoor 
een sensitiviteit van 50%, een specificiteit van 43%, een PPV van 86% en een 
NPV van 10% en voor de postsynaptische SPECT scan waren deze waarden 
respectievelijk 75%, 81%, 43% en 94%. De PPV van een afwijkende SN-TCD 
voor een afwijkende presynaptische SPECT was 88%.  
Wij concludeerden, dat de voorspellende waarde van de SPECT uitslag voor 
de klinische diagnose evident hoger is dan die van de SN-TCD. Omdat een 
afwijkende SN-TCD een hoge voorspellende waarde heeft voor een afwijkende 
presynaptische SPECT scan, kan de SN-TCD gebruikt worden als instrument 
voor screening, voordat een presynaptische SPECT scan wordt aangevraagd.   
 
In Hoofdstuk 7 wordt het onderzoeksprotocol beschreven van de prospectieve 
trial, die in augustus 2006 van start is gegaan. In deze prospectieve trial 
worden 250 patiënten geïncludeerd, die vanwege onduidelijkheid over de 
origine van hun parkinsonistisch beeld verwezen zijn naar de polikliniek 
neurologie van de twee betrokken ziekenhuizen.   
Bij alle patiënten werd een TCD, een presynaptische SPECT scan, cognitieve 
testen, motorische testen en een reuktest verricht. De gouden standaard is de 
klinische diagnose na een follow-up van 2 jaar. Deze diagnose wordt 
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vastgesteld op basis van de consensus, die bereikt wordt tussen twee 
onafhankelijke, geblindeerde neurologen gespecialiseerd in bewegings-
stoornissen.  
Deze studie is essentieel, omdat het een prospectieve opzet heeft en plaats 
vindt in zowel een academische als een perifere kliniek. In augustus 2008 
beëindigden we de inclusie en is een start gemaakt met de klinische 
herbeoordelingen. Wij verwachten, dat de resultaten van deze prospectieve 
studie eind 2010 bekend gemaakt kunnen worden. 
 
Conclusie 
Het diagnosticeren van de ZvP kan met name in een vroeg stadium van de 
ziekte vrij lastig zijn, gezien de overlap met symptomen van andere 
aandoeningen. Een betrouwbare diagnostische test zal daarom een positief 
effect hebben op de klinische zorg. Tot op heden bestaat de perfecte test voor 
de ZvP nog niet.  
Wij zijn van mening, dat enkel de presynaptische SPECT scan voldoende 
onderzocht en betrouwbaar is om als regulier diagnostisch onderzoek gebruikt 
te worden. Met de presynaptische SPECT scan is betrouwbaar onderscheid 
mogelijk tussen patiënten met de ZvP enerzijds en gezonde controles, 
patiënten met VP of een ET anderzijds. Het differentiëren tussen patiënten met 
de ZvP en APS is noch met een presynaptische noch met een postsynaptische 
SPECT scan mogelijk.  
SN-TCD is mogelijk een goed alternatief om de ZvP te diagnosticeren, 
aangezien een afwijkende SN-TCD een marker is voor de diagnose ZvP. 
Hoewel in onze onderzoeken de SN-TCD minder betrouwbaar is dan de 
SPECT scan, is het gezien de hoge positief voorspellende waarde zinvol de 
mogelijkheden van de SN-TCD verder te onderzoeken. Daarnaast biedt de 
SN-TCD ook voordelen boven de SPECT ten aanzien van kosten en 
belastbaarheid voor de patiënt. Evenals de SPECT scan lijkt TCD vooralsnog 
niet geschikt om patiënten met de ZvP te onderscheiden van die met APS. 
Hoewel de SN-TCD en SPECT zeker kunnen bijdragen in het uitwerken van de 
differentiaal diagnose, kunnen deze onderzoeken nooit een nauwkeurige 
anamnese en neurologisch onderzoek vervangen, aangezien fout positieve 
bevindingen altijd kunnen voorkomen. De diagnose ZvP blijft tot op heden 
primair gebaseerd op het aantonen van enkele karakteristieke neurologische 
kenmerken. 
Naar onze mening kan SN-TCD in de toekomst op twee manieren een rol 
spelen als screeningsinstrument. Ten eerste kan in de dagelijkse klinische 
praktijk bij patiënten met onduidelijkheid over de diagnose allereerst een TCD 
verricht worden. Afhankelijk van de TCD bevindingen kan daarna alsnog een 
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presynaptische SPECT scan worden uitgevoerd. In het geval van een 
afwijkende SN-TCD kan een presynaptische SPECT scan als overbodig gezien 
worden. Dit kan een kostenbesparing van de gezondheidszorg opleveren. Ten 
tweede is de SN-TCD een ideale techniek voor het screenen van grote 
groepen mensen met een verhoogd risico op de ZvP. Dit wordt vooral 
belangrijk op het moment, dat er preventieve of curatieve medicijnen 
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